An investigation into the function and regulation Of ERG Exon 7b by Jumbe, Samantha
  
 
 
An Investigation Into The 
Function and Regulation 
Of 
ERG Exon 7b 
 
Samantha Jumbe 
 
A thesis submitted in partial fulfilment of the requirements of the 
University of the West of England, Bristol for the degree of Doctor of 
Philosophy 
 
Department of Applied Science,  
Faculty of Health and Applied Sciences, University of the West of England 
June 2019 
 
 ABSTRACT  
The ETS family transcription factor ERG is a key oncoprotein in bone, blood, 
vascular and most notably prostate cancer where it is activated in at least 50% 
of cases. Of the several splice isoforms of ERG with variable biological activity 
those that include the cassette exon 7b are associated with aggressiveness and 
progression of disease in prostate cancer. Inclusion of exon 7b adds 24 amino-
acids in frame to the central ‘alternative domain’ which also contains binding sites 
for other transcriptional regulators.  
Alignment of the amino acids of exon 7b showed it is evolutionary conserved in 
echinoderms emphasizing its functional importance. Splice switching 
oligonucleotides (SSO) targeting the splice sites for exon 7b were designed to 
induce exon 7b skipping. Successful SSO-induced skipping of exon 7b in the 
osteosarcoma MG63 cell line resulted in decreased cell migration, invasion and 
proliferation and increased apoptosis in vitro. ERG was shown to bind to the 
promoter of tissue non-specific alkaline phosphatase, a marker of cell 
differentiation, and SSO-induced skipping of exon 7b attenuated its expression. 
Moreover several splicing regulatory elements and proteins were identified using 
bioinformatics prediction methods and an RNA pull down of the 3´ splice site of 
exon 7b identified several potential splicing regulatory proteins for this exon.  
This study provides evidence that the inclusion of exon 7b, which encodes the 
full length transactivation domain enhances the oncogenic activity of ERG in 
vitro. Further refinement of in vivo experimentation is required but if successful 
SSOs that target oncogenes could potentially be developed as therapeutic 
agents. The study also highlights the requirement to understand splicing 
  
regulation of disease associated splicing events in ETS transcription factors and 
has provided pilot data for further study of ERG exon 7b splicing regulation. 
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ENCODE The Encyclopedia of DNA Elements 
ERG ETS-related gene or v-ets avian erythroblastosis virus E26 oncogene 
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ERK extracellular signal-regulated kinase 
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GTEx Genotype-Tissue Expression  
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hnRNP heterogeneous nuclear ribonucleoprotein 
ISE intronic splicing enhancer 
ISS intronic splicing silencer 
kDa kilodalton 
LPA lysophosphatidic acid  
MAPK mitogen-activated protein kinase 
mRNA messenger RNA  
MSI2 musashi RNA binding protein 2 
ng nanogram 
NHEJ non-homologous end joining 
nM nanomolar 
NRG Neuroglian 
Nucleic acid bases A adenosine, T thymine, G guanine, C cytosine and  
U uracil 
PCa prostate cancer 
PCBP poly (rC) binding protein  
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p-NP p-nitrophenol 
p-NPP p-nitrophenylphosphate 
PRAD prostate adenocarcinoma  
Pre-mRNA pre-messenger RNA 
PS phosphorothioate 
PSI percent spliced in 
PSM peptide spectrum match 
PTBP1 polypyrimidine tract-binding protein 1  
qPCR quantitative polymerase chain reaction 
RBP RNA binding protein 
RNAPII RNA polymerase II 
RNA ribonucleic acid 
RNA-seq RNA sequencing  
RNPS1 RNA binding protein with serine rich domain 1 
RPKM reads per kilobase transcript per million  
RT-PCR reverse transcriptase polymerase chain reaction 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SELEX systematic evolution of ligands by exponential enrichment 
SF splice factor 
SF3A1 splice factor 3 subunit 1  
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SF3B4 splice factor 3b subunit 4  
SFPQ Splicing factor proline and glutamine rich 
siRNA small interfering RNA 
Sm smith antigen  
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smRNA small nuclear RNA  
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SNW1 SNW domain containing 1 
SR serine-arginine rich proteins 
SR-A1 steroid receptor RNA activator 1 
SRE splicing regulatory element 
SRPK serine-arginine protein kinase 
SRSF serine-arginine splice factor 
SSO splice switching oligonucleotide 
SXL Sex-lethal 
T-ALL T-cell acute lymphoblastic leukaemia 
TARBP1 transactivation response RNA-binding protein 1 
TCGA The Cancer Genome Atlas 
TCR T-cell receptor 
TNSALP tissue non-specific alkaline phosphatase 
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1.1 Alternative splicing 
The information of almost all living organisms is stored as DNA 
(deoxyribonucleic acid), a very stable molecule. However, the expression of the 
genetic information held in DNA requires the synthesis (transcription) of a more 
unstable and dynamic molecule called RNA (ribonucleic acid). Similar to DNA 
in structure, RNA has a different base (uracil, U in place of thymine, T) and 
sugar backbone where the hydroxyl group is in the 2´ position making RNA 
more chemically reactive (Holley et al., 1965). DNA is transcribed into RNA and 
this can then be translated into proteins where necessary. This fascinating 
mechanism of molecular biology is the means by which our genetic information 
is expressed. We now know that one gene can produce several proteins and 
this is because RNA is not a straightforward copy of the DNA but rather it 
undergoes processing allowing for the production of different RNA molecules 
from the one gene.  
The Nobel Prize winning discovery was made independently by Richard 
Roberts and Phillip Sharp in 1977. Adenovirus, responsible for causing many a 
common cold, was used as a model as it could be grown rapidly with ease and 
had a relatively short, simple genome that could be easily isolated. By 
comparing the Adenovirus hexon gene to its RNA molecule the experiment 
revealed that genes were interrupted by segments of DNA that were not present 
in the messenger RNA (mRNA) molecule (Berget, Moore and Sharp, 1977; 
Chow et al., 1977) something that was contrary to the thinking at the time. We 
now call these interrupting sequences introns and the parts of the gene that 
generally end up in mRNA are called exons. Exons are joined, or ‘spliced’ 
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together very precisely. However, further research revealed that alternative 
RNA transcripts can be made from a single processed primary transcript (Berget 
et al., 1978). This process of defining which sequences constitute the final RNA 
transcript is alternative splicing (AS). 
A mature mRNA molecule is made up of a protein coding sequence (open 
reading frame) flanked by a 5´ untranslated region (UTR) and 3´ UTR. The start 
of the coding region is demarcated by AUG or sometimes CUG (Lobanov et al., 
2010). AS not only affects the coding potential of RNA, it also affects the 5´ 
UTR, 3´ UTR, adjusting the rates of translation, stability and localisation of 
mRNA molecules. During transcription, other pre-mRNA processing events 
occur which are connected to splicing. The formation of the 5´ cap promotes the 
recruitment of the splicing machinery, and the process of polyadenylation is also 
closely linked to the splicing of the final intron (Schwer and Shuman, 1996). 
Each exon-exon junction has exon junction complexes placed on them during 
splicing which support RNA export and enhance mRNA translation (Luo et al., 
2001). Many years after the discovery of AS not only are we beginning to 
comprehend how essential it is to gene expression but also how understanding 
this process can aid us when determining the causes of disease as well as 
establishing novel contexts for potential therapies.  
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1.1.1 Prevalence of alternative splicing  
Upon the sequencing of the human genome it became apparent that the same 
number of genes present does not necessarily correlate with the evolutionary 
hierarchy of an organism. For example, Arabidopsis thaliana plants have an 
estimated 25,000 protein coding genes comparable to the estimated 20-24,000 
genes in humans. Human genes, however, are characterised by much greater 
alternative splicing. Of the more than 20,000 genes in the human genome over 
92% undergo AS (E. T. Wang et al., 2008). The highly flexible nature of AS; the 
selective combination of exons means that tens, hundreds or even thousands 
of isoforms can be produced from one gene. In comparison with fruit fly, mice 
or worms, humans were found to have the highest average number of mRNA 
isoforms per gene and the other organisms genomes did not undergo AS to 
nearly the same extent as humans (Lee and Donald C. Rio, 2015). Interestingly 
only 1.2% of the genomic sequence contributes to exonic sequence (Venter et 
al., 2001) further showing how alternative splicing is an important mechanism 
for creating proteomic complexity from a relatively limited protein coding 
genome. It also partially alludes that AS, as a means of the regulating gene 
expression, contributes to the specificity, depth and extent of the proteome of 
an organism.  
  
 Introduction 
Samantha Jumbe- June 2019   25 
1.1.2 Specificity and complexity of splicing 
The expression of isoforms is dependent on the conditions in and around the 
cell. This means some isoforms require external cues to be expressed or are 
only expressed during a certain developmental stage or in a specific tissue type. 
A number of Drosophila genes have been revealed to be tissue specific. The 
determination of sex requires the presence of Sex-lethal (SXL) and other slice 
factors (Penalva and Sánchez, 2003). ELAV-like protein 1 (ELAVL1) is a 
neuron-specific RBP that was identified as a regulator of Neuroglian (NRG) 
splicing, being required for the production of the neural specific isoform 
(Koushika, Lisbin and White, 1996).  
Not only are tissue specific RBPs important but the activation of signalling 
cascades can regulate AS. A signalling cascade is generally activated by a 
ligand that may bind to an extracellular or transmembrane receptor. The 
receptor then activates intracellular proteins activating the cascade that may 
ultimately result in the activation of a nuclear target that alters splicing patterns. 
An example is the splicing of the CD44 gene upon activation of the T-cell 
receptor (TCR). The TCR activates the ERK (extracellular signal-regulated 
kinase)/MAP (mitogen-activated protein) kinase signalling pathway leading to 
ERK phosphorylating SRC-associated substrate in mitosis of 68kDa (Sam68) 
which has RNA binding activity. Phosphorylated Sam68 can then bind to the 
CD44 pre-mRNA and promote inclusion of the v5 exon (Cheng and Sharp, 
2006).  
Similarly, the presence and function of SR proteins can be regulated by serine-
arginine protein kinase (SRPK) and cdc2-like kinase (CLK) families which can 
 26  Samantha Jumbe- June 2019 
be activated as part of more extensive signalling pathways (Jakubauskiene et 
al., 2015). The phosphorylation of newly synthesised SR proteins by SRPKs is 
required for them to be transported to the nuclear speckles, a nuclear sub-
compartment where they are stored. Subsequently hyperphosphorylation by 
CLKs releases SR proteins from the speckles and facilitates their recruitment to 
the transcription sites and pre-mRNA molecules (Naro and Sette, 2013).  
  
 Introduction 
Samantha Jumbe- June 2019   27 
1.1.3 Splicing regulatory elements and proteins involved in splicing 
regulation 
There are several modes of AS; exon skipping, mutually exclusive exons 
splicing, alternative usage of the 3´ and 5´ splice site and intron retention. The 
most common is exon skipping (Keren et al., 2010, Figure 1.2A). The mode of 
AS that occurs is influenced by the splicing regulatory elements (SREs) that 
exist within both intron and exon sequences. These and additional regulatory 
sequences can be referred to as cis-acting regulatory elements. They function 
to recruit splice factor (SF) proteins that may enhance or silence splicing. Hence 
the sequences are termed as follows: exonic splicing enhancers (ESEs), 
intronic splicing enhancers (ISEs), exonic splicing silencers (ESSs) and intronic 
splicing silencers (ISSs) (Lee and Donald C. Rio, 2015). As with splice site 
strength, bioinformatic tools have been developed to predict potential SREs and 
these tools can be informative for experimental validation (Fairbrother et al., 
2004; Desmet et al., 2009). 
In addition, trans-acting splicing factors are involved in the regulation of AS. 
RNA-binding proteins (RBPs) that are not part of the spliceosome can contribute 
to regulating splice site selection. These proteins can be classified into three 
main types; serine-arginine-rich (SR) proteins, heterogeneous nuclear 
ribonucleoproteins (hnRNPs) or tissue-specific RBPs. Classically SR proteins 
are splicing activators binding to ESEs and ISEs, whereas hnRNPs bind ISSs 
and ESSs to repress splicing (Black, 2003; Wang and Burge, 2008).  
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Figure 1.1 The regulation and patterns of alternative splicing (adapted from Park 
et al., 2018) 
A) Alternative splicing is regulated by an extensive protein-RNA interaction network 
involving cis elements within the pre-mRNA and trans-acting factors that bind to these 
cis elements and complex. The most essential splicing signals within the pre- mRNA 
are the 50 splice site (50SS), 30 splice site (30SS), branch site (A), and polypyrimidine 
tract (Y(n)). The 50 and 30 splice sites have highly conserved GU and AG dinucleotides 
as the first and last two nucleotides of the intron, respectively. The U1 snRNP complex 
recognizes the 50 splice site, and the U2 snRNP complex recognizes the branch site. 
The U2AF proteins recognise the 30 splice site and polypyrimidine tract. Exonic splicing 
enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing enhancers (ISEs), 
and intronic splicing silencers (ISSs) are pre-mRNA cis regulatory motifs that recruit 
various RNA-binding proteins (e.g., SR and hnRNP proteins) to regulate alternative 
splicing. B) Main patterns of alternative splicing. Dark-blue boxes represent 
constitutively spliced exons. Light-blue and green boxes represent alternatively spliced 
exons.  
 Introduction 
Samantha Jumbe- June 2019   29 
ESEs close to splice site can encourage the binding of the U1 and U2AF 
snRNPs to their respective splice sites. When SR proteins are bound to an ESE 
they can recruit other splice factors that interact with the arginine and serine 
residue rich RS domain on the SR protein (Graveley, 2000). This generally 
increases exon inclusion. SR-depletion of splicing extracts showed that two SR 
proteins, SRSF1 and SRSF2 are required for pre-mRNA splicing, splice site 
selection and splice switching (Fu and Maniatis, 1990; Ge and Manley, 1990; 
Krainer, Conway and Kozak, 1990).  
However, ESEs may have a wider ranging function in pre-mRNA splicing as 
they are expressed in constitutive exons (ones that are consistently conserved 
after splicing) as well as alternative ones. ISEs are equally important for 
enhancing splicing. The terminal exon in the Calcitonin gene has a conserved 
ISE that constitutes part of the sequence of a 5´ cryptic splice site facilitating 
the recognition of a 3´ splice site required for exon inclusion (Lou et al., 1995). 
Overall enhancer SREs are able to activate and define both alternative and 
constitutive exons as well as weak and strong splice site by appropriately 
recruiting SR proteins and other splice factors. 
Silencer SREs such as ISSs and ESSs typically recruit hnRNP proteins. 
Multimerization of hnRNPs across an exon can repress its inclusion by blocking 
access for the spliceosome and other auxiliary splicing factors. Polypyrimidine 
tract-binding protein 1 (PTBP1), also known as hnRNPI, has been characterised 
as a repressor of splicing often by binding to the polypyrimidine tract or in co-
operation with splicing co-factors (Bothwell et al., 1991; Spellman et al., 2005). 
Systematic evolution of ligands by exponential enrichment (SELEX) is a method 
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for producing RNA or DNA strands that bind a specific target ligand, and this 
method has been used to identify silencers. U1 binding to the 5´ss was shown 
to be altered by the presence of splicing silencers affecting splice site choice 
(Yu et al., 2008).  
Whereas cis-acting element tend to either repress or enhance splicing, studies 
have revealed trans-acting proteins are actually able to perform both functions 
depending on the binding motif sequence and position of the binding site. An 
example of this is hnRNPL which was initially thought to only repress CD45 
exon 4 splicing (House and Lynch, 2006) but has been shown to also enhance 
exon 4 and 5 inclusion by binding to weak splice sites (Motta-Mena, Heyd and 
Lynch, 2010). In addition the action of RBPs may involve interactions with 
snRNPs like U1 during spliceosome assembly and modulate their binding to the 
ss. PTBP1 represses splicing of the N1 exon in the proto-oncogene c-SRC 
through direct binding to U1 when it is part of the snRNP complex (Sharma et 
al., 2011).   
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1.1.3.1 Splicing, Transcription and RNA processing 
The transcription, 5´ capping and 3´ polyadenylation of an RNA molecule are 
closely linked to its splicing. Transcription is initiated by association of the RNA 
polymerase II (RNAPII) enzyme with a promoter sequence, where RNAPII and 
splice factors can interact. It has been suggested that the choice of promoter 
can change the profile of splice factors that associate with RNAPII (de la Mata 
et al., 2003). The kinetics of transcription can also regulate splicing as the timing 
of the production of competing exons, intron length, types of transcriptional 
activators and presence of RNAPII elongation mutants have all been shown to 
alter splicing patterns (de la Mata et al., 2003; Hicks et al., 2006). An example 
of this is the earlier mentioned Calcitonin gene ISE which is additionally required 
for exon 4 recognition and efficient polyadenylation (Lou et al., 1995). 
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1.1.4 The splicing reaction 
The RNA molecule produced after the transcription of protein coding genes is 
called a pre-messenger RNA (pre-mRNA) and it is made up of introns and 
exons which are defined by sequence markers and elements (Berget, 1995). 
Indeed the formation of the spliceosome, the core machinery that carries out 
the splicing reaction, can only happen with the recognition of these key 
regulatory elements (Reed, 1996). Although there are over 100 other proteins 
in the major spliceosome, the binding of small nuclear ribonucleoproteins 
(snRNPs) is fundamental to the reaction. A snRNP is an RNA-protein complex, 
and the major spliceosome snRNPs are U1, U2, U4, U5 and U6. The minor 
spliceosome contains others such as U11 and U12. These snRNPs bind to key 
RNA elements in the pre-mRNA sequence in a stepwise fashion (Black, 2003).  
The boundaries between introns and exons are defined by 3´ and 5´ splice sites 
(ss) also referred to as the acceptor and donor site respectively. The splice site 
splice siteare degenerate consensus sequences; YAG/GURAGU for the donor 
site and NYAG/G for the acceptor site in human genes (Zhang, 1998; Sun and 
Chasin, 2000). The Y represents a pyrimidine (U or cytosine, C), R is for 
adenosine (A) or guanine (G) and the / defines the actual splice site. Initially U1 
snRNP binds to the 5´ splice site and U5 and U6 follow in subsequent stages. 
The detection of the 3´ splice site also relies on the recognition of a 
polypyrimidine tract, a pyrimidine rich sequence in the upstream intron where 
the U2 auxiliary factor (U2AF) splicing factor binds. U2AF is made up of a 65kDa 
(U2AF65) and 35kDa (U2AF35) subunit with the former binding to the 
polypyrimidine tract and the later to the AG of the 3´ss (Zhang, 1998). U2 
 Introduction 
Samantha Jumbe- June 2019   33 
snRNP binds across the branch point site (BPS) containing a conserved A 
flanked by a degenerate sequence (YNYURAY) (Query, Moore and Sharp, 
1994). 
The conservation of the splice site  splice site sequence as well as the length of 
the polypyrimidine tract determine the strength of the ss. Indeed the stronger 
the conservation of these sites the more complementary and stronger affinity of 
the binding of the spliceosome components (Hertel, 2008). Several predictive 
matrices and tools have been developed to assess splice site  splice site 
strength based on the dependencies of adjacent and distant nucleotides that 
constitute the splice site  splice site (Shapiro and Senapathy, 1987; Yeo and 
Burge, 2004; Mani et al., 2011). There is a growing role of bioinformatics 
programs such as Human Splice Finder which have been developed to predict 
splice sites and how mutations in them may affect splicing (Desmet et al., 2009). 
The splicing reaction is a two-step transesterification reaction that converts pre-
mRNA to mature mRNA by the removal of introns. The reaction occurs in the 
nucleus and requires the assembly of various complexes at each stage to 
remove the intron and ligate the two exons remaining. The 2-hydroxyl group of 
the BPS attacks the phosphate of the phosphodiester bond at the 5´ splice site 
and forms a 2´-5´ phosphodiester bond between the BPS and 5´ splice site in 
the first step of the transesterification reaction. Next the 3-hydroxyl group of the 
upstream exon, which has been created in the first step, attacks the 3´ splice 
site. This ligates the 5´ and 3´ exons and the free intron is released as a lariat. 
In order to facilitate the splicing reaction, the spliceosome must assemble on 
the pre-mRNA molecule in a stepwise manner. In mammals this is more 
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commonly via the U2 dependent spliceosome made up of U1, U2, U5 and 
U4/U6 snRNPs and other non snRNP proteins. A snRNP is a made up of a 
small nuclear RNA (snRNA) in close association with so-called smith antigen 
(Sm) proteins and other particle-specific proteins. There are seven Sm proteins, 
SmB/B’, SmD, SmE, SmF, SmG, SmN, of decreasing magnitude and they are 
named after Stephanie Smith, the lupus patient in whom they were first 
discovered (Séraphin, 1995).  
The binding of U1 to the 5´ splice site and non-snRNP proteins such as U2AF 
(auxiliary factor) to the BPs and polypyrimidine tract results in the formation of 
the initial E complex. Following on the U2 snRNP binds to the BPS and this is 
the pre-spliceosome or A complex. Next a pre-assembled tri-snRNP of 
U4/U6.U5 is recruited to make a pre-catalytic B complex that is converted to an 
activated B complex due to rearrangements caused by changes in RNA-RNA 
and RNA-protein interactions. This also destabilises the U1 and U4 snRNPs 
which dissociate from the complex. The first transesterification reaction takes 
place when catalytic activation occurs upon the recruitment of pre-mRNA-
splicing factor ATP-dependent RNA helicase-like protein, Prp2. The reaction 
leads to the formation of the C complex catalysing the second step of the 
transesterification reaction. Finally the complex is remodelled and dissociation 
of the snRNP and associated proteins, which can be recycled occurs (Brow, 
2002; Staley & Woolford, 2009, Figure 1.1). 
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Figure 1.2 The splicing reaction 
This schematic represents the splicing cycle. The splicing reaction results in the 
formations of mature mRNA and requires the removal of introns from pre-mRNA 
followed by ligation of exons. The sequential steps of the splicing reaction lead to 
the formation of several complexes composed of the pre-mRNA, the five snRNPs 
(U1, U2, U5, and U4/U6) and other spliceosome machinery not shown. A, B and C 
complexes are shown in this figure but there are more. U5 and U2/U6 constitute the 
catalytic core and catalyse the two nucleophilic attacks (catalytic steps). The reaction 
commences with the binding of the U1 snRNP to the 5′ splice site and U2 snRNP to 
the branch site and 3´ splice site, forming the A complex. The B complex forms by 
addition of the U4/U6.U5 tri-snRNP. Catalytic activation of B complex requires the 
departure of U1 and U4 and forms activated B complex. The two catalytic reaction 
happen with 5′ splice site cleavage leading to the formation of the C complex and 
subsequent exon ligation. The spliceosome disassembles, releasing the intron lariat 
and mature mRNA as well as recycling the snRNPs for subsequent reactions. 
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1.1.4.1 Secondary RNA structure, chromatin modification and splicing 
Changes in RNA-RNA binding caused by secondary structure and chromatin 
changes affect AS mechanisms. Even though RNA is single stranded it is able 
to form secondary and tertiary structures as a result of interactions between 
many hundreds of nucleotides within the molecule. The effect of the structure 
can be both enhancement and repression of splicing as SREs or splice site may 
be concealed.  
An example of this is the splicing regulation of the exon 6 cluster in the 
Drosophila Downs syndrome cell adhesion molecule (DSCAM) gene which has 
over 38,000 alternative mRNA transcripts. The RNA molecule has a binding site 
and selector sequence in the exon 6 region. Each of the 48 mutually exclusive 
exons of the exon 6 cluster has a unique selector sequence and this can base 
pair with the docking site forming a secondary structure of 1,000-14,000 
nucleotides in size. This interaction is responsible for driving the mutually 
exclusive exon pairing in the gene (Graveley, 2005).  
G-quadruplexes (G4) are G-rich four-stranded quadruplex structures that can 
form in RNA and these have been implicated in the splicing regulation of B-cell 
lymphoma-extra-large (BCL-X) gene. The gene has pro-and anti-apoptotic 
isoforms that can be generated through the use of alternative 5´ ss. A G4 has 
been located next to each of these alternative splice site and the administration 
of G4 targeting ligands switched splicing in BCL-X (Weldon et al., 2018). 
Chromatin remodelling can alter splicing either through phosphorylation of 
RNAPII or recruitment of splicing factors influenced by chromatin binding 
proteins. Furthermore, modification to the nucleosome can influence exon 
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definition either by histone methylation or increase in nucleosome occupancy. 
Indeed in some cases alternative exon are less methylated and this can lead to 
splice switching (Tilgner et al., 2009; Luco et al., 2010). The discovery that 
SRSF1 and SRSF3 are associated with interphase chromatin via histone-
modification highlights the link between splicing regulation and chromatin 
modifications (Loomis et al., 2009). 
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1.1.5 Alternative splicing and cancer 
We know that many human diseases have a genetic origin or contribution, 
therefore the process of AS which is so crucial to gene expression is an obvious 
process that may be a target of some of these mutations. Not only splice site 
but also SREs and other cis-acting elements have been shown to have disease 
associated mutations in them. Changes in these sequences can prevent 
splicing, recruit a different profile of trans-acting splicing regulators or activate 
cryptic splice sites. Furthermore, mutation in the genes that encode for the 
splicing machinery, RBPs and even transcriptional proteins all have potential to 
change AS patterns and contribute to disease. However in the case of trans-
acting splicing factors the effects of mutations may be masked by functional 
redundancy. It has been evidenced that splice factors from the same family may 
have similar functions at the same motif (Barberan-Soler et al., 2011) or in the 
same tissue (Kuroyanagi et al., 2007). Therefore loss of function in a splice 
factor can be rescued by another splicing factor in the same family and is why 
there is a low prevalence of disease as a result of such mutations.  
Specific for cancer, several AS events have been identified and are being 
investigated to understand their role in pathogenesis and potential as a 
biomarker or therapeutic target. These changes often result in changes in 
expression of oncogenes and tumour suppressor genes. Oncogenes generally 
promote cell growth whereas tumour suppressor genes reduce growth rate or 
activate cell death. In cancer, mutations in these genes contribute to 
uncontrolled cell death either through activation or lack of control of the process. 
Proliferation, apoptosis, invasive ability, angiogenesis and evasion of 
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proliferation control and the immune system, common traits of cancerous cells, 
all have AS events associated with them that lead to aberrant gene expression.  
Mutation of cis-elements occurs less commonly in contrast to trans-acting 
proteins which are often mutated in several cancer types. For example, in 
malignant melanoma patients more than half express a V600E mutation in the 
B-Raf proto-oncogene, serine/threonine kinase (BRAF) oncogene which is a 
component of the MAPK/ERK signalling cascade (Zhang and Manley, 2013).   
Perhaps the best known angiogenesis gene is vascular endothelial growth 
factor (VEGF) which has both angiogenic and anti-angiogenic isoforms. These 
isoforms can be produced via differential inclusion of exons (for example exon 
8) as well as alternative use of 3´ ss. Further to this the splicing of VEGF is 
reliant on control by splice factors such as SRSF1. Protein kinase C signalling 
induced by insulin like growth factor 1 activates SR protein-specific kinase 1 
(SRPK1) which phosphorylates SRSF1. SRSF1 favours the splicing of the pro-
angiogenic VEGF isoform (Nowak et al., 2010). The anti-angiogenic VEGF-b is 
supressed by Wilms tumour suppressor (WT1) gene leading to the irregular 
angiogenesis and the production of Wilms tumours. The promoter of SRPK1 is 
directly bound by WT1, and mutant WT1 isoforms enhance SRPK1 expression 
causing hyperphosphorylation of SRSF1 and thus increasing VEGF expression 
alongside VEGF-b reduction (Amin et al., 2011). 
However aberrant alternative splicing can be an advantage to cancer cells as 
the protein produced may support disease development and progression. In the 
case of VEGF switching from the VEGF-165b to the VEGF 165 splice isoform 
increases angiogenesis, giving a tumour survival and growth advantage 
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(Woolard et al., 2004). Identifying which splicing events produce these 
advantageous proteins is important but equally understanding how a splicing 
event is regulated can provide a potential diagnostic marker or therapeutic 
target (Le et al., 2015). A comprehensive study, using high throughput reverse 
transcription PCR, of 600 cancer-associated genes found 41 alternative splicing 
events that were differentially expressed in breast cancer tissues compared to 
normal tissues. These changes were associated with increased cell survival and 
proliferation and some events could be stratified according to tumour grade 
meaning they had potential as biomarkers (Venables et al., 2008). 
Mutation in cell cycle control proteins can also contribute to malignant 
transformation due to aberrant cyclin-dependent kinase activity. One such 
example is cyclin D1 which can be alternatively spliced to produce two splice 
isoforms; cyclin D1a and cyclin D1b, in which intron 4 is retained and produces 
a truncated protein due the presence of a premature stop codon. Cyclin D1b is 
upregulated in prostate cancer (PCa) and its expression is influenced by two 
RBPs, Sam68 and SRSF1 (Olshavsky et al., 2010; Paronetto et al., 2010).  
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1.2 E26-transformation specific (ETS) family of transcription 
factors 
1.2.1 Transcription factors and gene expression 
Gene expression relies on the process of DNA transcription, in which DNA 
binding trans-factors better known as transcription factors play a regulatory role. 
By binding to DNA cis-elements such as enhancers (sequences that promote 
gene transcription), transcription factors can recruit co-factors and the 
transcriptional enzyme RNAPII and regulate the expression of the target gene 
(Ihn Lee and Young, 2013). A co-factor may activate or repress gene expression 
depending on whether a transcription factor regulates initiation or elongation of 
genes (Lelli, Slattery and Mann, 2012). In the case of transcription factors that 
regulate initiation co-activators are recruited with the P300 mediator complex 
(Malik and Roeder, 2010). Once RNAPII has begun transcribing the gene it will 
come to a pause 50 base pairs in, and whether it continues into elongation or 
terminates can be controlled by transcription factors (Adelman and Lis, 2012). 
The c-Myc transcription factor can stimulate positive transcription elongation 
factor b which restarts paused RNAPII via phosphorylation (Rahl et al., 2010; 
Luo et al., 2012). 
Furthermore, gene expression is also controlled by the conformation of the 
chromatin which is itself regulated by protein complexes and histone 
modifications. Chromatin may be in a configuration specifically intended to 
repress expression of genes. For example, the polycomb complex which 
includes histones such as H3K27me3, associates with genes that are only 
activated at specific stages of differentiation and development (Orkin and 
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Hochedlinger, 2011). Remodelling of the chromatin may be required to allow for 
gene activation and this can involve enzymes such as histone methylases, 
acetylases (Bannister and Kouzarides, 2011) and remodelling complexes such 
as the SWItch/Sucrose Non-Fermentable (SWI/SNF) family to allow 
transcription factors to bind their intended DNA target (Hargreaves and 
Crabtree, 2011). The crosstalk between chromatin structure and transcription 
factors adds an additional layer of complexity to the regulation of transcription. 
A gene can have a number of promoter elements with varying proximity to its 
target gene that can be bound by various transcription factors (Krivega and 
Dean, 2012). Each transcription factor can recognise and preferentially bind a 
set of binding motifs present in the promoter elements of a gene (Inukai, Kock 
and Bulyk, 2017). Moreover, every specific cell type will have a specific gene 
expression program dependent on the position, profile and number of 
transcription factors bound to the promoter and DNA sequence of a set of 
genes.  
The basic domain structure of most transcription factors includes a DNA binding 
domain and additional domains that interact with co-activators or co-repressors 
(Bhagwat and Vakoc, 2015). Consequently, dysregulation of transcription 
factors can manifest both via improper DNA binding and altered protein 
interactions. Subsequently downstream signalling pathways may also alter 
transcription factor expression or may in themselves be disrupted by improper 
gene expression driven by a mutated transcription factor. Therefore, mutations 
in promoter sequences, co-factors and the genes that encode transcription 
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factors themselves can all contribute to the aberrant gene expression seen in 
diseases especially cancer.  
1.2.2 Structure and binding specificity of ETS transcription factors  
It must be acknowledged that many of the recognised oncogenes are actually 
transcription factors (Introna and Golay, 1999). The ETS transcription factor 
family is an example of oncogenic transcription factors involved in the 
pathogenesis of a number of human cancers. The ETS gene family is thought 
to have arisen from an ancestral gene duplication that pre-dates the emergence 
of chordates. Thus ETS members are present in both vertebrates and 
invertebrates (Seth et al., 1992) and found in species across the metazoan 
phyla (Degnan et al., 1993).  
ETS-1 (E26-transformation specific 1) was the first member to be discovered 
and since then 30 members have been discovered in various species (Degnan 
et al., 1993, Table 1). Classification of ETS proteins into subfamilies is also 
based on the conservation and homology in the C terminal region that contains 
the conserved and crucial DNA-binding ETS domain in addition to nuclear 
localisation sequences (Seth et al., 1992; Laudet et al., 1999). There are 28 
human ETS family genes organised into 12 subfamilies and four classes (Class 
I-IV) based on the base at the +4 position of the consensus binding sequence 
for the subfamilies (Figure 1.3). In the case of class II members ETV6 and ETV7 
have a preference for binding to A rather than T at this position, and therefore 
this class is divided into class IIa and class IIb. The subfamilies are ELG, PDEF, 
SPI, TEL, ESE, ELF, PEA3, TCF, ETS, ERF, ERG and GABPA (Figure 1.1A, 
Table 1, Hollenhorst et al., 2011).  
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Figure 1.3 The ETS transcription factor family (adapted from Wei et al., 2010 and 
Hollenhorst et al., 2011) 
A. There are 12 subfamilies in the ETS family in humans divided into four classes (listed 
on the left). A schematic representative of each one is shown with the position of the 
ETS domain (teal), and if present, the pointed   domain (gold) and transactivation 
domain (purple) mapped. The members of each subfamily are listed on the right. B. The 
consensus binding sequence for each class of ETS transcription factor is defined by the 
base at position +4.  
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Gene 
Symbol 
Full Name 
Chromosome 
location 
EHF ETS homologous factor 11p13 
ELF1 E74 like ETS transcription factor 1 13q14.11 
ELF2 E74 like ETS transcription factor 2 4q31.1 
ELF3 E74 like ETS transcription factor 3 1q32.1 
ELF4 E74 like ETS transcription factor 4 Xq26.1 
ELF5 E74 like ETS transcription factor 5 11p13 
ELK1 ETS-like transcription factor 1 Xp11.23 
ELK3 ETS-like transcription factor 3 12q23.1 
ELK4 ETS-like transcription factor 4 1q32.1 
ERF ETS2 repressor factor 19q13.2 
ERG ETS related gene  21q22.2 
ETS1 
v-ets erythroblastosis virus E26 oncogene 
homolog 1  
11q24.3 
ETS2 
v-ets erythroblastosis virus E26 oncogene 
homolog 2 
21q22.2 
ETV1 ETS variant 1 7p21.2 
ETV2 ETS variant 2 19q13.12 
ETV3 ETS variant 3 1q23.1 
ETV3L ETS variant 3 like 1q23.1 
ETV4 ETS variant 4 17q21.31 
ETV5 ETS variant 5 3q27.2 
ETV6 ETS variant 6 12p13.2 
ETV7 ETS variant 7 6p21.31 
FEV Fifth Ewing variant 2q35 
FLI1 Friend leukaemia virus integration 1  11q24.3 
GABPA 
GA binding protein transcription factor subunit 
alpha 
21q21.3 
SPDEF 
SAM pointed domain-containing ETS 
transcription factor 
6p21.31 
SPIB Spleen focus forming virus proviral integration B  19q13.33 
SPIC Spleen focus forming virus proviral integration C 12q23.2 
SPI1 Spleen focus forming virus proviral integration 11p11.2 
Table 1 Gene names and locations of the ETS transcription family (adapted 
from Yates et al., 2017) 
The gene symbol, full gene name and chromosome location of for the 28 members 
of the ETS transcription factor. The names and chromosome locations used are 
according to HUGO Gene Nomenclature Committee (HGNC) classification in the 
HGNC database - data accessed 18th August 2018.  
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The structure of the ETS domain has been resolved using high resolution X-ray 
crystallography (Suwa et al., 2008) as well as NMR (Liang et al., 1994; Werner 
et al., 1997) and reveals an 85 amino acid helix-loop-helix structure of three 
alpha helices and four antiparallel beta sheets. The core recognition motif is 
GGA (A/T) (Karim et al., 1990). The sequence that flanks this core motif 
determines the binding specificity of each ETS transcription factor allowing for 
activation of specific gene targets (Seth et al., 1992; Donaldson et al., 1996; 
Shore et al., 1996). The two G residues interact with two conserved arginine 
residues found in the third alpha helix and a conserved tyrosine that interacts 
with the A base is also found in the same helix (Cooper et al., 2015). 
The class of an ETS transcription factor is based on the specificity of the binding 
motif sequence (Wei et al., 2010). Class I which includes the ERG, TCF and 
ETS subfamilies is the largest and have a consensus sequence of 
ACCGGAAGT which was determined through in vitro binding experiments 
(Wang et al., 1992; Wei et al., 2010). The next largest group is Class II (TEL, 
ESE and ELF subfamilies) and the consensus sequence for these ETS proteins 
is CCCGGAAGT (Wang et al., 1992). However as ETV6 and ETV7 have slightly 
different specificity to other class II members it has been suggested that class 
II be divided into class IIa and IIb (Wei et al., 2010). Class III and Class IV 
contain one subfamily each, SPI and SPDEF respectively. Adenosine rich 
sequences upstream of the core motif are the preference of class III ETS 
transcription factors (Ray-Gallet et al., 1995) whereas class IV favour a different 
core motif of GGAT(Oettgen et al., 2000). 
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Some ETS proteins have a pointed domain which has a 4 or 5 alpha helical 
structure (Mackereth et al., 2004). The domain has variable roles, some unique 
to each ETS protein, including protein-protein interactions that co-regulate 
transcriptional control and kinase interactions (Lacronique et al., 1997; Seidel 
and Graves, 2002). Indeed dimerization of ETS proteins can be facilitated by 
both the ETS and POINTED domains, either as homo- or heterodimers 
(Sharrocks et al., 1997; Carrère et al., 1998). Other specific regions in 
transcription factors include nuclear localisation domains (Hoesel et al., 2016), 
transcriptional activation domains (Siddique et al., 1993; Vlaeminck-Guillem et 
al., 2003), kinase phosphorylation sites (Seth et al., 1992; Slupsky et al., 1998; 
Seidel and Graves, 2002) and a B-box domain a conserved amino acid region 
which is facilitates interactions with serum response factors (Ling et al., 1997).  
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1.2.3 Expression and biological function of ETS transcription factors 
Generally ETS transcription factors are expressed in all tissues (Hollenhorst, 
Jones and Graves, 2004) and function as either transcriptional activators or 
repressors (Sharrocks et al., 1997). It is estimated that ETS binding sites are 
present in 25% of human promoters and although not all of them are necessarily 
functional, this proposes that the ETS family is important for regulating gene 
expression (Hollenhorst, McIntosh and Graves, 2011). Post-translational 
modifications of ETS proteins as effectors of signalling cascades modulate the 
proteins activity and can dictate whether the ETS transcription factor acts as an 
activator or repressor when it binds a promoter. For example, an ERK/MAPK 
phosphorylation site in the B box of TCF facilitates the formation of a complex 
with serum response factor that binds to serum responses elements in the Fos 
proto-oncogene, AP-1 transcription factor subunit (c-fos) promoter (Gille, 
Sharrocks and Shaw, 1992). The signalling pathway may also recruit 
transcriptional co-regulatory proteins. Auto-inhibition of ETS1 occurs when the 
protein is phosphorylated but this can be reversed with cooperation with Runt-
related transcription factor 1 (RUNX1) which relieves the inhibition at specific 
sites (Hollenhorst, McIntosh and Graves, 2011). 
ETS transcription factors are important to developmental processes such as 
haematopoiesis and embryogenesis (Sharrocks et al., 1997) as well as 
angiogenesis and vasculogenesis (Hollenhorst, McIntosh and Graves, 2011; 
Shah, Birdsey and Randi, 2016). Differentiation, proliferation, apoptosis, 
migration and cell matrix interactions have all been shown to involve ETS 
proteins as well (Oikawa and Yamada, 2003; Wei et al., 2010). Some ETS 
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proteins are expressed exclusively or more highly in specific tissues, such as 
SP1 which is expressed in macrophages, B cells and myeloid lineage cells 
(Lloberas et al., 1999).  
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1.3 The ERG transcription factor 
1.3.1 Structure and isoforms 
The ERG gene (ETS-related gene, also v-ets avian erythroblastosis virus E26 
oncogene homolog) was discovered in 1987 while investigating human 
oncogene homologues that belong to the ETS (erythroblast transformation 
specific) family of transcription factors. The ETS domain is a highly conserved 
DNA-binding domain present in ERG and other ETS family members (Watson 
et al., 1985).  The 1987 study screened a human complementary DNA (cDNA) 
library derived from COLO320 cells (derived from colorectal adenocarcinoma) 
with a probe comprising the conserved ETS domain from the E26 virus known 
to cause erythroblastoid leukaemia in chicken (Reddy et al., 1987).    
The ERG gene is located on chromosome 21 and is 300kb in size. When ERG 
was first discovered two mRNA transcripts were identified; these were named 
erg 1 and erg 2 producing a 41kDa and 52kDa polypeptide respectively (Rao et 
al. 1987). Two studies have sought to annotate ERG isoforms and now it is 
predicted that there are around 30 isoforms, although not all of them encode 
functional proteins, with 16 splice isoforms currently characterised (Owczarek 
et al. 2004; Zammarchi et al. 2013). The main open reading frame produces an 
mRNA transcript of 18 exons and encodes for a full length protein 486 amino 
acids long with a mass of 54.6kDa (Zammarchi et al. 2013; Owczarek et al. 
2004).  
The main isoform generating events in ERG are alternative polyadenylation 
sites, alternative promoter sites and the alternative splicing of two cassette 
exons; exons 4 and 7b, which are either included or excluded in most ERG 
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splice isoforms. There are also other cassette exons such as exon 7 but these 
are less commonly spliced (Zammarchi et al. 2013). It is not surprising that ERG 
is so thoroughly alternatively spliced considering its complex biological roles. 
The existence of so many isoforms can contribute to imparting a certain level of 
specificity as well as diversity to the transcriptional functions of ERG. 
The ERG protein can form homodimers and heterodimers with FLI-1, ETS2 and 
SPI1 ETS transcription factors and this is aided by the pointed domain (Carrère 
et al., 1998).  In addition to the ETS and pointed domains, ERG also has two 
transcriptional activation domains - one located in between the pointedand ETS 
domain (AD) and another in the C-terminus of the protein (cAD). Both the AD 
and cAD encourage the binding of proteins to increase ERG transcriptional 
activation (Siddique et al., 1993). Therefore, whereas the role of the ETS 
domain is to localise ERG, the AD is there to recruit and interact with 
transcriptional machinery.  
Alternative splicing of exon 7b results in the inclusion or skipping of 24 amino 
acids in the AD and maintains a functional protein as the change is in-frame 
(Prasad et al., 1994; Hagen et al., 2014; Adamo and Ladomery, 2015). This 
change in amino acid sequence alters the tertiary structure of ERG and it is 
therefore possible that the alternative splicing of exon 7b significantly changes 
the transcriptional activity of ERG. The structure of the AD of ERG in relation to 
its exon structure is shown in Figure 1.5A.  
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Figure 1.4 ERG: gene structure and isoforms (© Zammarchi et al., 2013) 
A. Top: The ∼300 Kb human ERG locus, roughly to scale with intron and exon (bars) sizes 
in Kb are shown. Red: first exons; blue: common alternative ones and grey uncommon ones. 
Middle: Exon structure, with exon sizes at the bottom. Blue boxes indicate the main predicted 
ORFs, white boxes the untranslated regions and grey the uncommon exons. Red circles 
indicate polyA sites. Bottom: alignment of the exons (7b in the red box) forming the main 
ORF (ERG-1b) with the protein’s domains. Numbers indicate size in amino acids. 
PNT = pointed domain, AD = alternative domain, Ets = Ets domain, TAD = transactivation 
domain. Asterisk and circle indicate position of the first and second ATG. B. Human ERG 
main variants. The splicing pattern of exon 7b is shown in the red box and isoforms that 
exclude the exon are highlighted in red. Alignment of exons forming the 30 main RNA 
variants of human ERG. Blue indicates the ORF, light blue the additional region from the 
ATG in exon 3. For each variant, the proposed name is indicated next to previous 
nomenclature (if available).  
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1.3.2 ERG and Cancer 
Cancer can be described as uncontrollable growth of cells and although this is 
true in part there are other key features that cells must develop to give them 
oncogenic properties. Loss of senescence, evasion of growth control signals 
and apoptosis, epithelial-mesenchymal transition (EMT) facilitating cell motility 
and angiogenesis are all additional attributes of cancerous development. 
Hanahan and Weinberg (2011) ascribe ten “biological capabilities” (originally 
six) to the stepwise progressive development of cancer. More recent evidence 
suggests that cell metabolism can be reprogrammed to better fuel 
tumorigenesis. Moreover, cells are able to evade detection and destruction by 
the immune system. 
ERG contributes to cancer progression via the transcriptional regulation of its 
target genes and the profile of ERG target genes can transform with cancer 
development and progression. Altered signalling pathways can change post-
translational modifications of ERG and therefore its transcriptional activity. The 
alternative splicing of ERG can produce an ERG protein with modified activity 
and this is regulated by a profile of splice factors, some of which may be 
alternatively spliced themselves in cancer. All of this can change cancer cell 
biology by excluding, and possibly introducing new ERG target genes.  
 
 
 
 54  Samantha Jumbe- June 2019 
1.3.2.1 Ewing’s sarcoma 
Ewing’s sarcoma, commonly afflicting children and adolescents, is a group of 
bone cancers with neurogenic origin and is characterised by undifferentiated 
small round cells (Ozaki, 2015). It is named after Dr James Ewing who first 
described it in the early 20th century (Ewing, 1921).  When present in the bone 
the main sites of malignancy are ribs, pelvis and femur however tumours can 
also develop in other sites such as the back and lower leg. Survival varies but 
worsens if metastases are present with a slightly reduced estimated 5 year 
survival of 58% in such cases compared to 68% overall (Ozaki, 2015).  The 
pathogenesis of the malignancy has been linked to the formation of 
chromosomal rearrangements that result in the production of oncogenic fusion 
proteins that drive tumorigenic transformation in the tissue (Lessnick and 
Ladanyi, 2012). As the development of the disease is significantly linked to the 
chromosomal translocations present they pose a clear potential therapy target. 
As a result, much effort has been put into identifying and characterising the 
molecular landscape of Ewing sarcoma.  
The presence of ETS gene translocations is critical for the tumorigenesis of 
Ewing sarcoma and is attributed to the combined gene regulation power of 
EWS, a transcriptional activator, and the DNA binding capability of the ETS 
domain. The EWS protein is produced from the EWSR1 gene, a member of the 
TET protein family. The protein contains RNA binding domains, RGG regions, 
a zinc finger and in the N terminal region a glutamine-glycine-serine-tyrosine 
rich transactivation domain. This region is able to interact with splice factors, 
bind calmodulin preventing protein kinase C mediated phosphorylation and also 
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interacts with RNAPII and transcription factors (Bertolotti et al., 1998; Cantile et 
al., 2013). The protein is therefore thought to act as a bridge between gene 
transcription and splicing. EWS also has important roles as an RNA and nucleic 
acid binding protein facilitated by the RNA binding domains and the RGG 
domain that favour polyU and polyG nucleic acid sequences.  
 Several ETS transcription factors form fusion proteins with EWS, most 
commonly FLI-1 (around 85% of occurrences) but ERG is the second most 
common fusion partner   (Delattre et al., 1992; Zucman et al., 1993; Sorensen 
et al., 1994). Detected consistently in Ewing patient tumours, cell lines and mice 
xenografts, the initial t(11;22) translocation was found in the late 1980s (Turc-
Carel et al., 1988). By 1992 EWS-FLI1 was discovered following cloning of the 
translocation breakpoints (Zucman et al., 1992). This is not so surprising as it is 
important to note that FLI-1 and ERG share some significant homology 
especially in their ETS binding domains as they belong to the same ETS 
subfamily (Laudet et al., 1999; Hollenhorst, McIntosh and Graves, 2011).  
What does vary between the two fusions is the breakpoints at which the two 
chromosomes combine. The EWS-ERG translocation t(21;22) (q22;q12) has 
four potential breakpoints in both the EWS and ERG giving several fusion 
variants. The EWS breakpoints maintain the transactivation domain and are 
located in exons 7-10 (Lin et al., 1999). In ERG the breakpoints are in exons 6-
9 and all exclude the pointedpointed domain but maintain the functionally 
important ETS domain (Zucman et al., 1993). In contrast the breakpoints in FLI-
1 are located in exons 4-7, and exclusion of exon 4 removes the pointed domain 
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(Lin et al., 1999). Fusion variants that have been described for are EWS-ERG 
7/6, EWS-ERG 7/8, EWS-ERG 7/9 and EWS-ERG 10/6 (Zucman et al., 1993). 
Although the EWS-ERG fusion has not been as well characterised as EWS-FLI, 
the oncogenic ability of EWS-ERG has been confirmed by several studies. The 
transcriptional activity of ERG is maintained and in combination with the 
conserved transactivation domain of EWS, it is thought the fusion protein 
functions as a dysfunctional transcription factor. The altered activation of 
downstream target genes contributes to the oncogenic activity of EWS-ERG in 
Ewing sarcoma.  The structural similarities would support the hypothesis that 
both fusions have very similar functions. Indeed a study confirmed this 
assumption by comparing EWS-FLI1 and EWS-ERG patients and found no 
significant differences in their clinical statistics, disease, progression or survival 
(Ginsberg et al., 1999). The transformative potential of EWS-ERG was further 
evidenced by the colony forming ability of the fibroblast-derived cell line NIH3T3 
although no tumours were made in a xenograft mouse model (Braunreiter et al., 
2006).  
The fusion protein can bind promoters of genes altering cell signalling pathways 
that may aid oncogenic transformation and promotion. Reduction of 
transcription of transforming growth factor β type II receptor (TGF-β RII) abates 
sensitivity to TGF-β and increases tumorigenesis. TGF-β RII is supressed by 
EWS-ERG. The cancer microenvironment is reliant on the building and 
reorganisation of the extracellular matrix. The expression of two extracellular 
matrix proteins COL11A2 and lamin β-3 are regulated by EWS-ERG (Matsui et 
al., 2003; Irifune et al., 2005). In the case of COL11A2, promoter binding by 
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EWS-ERG also involves interaction with RNAPII (Matsui et al., 2003). Lamin β-
3 encodes for a chain in the lamin 5 glycoprotein which is involved in cell 
migration, differentiation and adhesion. ASO repression of EWS-ERG resulted 
in reduced transcription of lamin β-3 providing a possible target that may drive 
oncogenic cell development.  
In addition another member of the TET protein family FUS (also called TLS)  
forms a fusion protein with ERG (Ichikawa et al., 1994). This protein plays a role 
in leukaemia specifically acute myeloid leukaemia (AML) (Panagopoulos et al., 
1994). The FUS-ERG fusion first described in four Ewing tumour patients is 
exactly the same t(16;21)(p11;q22) translocation found in AML. The FUS gene 
is found of chromosome 16 and the protein has a similar structure to other TET 
family members with the presences of an RNA binding domain that facilitates 
regulation of gene transcription and RNA metabolism. The FUS breakpoint in 
exon 7 observed in these initial cases maintain the N terminal transactivation 
and are fused to exon 8 or 9 of ERG. However one case did have a breakpoint 
part way through exon 6 instead fused to ERG exon 9 and it was suggested that 
this may indicate a distinct oncogenic mechanism for FUS-ERG (Shing et al., 
2003). A case with an Ewing sarcoma-peripheral neuroectodermal tumour of 
the kidney had a FUS-ERG fusion where exons 1-5 of FUS were fused to ERG 
at exon 6 (Berg et al., 2009). Overall the presence of FUS-ERG is rare and 
further attempt to identify it in small blue round cell tumours reported a 
prevalence of 8.2% of 85 cases assessed (Chen et al., 2016).  
Although the presence of TET-ERG fusions in Ewing diseases has been 
established their rarity means not as much classification has been performed. 
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Certainly the role of specific splice variants has not been established and 
therefore there is definite scope to increase our knowledge of ERG and ERG 
fusion as well their respective splice variants in the onset, development and 
progression of the Ewing family of malignancies. 
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1.3.2.2 Haematological cancers 
A role for ERG in the regulation of normal haematopoiesis is well established, 
as it was found that homozygous mutant ERG mice did not survive past E13.5. 
Furthermore, one of the characteristics of heterozygous mice was decreased 
levels of less committed progenitor cells. Eventually ERG was shown to be 
critical to the regulation of haematopoietic stem cell maintenance (Loughran et 
al., 2008). This is supported by the observation that endothelial stem cell 
differentiation is similarly dependent on ERG activity (Nikolova-Krstevski et al., 
2009). In addition to its regulation of haematopoiesis ERG is an oncogene in 
several haematological malignancies (Salek-Ardakani et al., 2009; Adamo and 
Ladomery, 2015). 
The aforementioned FUS-ERG fusion gene has been found to be expressed in 
AML and acute megakaryoblastic leukaemia (AMKL) patients and contribute to 
leukaemogenesis. AMKL is a subtype of AML, with more than 50% of blast cells 
of megakaryocyte lineage. The FUS promoter driven expression of ERG is able 
to lead to the transformation of NIH3T3 cells, increase cell proliferation and 
disrupt myeloid differentiation (Ichikawa et al., 1994; Yi et al., 1997; Pereira et 
al., 1998; Pan et al., 2008). Although initially it was thought that the presence of 
the fusion alone was sufficient to drive the development of leukaemia, it was 
later established that additional mutational events are required (Warner et al., 
2005). Mice with the EWS-ERG fusion can develop leukaemia however this 
mutation has not yet been reported in humans (Codrington et al., 2005). 
A recent study revealed that FUS-ERG fusion functions as a transcriptional 
repressor. In the presence of all-trans-retinoic acid, FUS-ERG binding to 
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promoters and enhancers is diminished. It was further found that the fusion 
protein interacts with and alters the activity of a heptad of transcription factors 
consisting of ERG, TAL1/SCL, GATA2, LYL1, LMO2, RUNX1 and FLI1 (Sotoca 
et al. 2015). Overexpression of ERG is one markers used for the classification 
of a specific complex AML karyotype (Marcucci et al. 2005). Therefore, the 
regulation of the transcriptional activity of ERG is an important contributor to 
AML and possibly other leukaemia.  
Another translocation t(X;21)(q25–26;q22) fusing the N-terminus of the ETS 
transcription factor E74 Like ETS Transcription Factor 4 (ELF4) to the C-
terminus of ERG was reported in an AML patient. Exon 2 of ELF4 fuses to exon 
2 of ERG mean the majority of the protein sequence in this fusion is attributed 
to ERG. Therefore it was suggested that its function would likely be similar to 
native ERG and as of yet no other AML cases have been reported to harbour 
this mutation (Moore et al., 2006).  
Individuals with trisomy 21 (Downs syndrome) have an increased risk of 
developing AMKL. This is thought to be in part because of the overexpression 
of genes such as ERG that play a significant part in megakaryoblast 
transformation on this chromosome due to its enhanced ploidy (Ng et al., 2015; 
Tsuzuki, Taguchi and Seto, 2015). In mice ERG overexpression was shown to 
lead to aggressive AMKL (Salek-Ardakani et al., 2009). This process is thought 
to involve other transcription factors including GATA1 (Xu et al., 2003; 
Stankiewicz and Crispino, 2013) which cooperates with ERG to promote colony 
formation but also possibly RUNX1 (Elagib et al., 2003; Salek-Ardakani et al., 
2009). Furthermore ETS2 has previously been reported to also contribute to 
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trisomy 21 associated AMKL and since different ETS transcription factors can 
work cooperatively this may be an additional way to enhance megakaryopoiesis 
and AMKL development (Sumarsono et al., 1996; Stankiewicz and Crispino, 
2009).  
In addition to this ERG overexpression has been observed in T-cell acute 
lymphoblastic leukaemia (T-ALL) and was associated with poor relapse free 
survival (Baldus et al., 2006). This overexpression profile has been linked to the 
leukaemia-specific and transient use of the +85 enhancer in the ERG promoter, 
and the transcription factor heptad associated with FUS-ERG was shown to 
bind as well (Thoms et al., 2011). At a protein level several serine 
phosphorylation sites were found on ERG in both AML and T-ALL cells. 
However, one site S283 stood out as it was phosphorylated significantly more 
than other haematopoietic cells and it was shown to promote use of the +85 
enhancer and increase cell proliferation. The phosphorylation at S283 is 
mediated by ERK which activates the RAS/MAPK signalling pathway and 
required a DEF domain located in exon 7b (Y. Huang et al., 2016).  
Not much is known about effect of alternative splicing on ERG in leukaemia. 
Variable use of the first exons (named exons 4 and 5 in this study) between 
AML and T-ALL patients has been shown with the former preferentially 
expressing isoforms using both exons and the later exon 5 only. Regulation of 
isoform expression was associated with CpG islands sites where methylation 
occurs on the promoter of the ERG2 isoform particularly in T-ALL. Furthermore 
the study identified an isoform that lacked of exon 7b (called exon 12) in T-ALL 
patients, suggesting the use of specific signalling pathways associated with the 
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change in transactivation of ERG that this splicing event leads to (Bohne et al., 
2009).  
More recently in a subtype of ALL, B-progenitor ALL (B-ALL) a novel ERG 
isoform was shown to be activated by the binding of the DUX4, a transcription 
factor commonly rearranged and overexpressed in B-ALL. The novel ERG 
isoform used exon 7b (called exon 6 in this study) as its first exon and inhibited 
the activity of native ERG (Zhang et al., 2016).This proposes there is an ongoing 
need to establish a better understanding of the role of ERG in leukaemia and 
the study of alternative splicing of ERG particularly in the context leukaemia 
merits immediate attention. 
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1.3.2.3 Prostate cancer 
The discovery of the TMPRSS2-ERG fusion gene, found in a remarkable 
proportion i.e. 50% of PCa cases, was reported by Tomlins et al. (2005). The 
TMPRSS2-ERG fusion gene occurs as a consequence of an interstitial deletion 
or translocation between ERG and the transmembrane protease serine 2 
(TMPRSS2) gene, which is found in three megabases (Mb) upstream of ERG 
and encodes for an androgen responsive serine protease (Tomlins et al., 2005). 
The mutation combines the promoter of TMPRSS2 and the coding region of 
ERG leading to the androgen responsive production of an ERG protein (Clark 
et al., 2007).  
The presence of the fusion gene has been associated with a poor prognosis, 
biochemical recurrence as indicated by levels of the PCa biomarker prostate 
specific antigen and decreased survival in patients (Wang et al., 2006; Mehra 
et al., 2007; Hu et al., 2008; J. Wang et al., 2008; Yoshimoto, Joshua and 
Cunha, 2008; Gopalan et al., 2009). There is an abundance of evidence 
demonstrating that ERG promotes pro-tumorigenic processes and signalling 
pathways in PCa (King et al., 2009; Bock et al., 2013). It is important to note 
that ERG is not significantly expressed in normal prostate epithelial cells 
(Mohamed et al., 2010). Inappropriate expression is observed frequently in 
prostatic intraepithelial neoplasia (PIN), a precursor tumour lesion that can 
develop  into malignant PCa (Tomlins et al., 2008; King et al., 2009). There is 
evidence to suggest that ERG targets genes that increase the motility and 
invasiveness of PCa tumour cells therefore aiding the progression of the 
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disease (J. Wang et al., 2008; Rickman et al., 2010; Wu et al., 2013; Tian et al., 
2014).  
C-X-C Motif Chemokine Receptor 4 (CXCR4), a chemoreceptor whose 
chemokine is stromal cell derived factor 1 (SDF1), is transcriptionally activated 
by ERG and mediates increased cell invasion and metastasis specifically to 
bone tissue (Singareddy et al., 2013). Invasiveness is also promoted via the 
involvement of ERG with matrix metalloproteases and WNT- signalling (Butticè 
et al., 1996; Brase et al., 2011; Wu et al., 2013). Moreover ERG affects EMT by 
promoting the loss of VE-cadherin and epigenetic regulation of migration via 
histone deacetylase 6 (Mohamed et al., 2011; Birdsey et al., 2012).  
In addition to this it has been suggested that the loss of phosphatase and tensin 
homologue (PTEN), which is associated with Protein kinase B (called AKT) 
overexpression, may play a role in the initiation of PCa. PTEN is a tumour 
suppressor gene that supresses AKT under normal physiology and is very 
frequently mutated in human cancers. AKT is part of a signalling pathway that 
promotes cell survival and proliferation (Carver et al., 2009; Squire, 2009). 
Several studies suggest that the concomitant loss of PTEN and the presence of 
TMPRSS2-ERG are also associated with PCa progression, aggressive disease 
and a poor prognosis (Carver et al., 2009; Leinonen et al., 2013; Barbieri et al., 
2013; Figure 2). This may be because ERG may repress PTEN when bound to 
its promoter (Adamo et al., 2017). 
Moreover, now EWS is thought to be essential to the role of ETS transcription 
factors in PCa tumorigenesis. Kedage et al. (2016) revealed a crucial role for 
EWS interaction with ERG in the tumorigenesis of PCa. This was shown to be 
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true when the N terminus of EWS was fused to ERG but a EWS interaction 
domain in the C terminus of ERG was also validated, which when mutated, 
reduced cell migration and colony formation ability. The interaction between the 
two proteins was shown to be required for transcriptional activity. Furthermore, 
when EWS was knocked down or the EWS interaction domain in ERG was 
mutated, there was a significant reduction in transcription of target genes. This 
data would suggest the EWS is a crucial co-activator of ETS transcription 
factors including ERG target genes (Kedage et al., 2016). 
Contrastingly other large cohort investigations have found no significant 
correlation between TMPRRS2-ERG and poor prognosis or disease 
progression. Gopalan et al. (2009) found that although TMPRSS2-ERG positive 
patients did overexpress ERG, the fusion gene was associated with low grade 
tumours and there was no association with outcome. They also suggested that 
associations with poor outcome may be due to general aneuploidy often found 
in cancer patients. Another study looked at the histological pathology of prostate 
tumour samples expressing TMPRSS2-ERG and found that samples positive 
for the rearrangement had a lower Gleason score in comparison to those 
without (Fine et al., 2010). Therefore, there is some debate as to whether the 
gene rearrangement can be used as a diagnostic or prognostic marker. 
It is important to note that the diversity of TMPRSS2-ERG variants including 
those due to alternative splicing means it is not always possible for all ERG 
isoforms to be expressed. Both ERG and TMPRSS2 are alternatively spliced 
and accordingly there are various combinations that can occur between the two 
genes and consequently several TMPRSS2-ERG fusion variants exist. Indeed 
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recent estimates show that there are nearly 20 TMPRSS2-ERG variants (Clark 
et al., 2007; Zammarchi, Boutsalis and Cartegni, 2013). The most common 
variant is a hybrid of exon 1 of TMPRSS2 and exon 4 of ERG often referred to 
as T1:E4 (Clark et al., 2007). The protein product of each variant is either type 
I ERG, a near full length product with the ETS domain, or the truncated protein 
lacking the ETS domain known as type II ERG (Clark et al., 2007; Rastogi et 
al., 2014).  
Interestingly Hagen et al. (2011) examined the expression of exon 7 and 7b in 
PCa patient samples. The splice isoform ratios of exon 7 and exon 7b inclusion 
and exclusion were compared in benign tissues, T2 localised tumours and stage 
T3a and T3b cancer tumour and, advanced stage tumours. The study reported 
that both exon 7 and 7b are increasingly included as disease progresses 
(Hagen et al. 2014). As previously detailed, studies using prostate cancer cell 
lines identified more oncogenic behaviour in ERG splice variants that included 
this 72 base pair exon which encodes part of the AD (J. Wang et al., 2008; Yin 
et al., 2011) and may therefore encourage the transcription of pro-tumorigenic 
genes.  
Therefore, the clinical manifestations associated with the presence of a fusion 
gene may not always be present in every patient as may be the case, for 
example, if the TMPRSS2 promoter region is not activated or functional. 
Furthermore some ERG splice isoforms are non-coding and may not produce 
an ERG protein at all (Zammarchi, Boutsalis and Cartegni, 2013). This is why it 
is important to measure ERG expression in combination with clinical outcomes 
as this is a more reliable measure of fusion effect on PCa status.  
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1.3.3 Function of ERG 
Compared to other ETS transcription factors ERG is highly expressed in 
endothelial cells, and significant research has revealed the several important 
roles that ERG supports in endothelial development and function (Baltzinger, 
Mager-Heckel and Remy, 1999; Hollenhorst, Jones and Graves, 2004; 
Nikolova-Krstevski et al., 2009). As the mouse embryo develops, endothelial 
cells, haematopoietic and cartilage tissue all express ERG (Mohamed et al., 
2010). In humans other tissue that express ERG include chondrocytes 
(Iwamoto et al., 2000), both B and T lymphocytes, myeloid cells and 
megakaryocytes (Rainis et al., 2005). ERG is generally a nuclear protein but 
the ERG8 isoform was shown to localise to the cytosol (Hoesel et al., 2016).  
1.3.3.1 ERG as an activator and repressor of transcription 
In an in vivo mouse model for haematopoiesis ERG was shown to be a positive 
regulator of the RUNX1 and GATA2 genes. The expression of both genes was 
downregulated when functional ERG was knocked down and ERG was 
observed to occupy enhancer sequences in the promoters of both genes in 
foetal liver where expression of these genes was high. This regulatory pathway 
was shown to be vital to maintaining haematopoietic stem cells and thus 
embryonic development  (Taoudi et al., 2011).  
Vascular endothelial (VE)-cadherin regulates the integrity of the endothelial 
layer affecting cell growth and permeability of the cell layer. Data from a 
chromatin immunoprecipitation (ChIP) assay of the vascular endothelial (VE)-
cadherin promoter demonstrated that ERG binds the promoter and further 
evidence from a transactivation assay showed increased transcriptional activity 
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at the promoter as a result of this binding (Birdsey et al., 2008). Further research 
revealed that ERG-dependent regulation of VE-cadherin affects vascular 
stability, that is the control of endothelial cell cytoskeleton and junction integrity, 
and angiogenesis through the canonical Wingless-related integration site (Wnt) 
signalling pathway (Birdsey et al., 2015). 
Leukocyte recruitment and adhesion is important in inflammatory disease and 
has been shown to be influenced by the expression of intercellular adhesion 
molecule 1 (ICAM-1) and vascular cell adhesion molecule (VCAM) as well as 
the cytokine interleukin-8 (IL-8). ERG directly binds to the ICAM-1 promoter and 
represses gene transcription suggesting an anti-inflammatory role for ERG. 
Repressed expression of IL-8 and VCAM was also observed. This was shown 
to be the case in vivo using a murine model where inflammation was induced 
by causing swelling the paws of mice. Normally tumour necrosis factor α (TNFα) 
stimulates inflammation and upregulates ICAM-1 gene expression. However 
when ERG was overexpressed inflammation was reduced in a TNFα –
dependent manner (Sperone et al., 2010). 
1.3.3.2 Function of ERG exon 7b isoforms 
The importance of ERG exon 7b was suggested quite early in the genes 
discovery. The exon was one of the first alternative exons identified in the full 
length protein then called p55 (Prasad et al., 1994) and the first study that 
investigated the role of the transactivation domains also carried out 
mutagenesis in this exon (Siddique et al., 1993). Owczarek and colleagues 
(2004) were one of the first to map out main human ERG variants but this was 
followed by a more detailed study by Zammarchi and colleagues in 2013. 
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Although both studies identified the 72 bp exon, one called it exon 12 
(Owczarek) whilst the other called it exon 7b (Zammarchi, Boutsalis and 
Cartegni, 2013). In this study the Zammarchi et al. naming system will be used. 
However, studies use variable naming systems and where a different one is 
used clarification will be made.  
In chicken there are two main isoforms of ERG, chERG that when expressed 
includes all three exons in the 222 base pair (bp) variable region (these exon 
are exon 7 (81 bp), exon 7b (72 bp) and exon 8 (69 bp)). The other main isoform 
is C-1-1 which lacks exon 7. This variant has been cloned and characterised 
across several organisms (Baltzinger et al. 1999). In developing epiphyseal 
chondrocytes of chicks, the C-1-1 variant is preferentially expressed, and 
overexpression of this variant imparts stabilizing and anti-maturation abilities to 
the cells when compared to chERG (Iwamoto et al. 2000).  
The function of the mouse isoform of ERG C-1-1 isoform was later examined. 
Transgenic mice which were made to conditionally express the human C-1-1 
ERG variant displayed severe morphological abnormalities in skeletal 
development, although it is important to note that observations were made in 
E18.5 embryos due to the lethality of the ERG phenotype to mice at birth. The 
transgenic mice embryos were generally smaller with hypomineralised 
skeletons when compared to wild type embryo littermates. Transgenic embryos 
also showed poor cellular organisation, absent growth plates, abnormal 
chondrocyte morphology as well as decreased expression of gene markers 
associated with maturation (Pacifici et al. 2006). All of these findings reveal a 
crucial role for ERG in the development of the articular chondrocyte structures 
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and suggest that ERG may be a potential target for the development of new 
anti-arthritic intervention development therapies. 
To better understand the biological role of the various splice isoforms of 
TMPRSS2-ERG expression a study by Wang et al. (2008) transiently expressed 
several TMPRSS2-ERG transcripts in PNT1a prostatic epithelial cells which do 
not normally express ERG. They particularly focussed on exon 7b (denoted 
72bp for this in the study) and found that the VCaP cell line expressed the type 
III isoform of TMPRSS2-ERG (exon 1 of TMPRSS2 bound fused to exon 4 of 
ERG) +/- exon 7b. Their finding showed that inclusion of exon 7b increased 
proliferation, increased invasive ability invasion (as assessed by the Matrigel 
assay), and increased motility (assessed using the wound healing assay). 
Although they were able to confirm that all isoforms can form heterodimers and 
homodimers, the isoforms including exon 7b bound significantly more protein 
suggesting that this the exon imparts an increased potential for exhibited 
stronger protein-protein interactions (Wang et al. 2008).  
High Gleason score and recurrence of the tumour in PCa has been associated 
with high expression of prostate specific membrane antigen (PSMA). Similar to 
the TMPRSS2-ERG fusion protein, PSMA is found to be overexpressed in 
around 50% PCa cases. TMPRSS2-ERG fusions decrease PSMA expression 
at the mRNA level in VCaP and an inverse correlation between the expression 
of ERG fusion and PSMA was confirmed by increased expression of PSMA with 
RNAi ERG knockdown mediated by RNA interference. Type III and VI 
TMPRSS2-ERG fusions +/- exon 7b were transfected into LNCaP cells and 
mRNA levels were quantified using real time PCR. PSMA mRNA levels were 
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generally higher in the + exon 7b isoforms both in the presence and absence of 
the synthetic androgen R1881. However, PSMA luciferase activity was lower in 
type III + exon 7b compared to type III – exon 7b but higher in type VI + exon 
7b compared to type VI – exon 7b, with the lowest overall activity found in type 
VI – exon 7b transfected cells (Yin et al. 2011). Thus, the study showed that the 
overexpression of specific TMPRSS2-ERG variants decreased PSMA levels, 
presenting new potential targets for treatment. This data suggests PSMA and 
ERG work cooperatively and broadens the potential targets and pathways that 
can be manipulated for treatment. 
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1.4 Aims of this Study 
The aim of this study was to gain an understanding of the biological function of 
the ERG exon 7b splice isoforms and how the inclusion of this exon is regulated. 
The rationale for focusing on this cassette exon was based on the literature that 
indicates that its inclusion makes ERG more oncogenic. Exon 7b adds, in frame, 
24 amino-acids to the transactivation domain a crucial part of ERG that 
influences its interactions and transcriptional activity. Presumably this splicing 
event leads to the selective expression of the full transactivation domain and is 
a specific mechanism for altering ERG activity. To explore this hypothesis, the 
project will used splice switching oligonucleotides to reduce exon 7b inclusion 
and therefore ablate the expression of the full transactivation domain isoforms 
of ERG. Upon successful achievement of exon skipping a series of functional 
assays were performed to characterise the oncogenic potential of the isoforms 
expressed in the cell model.  
The factors that regulate oncogenic splicing events have been identified for 
several human genes and  Furthermore a part of the project concentrated on 
identifying potential splice factors that play a regulatory role in the alternative 
splicing of exon 7b in ERG.  
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2 Materials and 
Methods 
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2.1 Cell Lines 
MOLT4 (obtained from ECACC, Public Health England), CMK, TK6 and K562 
(kindly provided by Dr Ruth Morse) cells were grown in RPMI media 
supplemented with 10% foetal bovine serum (FBS) and 4mM L-glutamine at 
37°C, 5% CO2 in a humidified incubator. Cells were sub-cultured every 2-3 
days.  
MG63 cells (kindly provided by Dr Jason Mansell) were grown in DMEM 
supplemented with 10% FBS at 37°C, 5% CO2 in a humidified incubator and 
sub-cultured every 3- 4 days. Where serum starvation was required cells were 
cultured in DMEM:F12 supplemented with essential amino acids. 
2.1.1 Cell counting and viability assessment 
Cells were counted using a haemocytometer using the Trypan Blue exclusion 
assay to determine viability. A 10μL aliquot of cell suspension was diluted 1:1, 
1:3, 1:5 or 1:10 depending on cell confluence with 0.4% Trypan Blue and loaded 
into the haemocytometer. The haemocytometer was observed on a light 
microscope using a x10 objective. Dead cells appeared blue as they took up 
the trypan blue dye whereas viable cells appeared bright and unstained. Viable 
cells and total cells were counted and viability was determined using the 
following equation:   
   % 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠)
(𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠)
 × 100   
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2.2 Cell treatments 
Phorbol myristate acetate (PMA) is a highly potent activator of protein kinase C. 
Changes in the downstream signalling pathways has been observed to increase 
the expression of several transcription factors. K562 and TK6 cells, which do 
not ordinarily express ERG, were treated with 15nM PMA for 72 hours to assess 
if the expression of ERG could be induced. All experiments also included a 
dimethyl sulfoxide (DMSO) control for which cells were treated with 0.5% DMSO 
as this was the maximum amount of DMSO ever used for each experiment. 
2.3 Designing and using splice switching oligonucleotides 
Splice switching oligonucleotides (SSOs) were designed, with assistance from 
Dr Lee Spraggon (Memorial Sloan Kettering, USA) complementary to the DNA 
sequence of the 3’ and 5’ splice site of the ERG gene as taken from the Ensembl 
Genome Browser (http://www.ensembl.org/index.html). All Vivo-morpholinos 
were manufactured by Gene Tools, LLC. An antisense morpholino was 
designed against the both the 5′ and 3′ splice site of ERG exon 7b. The 
antisense sequence of the ERG 7b 5′ss SSO (E7b5) 5′- 
UCCGGUCCAUGCUUUUGUGGGGACA -3′ and for ERG 7b 3′ss (E7b3) is 5′-
AAGGAAAACAGACGTCCCCCACGUC-3′. The sequence for the control SSO 
(designed by Gene Tools, LLC), targeting position 705 in the beta-globin mRNA, 
is 5′-CCTCTTACCTCATTACAATTTATA-3′. Stocks of each Vivo-morpholino 
were made in sterile PBS at a concentration of 0.5 mM. Each SSOs has an 
octaguanidine dendrimer moiety to facilitate delivery for cellular uptake meaning 
no transfection reagent is required and the SSOs are added directly to cell 
medium. 
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2.4 RNA extraction 
Total RNA was extracted using the Absolutely RNA Miniprep Kit (Agilent 
Limited) according to the manufacturer’s protocol. Samples were DNase treated 
on-column using kit provided RNase-free DNase I.  
For samples containing less than 500,000 cells RNA was extracted using the 
genesig easy DNA/RNA extraction kit (Primerdesign) and DNase treatment was 
performed with the Precision DNase kit (Primerdesign) according to 
manufacturer protocols. 
RNA preparation for quantitative PCR was carried out using a phenol chloroform 
based method as follows. Cells were lysed in lysis buffer (0.1 M Tris pH 8.0, 5 
mM EDTA pH 8.0, 0.1 M NaCl, 0.5% sodium dodecyl sulfate (SDS), 1% β 2-
mercaptoethanol was added just before use) and homogenised using a 21-23 
gauge needle and syringe. An equal volume of UltraPure™ 
Phenol:Chloroform:Isoamyl Alcohol (25:24:1, v/v) (Thermofisher) was added to 
each sample. Samples were vortexed thoroughly and spun at maximum speed 
on a bench top centrifuge (13,000 x g) for 5 minutes. The aqueous phase was 
removed and put into a fresh tube. An equal volume of chloroform was added 
to the sample which was then vortexed and incubated at room temperature for 
2-3 minutes. The samples were then centrifuged at 12,000 x g for 15 minutes 
at 4°C. This process was repeated.  
Two volumes of ice-cold ethanol was added with a 1:10 dilution of 3M sodium 
acetate (pH 5.2) and the sample were placed in a -80°C freezer for a minimum 
of 30 minutes up to overnight or a -20°C freezer for a minimum of 1 hour up to 
 Materials and Methods 
Samantha Jumbe- June 2019   77 
overnight to precipitate the RNA pellet. The samples were then centrifuged at 
12,000 x g for 30 minutes at 4°C. The RNA pellet was washed in ice cold 
ethanol, excess ethanol was aspirated and then the pellet was left to air dry. 
Pellets were resuspended in nuclease-free water. To remove gDNA 
contamination an appropriate volume of 10x DNase reaction buffer and 2U of 
DNase I (New England Biolabs, NEB) was added to the sample which was then 
incubated at 37°C for 10 minutes. To deactivate the DNase EDTA to a final 
concentration of 5mM was added and the sample was incubated at 75°C for 10 
minutes. 
All RNA samples were quantified using a Nanodrop 2000 (Thermofisher) and 
aliquots were made prior to cDNA synthesis and storage at -80°C. 
2.5 cDNA synthesis 
Between 150-2000ng of total RNA was used to synthesise cDNA using the 
Precision nanoScript2 Reverse Transcription kit (Primerdesign) according to 
manufacturer’s protocol with the following modifications. Samples that would be 
used for qPCR were spiked with 4ng of RNA sequence for the small RUBisCO 
subunit of Arabidopsis thaliana in order to normalise gene expression. To prime 
the reactions 0.5 μL each of oligo dT and random nonamer primers were used.  
The qPCR spike was made by as follows. A cDNA plasmid clone for the small 
RUBisCO subunit of Arabidopsis thaliana (U13397, from The Arabidopsis 
Information Resource) was cultured in selective medium and a maxi preparation 
was made to yield adequate plasmid. The plasmid was linearised and 
sequenced to confirm its identity. The linearized plasmid (1μg) was in vitro 
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transcribed using 30U T3 RNA polymerase with 50U RNase inhibitor, rNTP mix 
(2 mM final concentration), 10 μL 5x transcription buffer made up to a 50 μL 
reaction volume with nuclease-free water. The reaction was incubated at 37°C 
overnight before the in vitro transcribed RNA was purified using the phenol: 
chloroform method described above. The RNA was DNase treated, further 
purified using the phenol: chloroform method, quantified using the Nanodrop 
2000 and the final concentration was adjusted to make 10 μL aliquots with 1μg 
of RNA in each. These were stored at -80°C. 
2.6 Standard PCR and Gel Electrophoresis 
Hot Start Taq 2X master mix (NEB) was used for standard PCR reactions to 
determine gene expression. Reactions were set up at room temperature with 1-
2μL undiluted cDNA template and had a final reaction volume of 25 µL. The 
sequences for the primers in the appendix. The annealing temperature was 
calculated using the NEB Tm calculator (available on 
https://tmcalculator.neb.com/#!/main). The final concentration for each primer in 
the reaction was 0.4µM. PCRs were run as follows: initial denaturation 95°C for 
30 seconds, then 30-40 cycles of 95°C for 30 seconds, the annealing 
temperature for 1 minute, 68°C for 1 minute and a final extension at 68°C for 5 
minutes. The PCR samples were stored a 4°C until they could be run on an 
agarose gel. 
Agarose gels (1-2%) were made and stained with 5µL Midori Green Advance 
DNA stain (Geneflow) for every 100mL of TAE. Samples were loaded using 
purple 6X gel loading dye (no SDS) (NEB) and were run at 100V for 40-60 
minutes. Splice isoform ratios were be determined by using the ImageStudio 
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Lite software (Licor, available from https://www.licor.com/bio/products/ 
software/ image_studio _lite/).  The percent spliced in (PSI) was calculated by  
𝑃𝑆𝐼 =
𝑠𝑖𝑔𝑛𝑎𝑙 𝑓𝑜𝑟 𝑠𝑝𝑙𝑖𝑐𝑒 𝑖𝑠𝑜𝑓𝑜𝑟𝑚 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡
𝑡𝑜𝑡𝑎𝑙 𝑠𝑖𝑔𝑛𝑎𝑙 𝑓𝑜𝑟 𝑎𝑙𝑙 𝑠𝑝𝑙𝑖𝑐𝑒 𝑖𝑠𝑜𝑓𝑜𝑟𝑚𝑠
 × 1 
2.7 Isolating and Sequencing PCR products 
PCR bands were excised under UV light. The QIAquick Gel Extraction kit 
(Qiagen) was used to purify the PCR products for sequencing according to the 
manufacturer’s protocol. Samples were sent to Eurofins Genomic Service for 
sequencing. The sequencing results for ERG can be found in the appendix. 
2.8 Quantitative PCR 
Quantitative PCR was used to measure gene expression. Template cDNA (pre-
diluted as indicated in figures) was amplified using Precision FAST MasterMix 
with ROX (Primerdesign), 0.4 μM forward primer, 0.4 μM reverse primer and 
made up to 10μl using nuclease-free water. The cycling conditions comprised 
DNA denaturation for 3 minutes at 95°C and amplification repeated for 40 cycles 
at 95 °C for 15 seconds and 58-60 °C for 30 seconds. All PCR efficiencies were 
above 95%. Real-time PCR were performed using the StepOnePlus 
thermocycler (Applied Biosystems) and the results were analysed using 
StepOne Software version 2.3. The normalisation and quantification protocol 
can be found in the appendix. 
2.9 RNAi high-throughput RT-PCR screen 
The RNAi high-throughput RT-PCR screen was carried out by RNAomics 
Platform at University of Sherbrooke to determine the change in PSI as a result 
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of RNA binding protein knockdowns. This assay amplifies full length and exon 
7b skipped ERG isoforms using cDNA from 56 RNA binding protein siRNA 
knockdowns that have been carried out in MCF-7 cells. A lipofectamine 
transfection reagent control (siCTRL) was included for each set of knockdowns. 
The analysis of alternative splicing was determined using endpoint PCR 
coupled with microcapillary electrophoresis. PSIs were then calculated and the 
change in PSI (PSI) was determined by the following formula:  
ΔPSI =
𝑃𝑆𝐼 𝑠𝑖𝑅𝑁𝐴
𝑃𝑆𝐼 𝑠𝑖𝐶𝑇𝑅𝐿
 × 1 
PSI and calculated ΔPSI values for all 56 siCTRL and siRNA MCF7 cell samples 
tested are included in the appendix. Any PSI values with no useable control or 
an error were not included in analyses. 
2.10  Protein isolation and preparation 
Cells were washed twice with ice-cold PBS, and whole cell protein lysates were 
prepared using an appropriate volume of RIPA buffer (10 mM Tris-Cl (pH 8.0), 
1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS and 140 
mM NaCl) supplemented with protease inhibitor tablets (ThermoFisher). After a 
30 minute incubation, with periodical vortexing, lysates were centrifuged for 15 
min at 12,000 x g at 4°C for clarification. Samples were transferred to fresh 
tubes and quantified using the bicinchoninic acid (BCA) kit (Thermofisher) and 
a bovine serum albumin protein standard curve.  
To prepare MOLT4 nuclear protein lysate using a method by Yu, Huang and 
Lung (2013). Briefly cells pellets were washed twice in PBS before addition of 
the subcellular fractionation buffer. Cells were lysed in the buffer and incubated 
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on ice for 30 minutes. This was followed by centrifugation and the leftover pellet 
(the nuclear fraction) was sonicated in a nuclear lysis buffer. The lysate was 
quantified using the BCA kit, aliquoted and stored at -80°C. 
2.11 SDS-PAGE and Immunoblotting 
Immunoblotting was carried out using 10 to 20μg of total cell lysate. Samples 
were added to 2x Laemelli Sample Buffer and heated for 5 minutes at 100 °C. 
Proteins were separated by hand cast SDS-polyacrylamide gel electrophoresis 
(PAGE) or TruPAGE™ Precast Gels and electro-transferred to polyvinylidene 
difluoride (PVDF) membrane (Thermofisher). The membranes were blocked for 
1 hour at room temperature using 5% skimmed milk powder made in Tris-
buffered saline with 0.1% Tween-20 (TBST) then probed with primary 
antibodies against target proteins diluted in TBS-T overnight at 4 °C. The 
following antibodies used in this study: anti-ERG (1:500-1000, ab92513), anti-
beta-actin (1:10,000, ab8229), both antibodies were from Abcam. Following 
three TBST washes the membranes were then incubated with an appropriate 
HRP-linked IgG secondary antibody (1:2000, New England Biolabs) for 2 hours 
at room temperature. Following three TBST washes membranes were 
incubated in Luminata Forte Western HRP substrate (Millipore) for 
chemiluminescent detection for 2 minute prior to image acquisition using the 
Licor Odyssey Fc imaging system. 
2.12 RNA Pull-Down 
To determine proteins that associate with ERG exon 7b RNA an RNA pull-down 
experiment was performed using Pierce Magnetic RNA-Protein Pull-down kit 
(Thermofisher) following the manufacturers protocol. Firstly, 50 pmol synthetic 
 82  Samantha Jumbe- June 2019 
RNA oligonucleotide corresponding to the 3´ splice site of ERG exon 7b 
(gucuuuccuuuugucugcagGGGGUGCAGCUUUUAUUUUC, -20 to 20; 
ThermoFisher) was ligated with desthiobiotinylated cytidine bisphosphate at the 
3' end and then purified by ethanol precipitation. Subsequently, labelled RNA 
was bound to streptavidin magnetic beads at room temperature followed by 
incubation with 100 μg MOLT4 nuclear extract at 4 °C for 2 hours with agitation. 
After incubation, the magnetic beads were washed three times with wash buffer 
(20 mM Tris (pH 7.5), 10 mM NaCl, 0.1% Tween-20) and the bound proteins 
were eluted using biotin elution buffer. Bound proteins were separated by SDS-
PAGE and visualised by coomassie blue staining. Following imaging of gels, 
bands were excised using sterile scalpels and sent off for trypsin digestion prior 
to mass spectrometry analysis (Proteomics Facility, University of Bristol). The 
list of proteins identified using mass spectrometry can be found in the appendix. 
2.13  siRNA knockdown of splice factors 
RNAi was used to knockdown protein levels for candidate splice factors to 
establish if they have a role in regulating the expression of ERG exon 7b. MG63 
cells (5 x 105 in 500 µL per well) were seeded in DMEM media without serum 
in a 12 well plate. For each well 20nM of siGENOME Human SMART pool 
siRNA solution (Dharmacon) was added to 200µL of DMEM without serum and 
mixed well before 6 µL of Lipofectamine RNAiMax transfection reagent 
(ThermoFisher) was added. All siRNA were a pool of four siRNA to increase 
efficacy of knockdown and a pool of non-targeting siRNA was included as a 
control. The solutions were vortexed for 10 seconds and incubated at room 
temperature for 10 minutes. These solution were then added to the cells drop 
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wise and the plate was gently swirled. After 4.5 hours of incubation at 37°C 1mL 
of complete DMEM media was added. After 24 hours cells were sub-cultured 
into T-25 flasks for a further 24 hours at which point RNA and protein were 
isolated from the cells.  
2.14  Resazurin cell viability assay 
The conversion of resazurin is carried out by enzymes in viable cells and can 
be measured colorimetrically. The activity of the metabolic enzymes within the 
cells allow for the assessment of both cell viability and proliferation. A 10mg/mL 
stock solution of resazurin was used to make a fresh working stock at 
0.04mg/mL concentration every two weeks. All stocks were made in PBS. The 
resazurin reagent was added 1:10v/v to cells treated wells as well as to negative 
control wells (made up to the equivalent of the media volume) 2-4 hours prior to 
the end of the experimental incubation period in order to assess cell viability. 
The plates were then read at 570nm and 630nm in a plate reader (FLUOstar 
OPTIMA, BMG Labtech) to obtain readings for cell viability determination. The 
following equation was used to determine the percentage reduction of resazurin 
to resofurin.  
% reduction of resazurin =
(Eoxi630 × A570) – (Eoxi570 × A630) 
(Ered570 × C630) – (Ered630 × C570)
× 100  
 Eoxi630= molar extinction coefficient (E) of oxidised resazurin reagent at 
630nm = 34798  
 A570 = absorbance of test wells at 570nm 
 Eoxi570 = E of oxidised resazurin reagent at 570nm = 80586 
 A630 = absorbance of test wells at 630nm 
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 Ered570 = E of reduced resazurin reagent at 570nm = 155677 
 C630 = absorbance of negative control well (media, resazurin reagent, 
no cells) at 630nm 
 Ered630 = E of reduced resazurin reagent at 630nm = 5494 
 C570 = absorbance of negative control well at 570nm 
The percentage viability was determined by correcting the other percentage 
reductions against the media only or PBS treated cells which were considered 
to be 100% viable. 
2.15  Immunofluorescence analysis of Ki-67  
Ki-67 is a nuclear protein that is expressed in all active stages of the cell cycle 
and can be used as a proliferation marker as high expression of the protein are 
found in proliferating cells. MG63 cells were treated with SSOs or PBS in flat 
bottomed 6 well plates for 48 hours and 72 hours. The media was removed and 
cells were washed three times in PBS. The cells were then fixed in 3.7% 
paraformaldehyde for 15 minutes at room temperature. The paraformaldehyde 
was discarded, and after three PBS washes, a solution of 0.1% Triton X-100 
was applied for 5 minutes to permeabilise the cells. The cell layer was blocked 
in 3% FBS solution (in PBS) for 30 minutes at room temperature followed by 
incubation in a 1:200 dilution of Ki-67 primary antibody (Abcam, ab15580) made 
up in blocking solution for 2 hours. Three PBS washes were then followed by 1 
hour incubation with the Alexa 568 fluorophore conjugated secondary antibody 
(Thermofisher, #A10042, 1:2000) made in 3% FBS in the dark, three PBS 
washes, a 2 minute incubation in 2 μg/mL Hoechst 33342 and storage in PBS. 
Images of six representative fields of view per treatment were acquired using 
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the using the 20x objective on the Eclipse 80i microscope (Nikon). An image 
using the Texas red fluorescent filter and the 4′,6-diamidino-2-phenylindole 
(DAPI) filter setting were taken for each field of view.  
2.16  Caspase 3/7 assay 
The process of apoptosis has two main pathways; the intrinsic and extrinsic 
pathway. These pathways converge at the activation of effector caspases which 
are a type of protease (Lamkanfi and Kanneganti, 2010). Measurement of the 
activity of caspase 3 and 7 allows reveals cells that are committed to the final 
events of the apoptotic process as the cleavage of substrates by caspase 3 and 
7 initiates key structural and biochemical changes cell. 
After seeding in 6 well plates, MG63 cells were treated with SSOs or PBS for 
48 hours and 72 hours and 45 minutes prior to the end of the incubation period 
the Cell Event Caspase 3/7 reagent made in pre-warmed PBS was added to 
cells. Images of 6 fields of view per treatment were taken using the 20x objective 
on the Eclipse 80i microscope. An image using the green fluorescein 
isothiocyanate (FITC) fluorescent filter and the phase contrast setting were 
taken for each field of view.  
2.17 Transwell invasion and migration assay 
Tumour cells migration and invasion is a characteristic of a advancing disease 
in malignancy and in vitro investigation of a cells capacity for mobility is a useful 
indicator of oncogenicity. Invasion requires that a cells pass through a barrier 
which in the assay is a layer of basement membrane components. Cell 
migration is also an indicator of a cells motility a characteristic that contribute to 
its invasive ability.  
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For the invasion assay polyethylene terephthalate inserts (membrane pore size, 
8 μm; Millipore) were coated with 50uL of Geltrex® Matrix (ThermoFisher) 
diluted 1:1 in serum-free medium for at least 2 hours and up to 24 hours to 
create an artificial basement membrane to facilitate cell invasion. Uncoated 
inserts were used for the migration assay. Inserts were set up in 24 well plates 
for both migration and invasion assays. MG63 cells were treated with SSOs or 
PBS for 24 hours and then were harvested. Subsequently 1 × 105 cells in 100 
μL serum-free medium was added to the upper chamber of the insert with 
(invasion) or without (migration) Geltrex® Matrix and 600 μL of medium 
supplemented with 10% FBS was added to the lower chamber of a 24-per well. 
Following 24 hours of culture at 37 °C, the cells remaining on the upper 
membrane of the insert were removed and inserts were washed in PBS. After 
15 minutes fixation in methanol and 2 minutes staining with haematoxylin the 
inserts were air dried prior to imaging of six representative fields of view using 
a camera attached to a light microscope (x20 objective). The number of cells 
adhering to the lower membrane of the inserts was counted. All experiments 
were carried out in triplicate. 
2.18  Alkaline Phosphatase assay 
Alkaline phosphatase activity increases during osteoblast maturation and can 
reliably be measured by the generation of p-nitrophenol (p-NP) from p-
nitrophenylphosphate (p-NPP) under alkaline conditions. Cells were seeded 
into 96 well plates and starved in phenol red-free, serum-free DMEM:F12 
medium overnight. The relevant wells were dosed with 3μM of SSOs or PBS 
and incubated for 24 hours. Subsequently a phosphatase resistant analogue of 
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lysophosphatidic acid (LPA), (3S)1-fluoro-3-hydroxy-4-(oleoyloxy)butyl-1-
phosphonate (FHBP) and calcitriol, the active metabolite of vitamin D3 (1,25D), 
were added to the relevant wells as well as an additional dose of SSO to 
maintain the expression of ERG exon 7b skipped isoforms. Following another 
24 hour incubation resazurin reagent was added to treated wells as well as to 
empty control wells 2-4 hours prior to the end of the incubation period in order 
to assess cell viability. The plates were then analysed to obtain readings for cell 
viability determination. 
The resazurin reagent was removed and the monolayers were washed for 5 
minutes in fresh phenol red-free DMEM:F12 media to remove the residual 
resazurin and its metabolites. Following this, the medium was removed and the 
monolayers lysed with 50 μL of lysis buffer (25mM sodium carbonate (pH 10.3) 
and 0.1% (v/v) Triton X- 100). After 2 minutes, each well was treated with 100 
μL of 15mM p-NPP (di-Tris salt, Sigma, UK) in 250mM sodium carbonate (pH 
10.3), 1mM MgCl2. The cell culture plates were then placed in an incubator at 
37°C for 1 hour. After the incubation period the cell culture plates were 
transferred to the plate reader, and an ascending series of p-NP (10–500 μM) 
controls prepared in the incubation buffer were added to empty wells on the 
plate to enable quantification of product formation. The absorbance was read at 
405 nm. Reported total alkaline phosphatase activity was corrected to the cell 
viability determined using the resazurin assay for each well. 
2.19 Chromatin immunoprecipitation assay  
Chromatin immunoprecipitation was used to determine if ERG interacts with the 
promoter of the alkaline phosphatase gene and was performed using the Imprint 
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Chromatin Immunoprecipitation Kit (Sigma, UK) according to the 
manufacturer’s protocol. Briefly, 1x106 MG63 cells were incubated for 10 
minutes with 1% formaldehyde at room temperature to allow DNA to be cross-
linked to the protein. Cells were then lysed and DNA sheared to produce 
fragments of about 1000bp using a sonicator  six pulses for 15 seconds at 50% 
power output followed by incubation on ice for 60 seconds after each pulse. The 
DNA-protein mixture was incubated with in well of a cell culture plate coated 
with either 3μg of anti-ERG antibody (Santa Cruz, UK), 1μg RNA polymerase II 
antibody or 1μg non-specific IgG at room temperature for 3 hours. This was 
followed by six washes with the IP wash buffer. The cross-linked DNA-ERG 
complexes were released using Proteinase K at 65°C for 15 minutes. The DNA 
was cleaned up and eluted using GeneElute Binding Colum (Sigma, UK). PCR 
was then carried out using primers shown in the appendix for ALPL. 
2.20 Xenograft mouse model and in vivo tumour growth 
The xenograft mouse model was used as an in vivo model to measure the 
effects of a ERG SSOs on malignant growth. Two-month-old male nude mice 
(CD1; Charles River, USA) were housed under pathogen-free conditions. All 
animal operations were approved by the Animal Ethics Committee of University 
School of Exeter. Six mice were used for each experimental group and the 
experiment was repeated three times (a total of 18 mice per experimental 
group). MG63 cells were harvested, counted and resuspended in PBS.  
To establish tumours mice MG63 cells (7 x 106) were injected subcutaneously 
with a 27- gauge needle under general anaesthesia (inhalation of isoflurane 
allowed to reach 3mm by 3mm in size. Once tumours reached this size 
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12.5mg/kg of SSO or PBS was administered by intraperitoneal injection into the 
mouse twice weekly. Health checks were performed daily, body weight was 
measured using scales and tumour sizes were measured using vernier callipers 
on dosing days. Once tumours reached 12mm in one direction, mice were culled 
under Schedule 1 procedure and tumours harvested. These experiments were 
conducted by Dr Sean Porazinski in collaboration with Dr Sebastian Oltean at 
the University of Exeter.  
2.21   Bioinformatic analysis  
2.21.1 Databases used for expression analysis  
The Genotype-Tissue Expression (GTEx) Project was used to assess ERG 
expression across in human tissues. GTEx is supported by the Common Fund 
of the Office of the Director of the National Institutes of Health, and by NCI, 
NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses 
described in this thesis were obtained from the GTEx Portal on 25 June 2018. 
The Encyclopedia of DNA Elements (ENCODE) database  was accessed via 
the UCSC Genome browser to assess ERG exon 7b in various human derived 
cell lines (Kent et al., 2002; Rosenbloom et al., 2012; Raney et al., 2014).  
2.21.2 Gene sequence annotation 
Gene and amino acid sequences were obtained from GenBank 
(http://www.ncbi.nlm.nih.gov/genbank/) or Ensembl and annotated using Snap 
Gene Viewer (software can be downloaded from 
http://www.snapgene.com/products/snap 
gene_viewer/).  
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2.21.3 Sequence alignments 
Nucleotide and protein alignments of genes orthologous to the human ERG 
gene were carried out using Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) or MUSCLE (MUltiple Sequence 
Comparison by Log- Expectation) (https://www.ebi.ac.uk/Tools/msa/muscle/) 
and further annotation was carried out using MEGA6 (downloaded from 
http://www.megasoftware.net/). 
2.21.4 Prediction of splicing regulatory elements 
To predict for the presence of potential exonic splicing enhancer sequences 
present in exon 7b exon and flanking intronic sequence ESEfinder 3.0 
(http://krainer01.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home) 
and RESCUE-ESE (http://genes.mit.edu/burgelab/rescue-ese/) were used 
(Cartegni et al., 2003; Fairbrother et al., 2004; Smith et al., 2006). 
2.21.5 Splice factor binding prediction 
Bioinformatic tools were used to predict potential splice factor binding sites in 
and around the ERG exon 7b sequence. This analysis was carried using Splice 
Aid 2 (http://193.206.120.249/splicing_tissue.html) and the Splice Aid F 
database (http://srv00.ibbe.cnr.it/SpliceAidF/).  
2.22 Statistical Analysis 
All statistical analysis was performed using the GraphPad Prism 7 software. The 
Shapiro-Wilk test, the kurtosis value, the skewness value and distribution graph 
for each treatment group was used to assess normality. At least one treatment 
group for all experiments did not have normal distribution meaning non-
parametric tests were used. The Kruskal-Wallis (one-way analysis of variance 
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on ranks) non-parametric test was used to test for significant difference between 
groups. Multiple comparisons between different treatment groups were 
assessed using the Dunn’s test. Significance was a p-value of ≤0.05. 
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3.1 Introduction  
The aberrant expression of ERG in disease particularly PCa and 
haematological cancers is well established suggesting that the gene plays a key 
role in the development of these cancers. The overall expression patterns of 
ERG are well characterised and several databases and research papers 
provide information of both mRNA and protein expression levels in normal 
tissues (Iwamoto et al., 2000; Shon et al., 2015) and several cell lines (Reddy 
and Rao, 1991; Mohamed et al., 2010).  
The expansion and usability of RNA sequencing (RNA-seq) technology has 
opened up a new era of transcriptome analysis allowing us to establish the 
changes in expression of specific splice variants of a gene in human tissues 
and cell lines in different conditions. According to the Genotype-Tissue 
Expression (GTEx) project data ERG is expressed at moderate levels in most 
tissues with highest levels of expression in arterial tissue. High ERG expression 
has also been observed in peripheral blood mononuclear cells, adipocytes, 
breast, prostate, lung, thyroid and spleen (Figure 3.1). Within the developmental 
context ERG is expressed including in haematological (Loughran et al., 2008) 
and cardiovascular progenitor tissues and cells (Nikolova-Krstevski et al., 
2009). Expression of ERG exon 7b specifically in human tissues is limited to 
arteries, breast, ovary, cervix and adipose tissue all at comparable levels 
(Figure 3.2). This corresponds to tissues in which overall ERG expression is 
greater and suggests that the inclusion of this exon is particularly important in 
these tissues.  
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Figure 3.1 ERG expression in human tissues according to the Genotype-
Tissue Expression project (GTEx) 
Differential ERG expression across human tissues (x-axis). For each box the 
middle line is the median expression and outliers are shown as circles. The y-
axis is reads per kilobase transcript per million (RPKM) and x-axis shows the 
different human tissues, those in red have the highest expression levels. The 
graph was obtained from the GTEx Browser 
(http://www.gtexportal.org/home/).  
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Figure 3.2 ERG exon 7b expression in human tissues (GTEx) 
Data from GTEx portal showing the mRNA expression of ERG exon 7b (exon 
13 in this figure) is shown in the column highlighted in red. Each column 
represents an exon as shown in the ERG gene model at the bottom of the 
figure (exon 7b shown in the red box). The exon nomenclature used by GTEx 
varies to the one used in this thesis (Zammarchi, Boutsalis and Cartegni, 
2013), however the exon size and position are equivalent. The colour gradient 
scale is the median read count per base where the more intense the blue 
colour the more reads per base and therefore the higher the expression. Grey 
indicates tissues for which no expression data is available. The human tissues 
(on the right hand side panel) in which exon 7b are expressed are shown in 
red.  
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There has been significant focus on the understanding the importance of the 
fusion genes that are formed by ERG namely TMPRSS2-ERG in PCa (Tomlins 
et al., 2008), FUS-ERG in leukaemia (Panagopoulos et al., 1994) and EWS-
ERG in Ewing sarcoma (Sorensen et al., 1994) but not much attention has been 
given the differential expression of ERG splice isoforms or splicing events 
(Hagen et al., 2014; Hoesel et al., 2016). Increasingly the significance of the 
generation of splice variants of several oncogenes via the process of alternative 
splicing has been shown to contribute to the development, maintenance and 
progression of the malignant phenotype. Therefore identification and 
characterisation of the expression of these splice isoforms is the foundation of 
better understanding their contribution to a specific disease and thus deciding 
their potential as a clinical marker. 
3.1.1 Modification of alternative splicing using splice switching 
oligonucleotides (SSOs) 
Splice switching oligonucleotides (SSOs) are a type antisense oligonucleotide 
(ASO); agents that utilise Watson-Crick base-pairing to inhibit gene expression 
(Aartsma-Rus and van Ommen, 2007). As RNA is transcribed into protein the 
use of ASO technology to modulate protein expression and production has been 
explored for some decades now as a potential therapeutic strategy. However, 
translation from bench top to clinic has been slow as issues with ASO chemistry, 
deliver and side effects have posed challenges. Encouragingly recent 
breakthroughs have been made. With improved ASO design and delivery 
solutions several clinical trials are ongoing and there is even a therapeutic ASO 
being used to treat patients.  
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The main challenges that come with using RNA oligonucleotides are their rapid 
degradation, insufficient uptake, poor biological distribution and poor target 
affinity (Shen and Corey, 2018). To overcome this, modifications to the 
nucleotide structure are made to the oligonucleotide to improve its 
pharmacokinetic properties. The non-bridging phosphodiester oxygen can be 
replaced by sulphur to make a phosphorothioate (PS) which is more resistant 
to nuclease digestion and increases binding to serum proteins facilitating 
systematic circulation and chances of successful uptake (Eckstein, 2014; Figure 
3.3Error! Reference source not found.A).  
Other common modifications are to the 2´ ribose where the 2´-hydroxyl group 
is replaced. Common substitutions are 2´-O-methyl, 2´-O-methoxyethyl and 2´-
O-fluoro. As the 2´-hydrdoxyl is a site of nuclease attack the replacement of this 
moiety increases stability as well as increasing bonding affinity. The structural 
similarity of these 2´ modified ASOs to RNA means that RNase H does not 
cleave the hybridise molecules formed between the two and therefore these 
ASOs are popularly used to change alternative splicing (Prakash, 2011).  
The SSOs used in this study are specifically antisense morpholino 
oligonucleotides. The structure of these ASOs mimics natural nucleic acids but 
have a 6-membered sugar ring in their backbone and non-charged 
phosphorodiamidate linkages instead of the phosphate linkages found in DNA 
and RNA molecules (Figure 3.3A). These structural modifications contribute to 
the biological stability, improved affinity and solubility of morpholinos (Morcos, 
2007).  
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Figure 3.3 Antisense oligonucleotide chemistry and mode of action 
A. The structure of a normal phosphodiester can be modified to produce ASO 
structures such as phosphorothioates and phosphodiamidate morpholinos. Sites 
of modification are circled in blue. B. SSOs are able to bind to intron-exon 
boundaries and block splice factors to cause exon skipping or inclusion. 
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On top of this the lack of charge means morpholinos do not significantly interact 
with proteins and assists with their easy delivery to biological models in vitro 
(Morcos, 2007). The method of delivery of ASOs does depend on the tissue and 
disease. Although PS ASOs can be delivered without a delivery moiety or 
reagent, high concentrations in the micromolar (μM) rather than nanomolar (nM) 
are required and the cost of such concentrations are quite high. In terms of 
formulation most ASOs can be made up in saline and indeed this is how they 
tend to be delivered in clinics (Shen and Corey, 2018). To counteract this 
transfection reagents can be to assist with delivery but these are associated 
with increased toxicity and are not translatable to the clinic. The morpholinos 
(Vivo-Morpholinos) used in this study have an octaguanidine dendrimer moiety 
that facilitates uptake and removes the requirement for transfection reagent 
facilitating in vivo delivery (Morcos, Li and Jiang, 2008). However, the 
recommended in vitro dosage is still relatively high at 1-10 μM as opposed to 
the ideal nM concentrations. 
ASOs can be target nucleic acids using several mechanisms. Inhibition of 
translation via activation of RNase H activity or steric hindrance by microRNA 
or regulatory non-coding RNA inhibition, and modulation of alternative splicing 
via blockage of cis- or trans-acting elements (Aartsma-Rus and van Ommen, 
2007; Schoch and Miller, 2017; Shen and Corey, 2018). SSOs work to 
encourage exon inclusion or exclusion by binding to pre-mRNA molecules and 
affecting splice factor recognition (Figure 3.3B). Development of an SSO 
requires identification of an appropriate disease linked splicing event, design 
and validation of several oligonucleotides near the intron-exon boundary to 
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identify the most efficient ones. Target sites can also be SRE such as ESEs and 
ISEs which have been shown to be able to significantly modulate the splicing of 
an exon (Aartsma-Rus and van Ommen, 2007). 
Beta-thalassaemia was one of the first conditions to have SSOs used to restore 
normal phenotype (Suwanmanee et al., 2002). Indeed much focus on 
therapeutic ASOs has been in the neurological conditions such as Duchenne 
muscular dystrophy (DMD) and famously spinal muscular atrophy (SMA) 
however interest in cancer treatment is beginning to increase (Bauman, 
Jearawiriyapaisarn and Kole, 2009). Mutations in the survival motor neuron 1 
(SMN1) gene are the cause of SMA. Although humans have a paralogue gene 
survival motor neuron 2 (SMN2), the 11 nucleotides that vary in exon of the 
gene produce a truncated protein that is degraded. Therefore, patients are 
unable to produce sufficient SMA protein. Spinranza®, also called ISIS 396443, 
restores SMN level in patients by blocking an hnRNPA1/A2 ISS causing exon 
7 inclusion in SMN2 and leading to the synthesis of more functional protein. 
Intrathecal injections directly into the cerebrospinal fluid following lumbar 
puncture allows for optimum uptake into the target neuron sites (Prakash, 
2017). 
In terms of cancer, targets continue to be discovered and tested. Myeloid cell 
leukaemia-1 protein has two alternatively spliced isoforms, a long isoform that 
is anti-apoptotic and a shorter apoptotic isoform. ASOs were used in a skin 
basal cell carcinoma cell line to shift Mcl-1 splicing to the short isoform and 
induce apoptosis (Shieh et al., 2009). Some cancer related target proteins have 
been taken forward to clinical trials. The human oncogene eukaryotic translation 
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initiation factor 4E (eIF4E) is dysregulated in several cancers including 
colorectal cancer. The protein assists in the translation of cell survival genes. 
The ASO called ISIS183750, was initially used in cell lines and reduced eIF4E 
expression and proliferation. Success in the lab led to the ASOs against eIF4E 
being used in a clinical trial to treat patients with advanced colorectal cancer. 
The ASO was tested on its own and in combination with irinotecan 
chemotherapy (or its active component). Irinotecan works by interacting with 
DNA-topoisomerase I complexes disrupting DNA replication in S phase of cell 
cycle driving cells to apoptose. Both phase 1 and phase 2 patients had anti-
proliferative profiles after both ASO and combination therapy. Samples 
collected from patients showed reduced eIF4E mRNA levels but protein 
remained unaffected. The research group suggested that the reason for these 
observations may be an increased binding of the ASO to the stroma or levels of 
eIF4E binding proteins. What did also clearly improve was survival with median 
progression-free survival of 1.9 months and median overall survival of 8.3 
months based on an 11.4 month follow up period (Duffy et al., 2016).  
This results chapter aims to establish the evolutionary importance of exon 7b 
by analysing its sequence conservation in orthologues. In addition it will analyse 
the expression of exon 7b according to RNA sequencing data from the cancer 
genome atlas (TCGA) and the Encyclopedia of DNA Elements (ENCODE) 
consortium. Lastly it will demonstrate how the expression of exon 7b can be 
altered by splice switching oligonucleotides (SSO). These SSOs induce exon 
7b skipping by blocking access to the splice sites for the exon. 
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3.2 ERG exon 7b is evolutionarily conserved in ERG 
orthologues 
The conservation of ETS transcription factors in metazoa is well established 
(Degnan et al., 1993). In the case of the ERG protein family predicted members 
have been identified in nematode and sea urchin species (Degnan et al., 1993; 
Rizzo et al., 2006). It is important to state at this point that most often 
conservation analysis was based on the identity with the ETS domain, though 
pointed domain conservation has also been analysed (Mackereth et al., 2004). 
With this in mind an analysis was carried out to determine the conservation of 
ERG exon 7b in order to determine when it may have emerged during evolution, 
as this would indicate when its presence became biologically significant. Initially 
an alignment of amino acid sequences of the main ERG isoforms identified in 
the NCBI database was performed to determine which isoforms include and 
exclude ERG exon 7b (Figure 3.4). It was found that all isoforms except ERG2, 
ERG5 and ERG8 included exon 7b. ERG6 and ERG7 encode for proteins that 
have a truncated C-termini lacking the ETS domain and therefore most likely 
lack DNA binding function. ERG4 and ERG5 had truncated N termini but the 
truncation does not affect the pointed domain.  
To aid subsequent analysis predicted serine residues that are known to be 
phosphorylated were identified to establish which ones arose earliest, are best 
conserved and therefore of most potential functional importance. These serine 
residues are annotated with an asterisks in all alignments. Two of these 
residues are located in the transactivation domain with one in exon 7b. Within 
ERG isoforms two of the six serines are present across all isoforms analysed 
 Analysis of ERG exon 7b sequence and expression 
Samantha Jumbe- June 2019   105 
here. For three residues the lack of presence of the relevant amino acids rather 
than substitutions is the reason why they are not present in all isoforms. One 
residue sees an S to R substitution in ERG7 although the alignment is not 
particularly strong for this part of the sequence.  
Upon this analysis all subsequent alignments to human (Homo sapiens) were 
to ERG3 (termed hERG) which includes exon 7b and produced a protein 486 
amino acids in length. Next an alignment of the amino acid sequence of hERG 
and various vertebrate species was performed to establish the conservation of 
exon 7b (Figure 3.5). Isoforms similar in size to hERG3 were chosen in the 
vertebrate species to aid comparison. Evidence suggests that ERG exon 7b is 
highly conserved at the amino-acid level in vertebrates as are 4 of the 6 serine 
residues identified, including the residues in the transactivation domain. In 
addition the docking site for ERK (DEF) domain, an ERK and MAPK docking 
site, located in exon 7b was highly conserved. The DEF domain consensus 
sequence is FXFP where X represents any amino acid residue (Jacobs et al., 
1999). This domain is located upstream of the serine residue in exon 7b and is 
thought to be important in facilitating its phosphorylation (Selvaraj, Kedage and 
Hollenhorst, 2015). In summary evidence points to ERG exon 7b amino-acids 
being strongly conserved throughout evolution. 
With knowledge that ERG conservation has been established from humans to 
echinoderms we aimed to identify exon 7b in species within this phylum. Exon 
7b like sequences were identified in two species, the purple sea urchin 
(Strongylocentrotus purpuratus) and crown-of-thorns starfish (Acanthaster 
planci). Although the serine in exon 7b was not conserved the DEF domain was, 
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establishing this as a potentially important site within exon 7b and the 
transactivation domain overall (Figure 3.5). Similarly the serine upstream of 
exon 7b was present in starfish but not sea urchin ERG. Therefore it has been 
established that exon 7b was present as far back as the echinoderm lineage.  
Finally the overall conservation of ERG was investigated by scrutinizing the 
sequence conservation of the ETS domain in orthologous protein sequences 
present in the most primitive species. Figure 3.7 shows ERG-like proteins were 
found in a species as primitive as Amphimedon queenslandica, a marine 
sponge as well as two worm species (Priapulus caudatus and Saccoglossus 
kowalevskii) and a brachiopod (Ligula anatina). This provides further evidence 
of ERG conservation in metazoan possibly back to a common ancestor species. 
An ERG gene has not been reported in sponges and was identified in this 
analysis. 
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Figure 3.4 Amino acid alignment of human ERG protein isoforms 
A MUSCLE amino acid alignment of the main human ERG isoforms. NCBI 
protein database accessions numbers are as follows: ERG1 NP_891548.1, 
ERG2 NP_004440.1, ERG3- NP_001129626.1, ERG4 NP_001129627.1, 
ERG5 NP_001230358.1, ERG6 NP_001230361.1, ERG7 NP_001278320.1 
and ERG8 NP_001317954.1. Exon 7b (orange box) is excluded in three of the 
isoforms. Functional domains are indicated: pointed domain (green box), 
transactivation domain (underlined in purple) and ETS domain (red box). The 
sequences of the three alpha helices (underlined in orange) and four beta 
sheets (underlined in green) of the ETS domain are also labelled. Homologous 
regions with identical amino acid residues are box-shaded black and 
conserved amino acid substitutions in grey. Asterisks (*) are serine residues 
predicted to be phosphorylation site. 
 Analysis of ERG exon 7b sequence and expression 
Samantha Jumbe- June 2019   109 
 
 110  Samantha Jumbe- June 2019 
Figure 3.5 Amino acid alignment of ERG in representative vertebrate 
species 
A MUSCLE amino acid alignment of ERG (corresponding to human ERG3] from 
different vertebrate species. NCBI protein database accessions numbers are 
as follows: Homo sapiens (human) NP_001230357.1, Mus musculus (mouse) 
XP_489769.1, Loxodonta africana (elephant) XP_010596953.1, 
Ornithorhynchus anatinus (platypus) XP_007665373.1 Gallus gallus (chicken) 
XP_015155738.1, Chelonia mydas (green sea turtle) XP_007064464.1, 
Xenopus tropicalis (clawed frog) XP_012812010.1, Scleropages formosus 
(Asian arowana fish) XP_018611073.1 and Callorhinchus milii (ghost shark) 
XP_007907661.1. Exon 7b (orange box) contained a DEF domain (labelled and 
highlighted by a red box) which suggests a MAPK/ERK docking site. Functional 
domains are indicated: pointed domain (green box), transactivation domain 
(underlined in purple) and ETS domain (red box). Homologous regions with 
identical amino acid residues are box-shaded black and conserved amino acid 
substitutions in grey. Asterisks (*) are serine residues predicted to be 
phosphorylation sites. 
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Figure 3.6 Amino acid alignment of human ERG and echinoderm ERG 
isoforms 
A MUSCLE amino acid alignment of ERG isoforms from human versus two 
echinoderm species. NCBI protein database accessions numbers are as 
follows: Homo sapiens (human) NP_001230357.1, Strongylocentrotus 
purpuratus (purple sea urchin) and Acanthaster planci (crown-of-thorns 
starfish). Exon 7b (orange box) contained a DEF domain (labelled and 
highlighted by a red box) which is a MAPK/ERK docking site. Functional 
domains are indicated: pointed domain (green box), transactivation domain 
(underlined in purple) and ETS domain (red box). Homologous regions with 
identical amino acid residues are box-shaded black and conserved amino acid 
substitutions in grey. Asterisks (*) are serine residues predicted to be 
phosphorylation sites. 
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Figure 3.7 Amino acid alignment of ERG in primitive species 
A MUSCLE amino acid alignment of human ERG versus ERG-like proteins in 
four metazoan species. NCBI protein database accessions numbers are as 
follows: Homo sapiens (human) NP_001230357.1, Ligula anatine 
(brachiopod) XP_013389107.1, Priapulus caudatus (worm) 
XP_014673650.1, Saccoglossus kowalevskii (acorn worm) XP_006822774.1 
and Amphimedon queenslandica (marine demosponge) XP_019852323.1. 
Exon 7b (orange box) contained a DEF domain (labelled and highlighted by a 
red box) which is a MAPK/ERK docking site. Functional domains are 
indicated: pointed domain (green box), transactivation domain (underlined in 
purple) and ETS domain (red box). Homologous regions with identical amino 
acid residues are box-shaded black and conserved amino acid substitutions 
in grey. Asterisks (*) are serine residues predicted to be phosphorylation sites. 
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3.3 ERG exon 7b expression in prostate cancer  
The Cancer Genome Atlas (TCGA) is a publically available dataset of 
comprehensive genomic analysis of 33 types of cancer. The collaborative 
project between the National Cancer Institute (NCI) and National Human 
genome Research Institute (NHGRI) uses tumour and normal matched tissues 
from over 10,000 patients.  
Using data from TCGA, kindly provided by Dr Eduardo Eyras (Pompeu Fabra 
University & ICREA, Spain), the PSI of exon 7b in prostate adenocarcinoma 
(PRAD) patients was determined. PSI is a measure of the extent by which an 
exon is spliced in where 1 is complete inclusion and 0 complete exclusion. For 
the dataset analysed the cohort was made up of 243 samples and for each 
patient a normal tissue sample was taken alongside the tumour sample to allow 
for comparison. The tumours were given T scores which assess the size and 
extent of the tumour, where T2 is a tumour contained in the prostate, T3 a 
tumour that is extending out of the border of the prostate and T4 for tumours 
that have spread to other organs nearby.  
The mean PSI of ERG exon 7b in tumour patients was 0.711 with a range of 0-
1. Compared to normal tissue there is no significant difference in PSI in tumour 
(Figure 3.8A, p=0.233) or between the various tumour grades (Figure 3.8B, 
Figure 3.8p=0.4113). However due to the cohort size of the higher tumour grade 
group being smaller (5 patients for T4) the data may not be fully reflective of the 
population.  
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Figure 3.8 ERG exon 7b PSI values in prostate adenocarcinoma patients 
A. PSI values for ERG exon 7b in normal and PRAD tumour tissue from the 
TCGA. B. PSI values for ERG exon 7b according to tumour grade. The middle 
line represents the mean PSI value and error bars show 95% confidence 
intervals (95%CI). Number of patient samples= 243 
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3.4 ERG exon 7b is alternatively spliced in several malignant 
cell lines 
ERG is expressed in a number of haematological tissues but the rate of exon 
7b inclusion has not been examined in detail. To determine expression of ERG 
exon 7b isoforms in a range of haematological cell lines a standard PCR was 
performed to determine exon 7b inclusion rates.  
Of the seven cell lines tested four expressed ERG isoforms with and without 
exon 7b. K562 cells are chronic myeloid leukaemia derived cells and have 
previously been induced to express ERG after treatment with phorbol myristate 
acetate (PMA) as confirmed in this investigation (Rainis et al., 2005, Figure 3.9). 
When treated with PMA the lymphoblast like TK6 cell line did not express ERG. 
Most cell lines favoured exon 7b inclusion, as indicated by the PSI values, but 
an exception to this was the U937 cell line with a 0.43 PSI value suggesting 
almost equal ERG exon 7b isoform expression (Figure 3.9).  
To determine if K562 expression could be detected by more sensitive means 
RNA-seq data from the ENCODE consortium database was analysed via the 
UCSC Genome browser. In addition to K562 two additional cells lines were 
chosen, HUVEC (human umbilical vein endothelial cells), K562 and human 
embryonic stem cells (hESC). HUVEC cells have been used to study ERG in 
previous studies (Yuan et al., 2009; Birdsey et al., 2012). In the 2005 study by 
Rainis et al. the expression of ERG in K562 was determined using PCR which 
is not as sensitive as RNA-seq. Expression of ERG exon 7b was considerably 
high in HUVEC and hESC cells but was not detected in K562 (Figure 3.10), 
consistent with findings shown in Figure 3.9.  
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Figure 3.9 ERG exon 7b expression in haematological cell lines 
Expression of ERG exon 7b was determined in CMK (acute megakaryocytic 
leukaemia), U937 (histiocytic lymphoma), HL-60 (acute myeloid leukaemia), K562, 
RPMI 8226 (multiple myeloma), MOLT4 (T-cell leukaemia) and TK6 (lymphoblast) 
human cell lines. Cell pellets were used for RNA isolation and cDNA synthesis. K562 
and TK6 cells were treated with phorbol myristate acetate (PMA) to induce ERG 
expression. A standard PCR was carried out using primers that hybridise in the 
constitute exons 6 and 8 to detect skipping of exon 7b in mRNA. An actin cDNA 
control. PSI values indicate the degree of exon 7b skipping – lower values correlate 
with more skipping.   
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Figure 3.10 ERG RNA expression in human cell lines 
The top panel shows is a screenshot of UCSC Genome browser data for ERG. 
A density graph of signal enrichment for RNA sequencing data from the 
ENCODE project for hESC K562 and HUVEC cell lines shows the read density 
in reads per million (RPM) on y-axis and the nucleotide position on the x-axis. 
The main ERG isoforms of ERG are shown above the enrichment graphs, and 
include isoforms that do not express exon 7b. The bottom panel is a close up 
of the data for exon 7b with the exon sequence at the top and the signal for 
each base position in each cell line. 
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3.5 ERG exon 7b can be skipped with splice switching 
oligonucleotides (SSOs) targeted to the 5´ and 3´ splice 
sites 
To facilitate the functional investigation of ERG exon 7b, detailed in the next 
chapter, two SSOs were designed with the assistance of Dr Lee Spraggon 
(Memorial Sloan Kettering, USA) against the splice sites of the exon in order to 
induce its skipping. The position and sequences of these SSOs in relation to 
the exon and its flanking introns are shown in Figure 3.11. In order to account 
for effects of SSO transfection a control SSO was included in all experiments. 
This SSO is designed to correct the mutation found at position 705 in the beta-
globin mRNA present in human beta-thalassaemia patients’ reticulocytes. A 
PBS control equivalent to the maximum volume of SSO transfected was also 
included. 
The recommended range of SSO efficacy in vitro is 1-10 μM (GeneTools LLC, 
Oregon USA). Therefore with this in mind a titration of concentrations was 
carried out. Initially SSO were transfected into the MOLT4 cell line, a T-cell 
acute lymphoblastic leukaemia cell line. This cell line has previously been used 
to study the function of ERG (Thoms et al., 2011) and as seen in Figure 3.9 has 
a predisposition for exon 7b inclusion.  
Figure 3.12 A shows that the maximal dose of 10 μM is required to attain near 
complete exon 7b skipping. More effective of the two ERG SSOs is E7b3 with 
a PSI of 0.06 achieved at 10 μM as compared to the 0.34 PSI of E7b5. As 
expected the control SSO did not significantly alter exon 7b skipping. 
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As a dose of 10 μM is quite high an alternative cell line model was examined. 
Knowing that ERG is expressed in developing bone (Iwamoto et al., 2001, 
Iwamoto et al., 2000), the possibility that ERG may be expressed in the MG63 
osteosarcoma cell line was explored. The cell line was found to express both 
exon 7b skipped and included isoforms of ERG and this is the first reporting of 
MG63 being used to study ERG. Therefore an SSO titration was also carried 
out in this cell line. 
In contrast to the MOLT4 cell line much lower doses of ERG SSO were required 
to induce exon 7b skipping (Figure 3.12B). At 3 μM complete skipping of exon 
7b was achieved with E7b3 SSO (PSI=<0) whereas near complete skipping of 
exon 7b was observed with E7b5 SSO (PSI=0.22). More impressively even at 
1 μM the E7b3 SSO showed near complete exon 7b skipping (PSI=0.11). The 
dose of 3 μM is sufficient to cause skipping confirmed at the protein level after 
72 and 96 hours of treatment (Figure 3.12C). 
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Figure 3.11 Schematic of ERG exon 7b splicing pattern and SSO 
sequences used in this study 
A. Exon 6 to 8 of ERG and the sizes of each exon in base pairs (bp) are shown. 
The red bars show PCR primer positions and the light blue boxes the position 
of the SSOs. Three potential PCR products are produced, the full length (FL) 
product is 352bp long, the full length product with exon 7b skipped (FLΔ7b) is 
280bp. The rarer skipping of both exon 7 and 7b (FLΔ7b+7) produces an even 
smaller 199bp PCR product. B. SSO sequences used in this study are in light 
purple and the boundaries of exon 7b in light pink. Intronic sequence is in 
lowercase and exon sequence in uppercase letters. 
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Figure 3.12 Titration of ERG exon 7b SSOs in MOLT4 and MG63 cells 
A. MOLT4 cells were treated with control, E7b5 and E7b3 SSO at 1, 5 and 10 
μM for 48 hours. The PCR show exon 7b skipping is detectable at all doses 
but is best achieved at the highest dose of 10 μM. B. MG63 cells were treated 
with control, E7b5 and E7b3 SSO at 0.5, 1 and 3 μM for 48 hours. The PCR 
show exon 7b skipping is detectable at 1 and 3 μM. The level of exon 7 b 
skipping with E7b3 is much higher even at the 1 μM dose. N=2 C. MG63 cells 
were treated with control, E7b5 and E7b3 SSO at 3 μM for 72 and 96 hours. 
An ERG western blot was performed using whole cell lysate extracted after 
treatment. Exon 7b encodes 24 amino acids which give a difference of 2kDa 
in protein size between full length and exon 7b excluded ERG proteins. Actin 
is included as a loading control. N= 3. 
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3.6 Summary of findings  
A search of available isoforms on the NCBI GenBank database revealed that 
most ERG isoforms in humans include exon 7b with exception of ERG2, ERG5 
and ERG8. Analysis established exon 7b conservation in echinoderms 
suggesting an evolutionarily conserved importance in ERG biological function. 
Exon 7b was one of the first alternative exons described along with exon 7 
(Duterque-Coquillaud et al., 1993). These two exon encode for part of the AD; 
this domain is known to be required for ERG’s transcriptional activity and 
protein-protein interactions (Siddique et al., 1993; Carrère et al., 1998). The 
inclusion of the 24 amino-acids encoded by exon 7b is likely to modify ERG 
function in different developmental, physiological and disease contexts.   
The presence of a DEF domain in exon 7b suggests that it is involved in 
ERK/MAPK signalling pathways. This domain may facilitate post-translational 
modification at serine and threonine residues. The observed conservation of the 
DEF domain and serine residues, particularly the flanking serine residues in 
metazoa in ERG suggests that these are similarly important to modulating ERG 
transcriptional activity. ERK phosphorylates ERG at serine 215 which is 
upstream to the DEF domain in exon 7 (Selvaraj, Kedage and Hollenhorst, 
2015). Serine 215 is completely conserved in the metazoan sequences 
analysed in this study further suggesting that these two sites have important 
biological functions. 
In general there seems to be a preference to include exon 7b in the majority of 
cell lines examined. Of the cell lines for which RNA-sequencing data is available 
HUVEC cells showed the highest levels of exon 7b expression. The main 
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exception was the U937 cell line in which exon 7b was predominantly skipped, 
contrary to a previous study (Rainis et al., 2005) in which ERG was not seen to 
be expressed in U937.   
Tumours for PRAD patients from the large TCGA cohort showed a shift to 
inclusion of ERG exon 7b as disease stage progressed confirming the findings 
of Hagen et al. (2014). Exon 7b encodes for part of the AD and truncation of 
this domain reduces transcriptional activity; therefore the conservation and 
inclusion of the exon may be important in modulating ERG’s transcriptional 
activities. Increased inclusion in cancer may be linked to increasing the 
proportion of transcriptionally active ERG isoforms, contributing to disease 
progression. 
By pushing splice isoform ratios in one direction (i.e. skipping or inclusion) the 
contribution of exon 7b to biological function can now be assessed. However to 
design SSOs with reasonable efficacy can be challenging as the sequences 
that are blocked may not modulate the splicing machinery adequately. In this 
study SSOs designed against the splice sites of ERG exon 7b successfully 
caused near complete exon skipping, detectable in the mRNA of MOLT4 and 
MG63 cell lines. Better efficacy was observed with the 3´ splice site targeting 
SSO suggesting that the design of this SSO comparatively better reduced the 
spliceosome’s ability to include the exon. The SSO dose that induced exon 
skipping between the two cell lines differed with a higher dose required for the 
MOLT4 cells. This may be due to the MOLT4 cells being in suspension versus 
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the adherent MG63 cells. Furthermore the abundance of the mRNA in the two 
cell lines may vary as well. 
In summary this chapter has demonstrated the importance of ERG exon 7b 
through its evolutionary conservation. SSOs are now available to reduce exon 
7b inclusion, providing a valuable experimental tool to study the biological 
functions of this exon. The next chapter will describe a functional analysis of 
exon 7b, making use of these SSOs. 
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4.1 Introduction  
As a transcription factor the function of ERG is to regulate gene expression. The 
profile of its target genes will vary according to the cell type that ERG is 
expressed in and is likely to be controlled by external stimuli as well. 
Furthermore the alternative splicing of ERG creates different protein isoforms 
with, presumably, different abilities to regulate transcription. The latter is 
particularly relevant in cancer where dysregulated signalling pathways are 
driven by the overexpression of oncogenes and tumour suppressor genes such 
as ERG.   
Most studies that have looked at ERG isoform function in cancer have focussed 
on the TMPRSS2-ERG fusion variants. Overall the presence of these isoforms 
is hypothesised to drive the development and progression of prostate in an 
androgen responsive manner as the overexpression of the fusion gene leads to 
the overexpression of oncogenic ETS target genes such as CXCR4 and ADAM 
metallopeptidase with thrombospondin type 1 motif 1 (ADAMST1) (Seth and 
Watson, 2005; Carver et al., 2009). TMPRSS2-ERG fusion isoforms can be type 
I (which encode full length ERG that has an ETS domain) or type II (encode 
ERG without and ETS domain) (Hu et al., 2008). Of the two ERG exon 7b is 
included in type I variants only. Changes in motility, proliferation, invasion and 
apoptosis both in vitro and in vivo has been shown to be affected by the 
combination of 5´ fusion junction and coding exons of TMPRSS2-ERG variants 
and generally the isoforms that include exon 7b were more oncogenic (J. Wang 
et al., 2008; Zammarchi, Boutsalis and Cartegni, 2013; Urbinati et al., 2015).  
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More recently a study by Hoesel et al. (2016) studied native ERG isoform 
localisation and function focussing on the role of the nuclear localisation 
sequence (NLS), nuclear export sequence (NES) and ETS domain. Findings 
revealed that all isoforms could shuttle between nuclear and cytosolic 
compartments but the ERG8 isoform that lacked the NLS and ETS domain 
localised to the cytosol mainly whereas other isoforms were predominantly 
nuclear. In addition ERG8 may act as a transcriptional inhibitor of the active 
ERG isoforms studied (ERG1-4). Finally qRT-PCR was used to determine the 
differential expression of isoforms in four cancer cell lines vs non- cancer cells. 
Non-cancer cells had a greater ratio of active ERG isoforms to ERG8 compared 
to cancer cell lines.  
With an established body of evidence that ERG splice isoforms have variable 
biological functions the aim of this chapter is to establish the biological function 
of the ERG exon 7b in a cancer cell line model. MG63 osteosarcoma cell line 
SSOs will be used to induce ERG exon 7b skipping after which cell growth, 
proliferation, apoptosis, invasion and migration will be assessed. In addition as 
a measure of cell differentiation alkaline phosphatase, liver/bone/kidney 
(TNSALP) activity will be determined and the expression of bone maturation 
genes will also be assessed.  
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4.2 SSO-induced ERG exon 7b skipping alters cell growth in 
MG63 cells  
Initially the effect of SSO-induced exon 7b skipping on cell growth was assessed 
by monitoring cell numbers over time after SSO treatment. For each time point 
cells were seeded into a 12 well plate at 104 cells per well, and treated with 3μM 
of SSO or PBS as a control. Cells were re-dosed with SSO at the 96 hour time 
point. After 24, 48, 72, 96 and 168 hours cells were collected and counted using 
the trypan blue exclusion assay to determine the number of live cells. RNA and 
protein were then isolated from these samples to determine the degree of exon 
skipping at each time point. Three biological repeats were assessed. Cell 
growth was significantly inhibited in SSO treated cells (Figure 4.1). After 168h 
both E7b5 and E7b3 SSO treated cells exhibited significantly reduced growth 
when compared to the control SSO (Figure 4.1, p<0.0001, in both instances).  
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Figure 4.1 Growth curve of MG63 cells treated with ERG exon 7b SSO 
MG63 cells were dosed at time zero and again at 96 hours with 3 μm of SSO. A. 
The Trypan blue assay was used to determine cell number at each time point. 
(**** p≤0.0001). Error bars show 95%CI. B. RNA was isolated in order to run PCR 
to confirm ERG exon 7b skipping at each time point. N=3 
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4.3 SSO-induced ERG exon 7b skipping alters cell proliferation 
in MG63 cells  
A defining feature of cancer development is dysregulated proliferation 
(Hanahan & Weinberg, 2011). ERG is a regulator of key growth receptors and 
factors required for cellular proliferation (Stankiewicz and Crispino, 2013; 
Urbinati et al., 2015). Initially a comparison of proliferation between tumour and 
normal tissue was determined using the proliferative index which was 
determined for PRAD patients from the TGCA database. This index was 
developed by assessing the expression of proliferation genes, shortlisted from 
microarray, gene ontology and gene expression studies across many tissues 
and developmental stages (Sandberg et al., 2008). The values which range 
between 0 and 1 represent the proportion of genes in this gene set that are 
above median expression for each patient. Tumour tissue samples were shown 
to have a higher mean proliferation index of 0.8172 than normal control tissue 
of 0.6612 (Mann-Whitney, p<0.0001). 
Therefore two assays were used to evaluate the effects of manipulating ERG 
exon 7b splicing on cell proliferation. The resazurin assay measures the 
reducing potential of a cell. The blue non-fluorescent resazurin is reduced to 
resofurin, which is pink and fluorescent by mitochondrial reductases and other 
metabolic enzymes such as NADPH dehydrogenase. These facilitate the 
reduction of resazurin by transferring electrons from NADPH + H+. The colour 
change can be monitored either colorimetrically and the more proliferating cells 
are present the greater the reduction observed (Rampersad, 2012).   
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Cells were seeded into a 96 well plate (104/well) and treated with SSO (3μM) 
for 48, 72 and 96 hours. Two to four hours prior to the end of the time point the 
resazurin reagent was added. A microplate reader was used to measure the 
colorimetric changes compared to a control (of resazurin with no cells). The 
percentage difference in proliferation in comparison to the PBS control was 
determined.  For each time point five biological repeats were assessed. After 
48 hours of SSO treatment no significant changes in proliferation were detected 
(Figure 4.3). However 72 and 96 hours after SSO treatment significant changes 
were detected. For the 72 hour time point, E7b3 SSO treatment reduced cell 
proliferation (p<0.0001) more significantly than E7b5 SSO treated cells 
(p=0.0485) when compared to the control SSO (Figure 4.3C-D). Similar 
observations were made 96 hours post SSO (Figure 4.3E-F).  
Another method to assess proliferation is by measuring the expression of Ki-67, 
a protein highly expressed in actively dividing cells. After SSO treatment cells 
were fixed, permeabilised and stained with primary and fluorescent secondary 
antibody in cell culture plates to permit detection using fluorescent microscopy. 
Counterstaining with DAPI allowed co-localisation analysis of Ki-67-positive 
foci. Three biological repeats were assessed.  
Figure 4.4 shows after 72 hours of SSO treatment there is a reduction in Ki-67 
positive foci in both E7b5 and E7b3 treated cells indicating a decrease in 
proliferation (p=0.0012 and p=0.0036, respectively). The observations 
demonstrate that the exclusion of exon 7b by SSOs reduces proliferation in 
MG63 cells. 
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Figure 4.2 Proliferation index of PRAD patients from TCGA database 
The proliferation index is a gene-expression based measure of proliferation and 
the values for normal and tumour tissue from the PRAD patients from the TCGA 
are shown. The middle line represents the mean and the error bars are 95%CI. 
(****p≤0.0001 Number of samples=243 
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Figure 4.3 Proliferation of MG63 cells following SSO treatment 
The resazurin assay was used to measure cell proliferation in MG63 cells 
treated with 3 μM SSOs for A. 48 hours C. 72 hours and E. 96 hours. The 
graphs shows the percentage difference of proliferation for each treatment in 
relation to the PBS control which is considered to be 100% proliferation. 
(*p≤0.05, **** p≤0.0001). Error bars show 95%CI. B, D, F. ERG exon 7b 
skipping was confirmed by PCR. N=5. 
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Figure 4.4 Ki-67 expression in MG63 cells following 72 hours of SSO       
treatment 
A. After 72 hours of treatment with 3μM SSO Ki-67 expression was determined 
using immunofluorescent microscopy to measure proliferation. Top panel: Ki-67 
foci. Bottom panel: overlay with DAPI. Arrows indicate Ki-67 positive foci under 
the Texas red filter (top panel) and merged Texas red and DAPI filter (bottom 
panel). Scale bar = 40 μm.  B. Graph represent the fold change in Ki-67 foci 
positive cells when compared to the PBS control. **p=0.01. Error bars show 
95%CI.  C. ERG exon 7b skipping was confirmed using PCR. N=3 
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4.4 SSO-induced ERG exon 7b skipping induces apoptosis in 
MG63 cells 
The ability to undergo programmed cell death (apoptosis) is often inhibited in 
cancer cells. Some cancer treatments are based on the induction of apoptosis. 
Several genes that regulate apoptosis are ERG targets; for example, VE-
cadherin (Birdsey et al., 2008). VE-cadherin works via interactions with VEGF 
receptor 2 and β-catenin to prevent apoptosis by modulating the balance of pro- 
and anti-angiogenic factors in endothelial cells. The integrity of cell-cell 
junctions is degraded due to a reduction of ERG which interferes with signal 
transduction to VE-cadherin and other pathways and increasing pro-apoptotic 
factors such as Bcl-2 (Mallat and Tedgui, 2000).  
Therefore apoptosis levels were investigated by assessing expression of 
caspase 3 and caspase 7 using the CellEvent Caspase 3/7 green detection 
reagent. The reagent labels apoptotic cells by staining their DNA with a 
fluorescent nucleic acid binding dye. A short peptide cleavage site sequence for 
caspase 3/7 is conjugated to the dye; in this state it remains non-fluorescent 
until it is cleaved by caspase 3/7 allowing it to bind DNA. The dye can then be 
detected using a FITC filter set.  
Following 48 hours and 72 hours SSO treatment the caspase3/7 reagent was 
added 45 minutes prior to the end of the treatment time point. The experiment 
was carried out in triplicate. Images in six fields of view were taken to estimate 
the number of caspase3/7 positive cells. Results were expressed as a 
percentage of the total number of cells. At both time points three biological 
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repeats were assessed. The data presented in are fold change ratio of caspase 
3/7 positive cells compared to the PBS control. 
Both ERG exon 7b targeting SSOs induced significantly increased levels of 
caspase3/7 at both time points (Figure 4.5; Figure 4.6). Compared to the control 
SSO after 48 hours of treatment E7b3 SSO resulted in a 10.9 fold increase in 
apoptosis (p<0.0001) and at 72 hours of treatment the fold increase was even 
greater (182.8, p<0.0001). For the E7b5 SSO an increase in apoptosis was also 
observed when compared to control SSO after both 48 hours and 72 hours of 
treatment (4.8, p=0.0323 and 143.8,p=0.0006 respectively) although it was not 
as large an increase as obtained with the E7b3 SSO. The difference between 
the two treatments was statistically significant at the 48 hour time point 
(p=0.0234) but not at 72 hours. 
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Figure 4.5 Caspase 3/7 expression following 48 hours of SSO treatment in 
MG63 cells 
A. Caspase 3/7 positive foci were quantified using immunofluorescent microscopy 
to determine apoptosis in MG63 cells following treatment with 3μM SSO. Arrows 
identifying caspase 3/7 foci under FITC filters (top panel) and merged FITC and 
phase contrast images taken under a x20 objective. Scale bar = 40 μm. B. Graphs 
represent the fold change in caspase 3/7 positive foci quantified when compared to 
the PBS control. (***p≤0.001, ****p≤0.0001). Error bars show 95%CI. C. ERG exon 
7b skipping was confirmed using PCR. N=3 
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Figure 4.6 Caspase 3/7 expression following 72 hours of SSO treatment in 
MG63 cells 
A. Caspase 3/7 positive foci were quantified using immunofluorescent microscopy 
to determine apoptosis in MG63 cells following treatment with 3μM SSO. Arrows 
identifying caspase 3/7 foci under FITC filters (top panel) and merged FITC and 
phase contrast images taken under a x20 objective. Scale bar = 40 μm. B. Graphs 
represent the fold change in caspase 3/7 positive foci quantified when compared to 
the PBS control. (***p≤0.001, ****p≤0.0001). Error bars show 95%CI. C. ERG exon 
7b skipping was confirmed using PCR... N=3 
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4.5 SSO-induced ERG exon 7b skipping alters cell migration in 
MG63 cells  
Migration was assessed using the transwell assay. Transwell inserts were set 
up in triplicate into the wells a 24 well plate. In this assay cells were pre-treated 
with SSO for 24 hours before addition to the inserts in serum free medium. 
Treatment was also carried out in serum free medium. A chemotactic gradient 
was created by addition of DMEM media with 10% FBS in the wells below the 
inserts. The transwell set up was incubated for 24 hours prior to collection, 
washing, fixing and staining of the inserts. Images of several fields of view of 
the bottom of the inserts were taken to assess cell number per insert. Three 
biological repeats were assessed. When compared to the control SSO 
treatment both E7b5 and E7b3 SSO treatment significantly reduced cell 
migration (Figure 4.7; p=0.0022 and p=0.0062, respectively). No significant 
change was seen between both ERG exon 7b-specific SSOs.  
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Figure 4.7 ERG exon 7b skipping causes reduction in MG63 cell migration 
Following 24 hours of SSO treatment the transwell migration assay was carried 
out to measure migration after a total of 48 hours of SSO treatment. Cells were 
counted on images taken of the bottom of the filters using a x20 objective on a 
light microscope. A. The arrows indicate cells in representative images of the 
filters. The darker spots and transparent circles visible are pores in the filters. 
Scale bar= 40 μm. B. Graphs represent the fold change in cell numbers when 
compared to the PBS control. (**p≤0.01). Error bars show 95%CI. C. ERG exon 
7b skipping was confirmed using PCR. N=3 
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4.6 SSO-induced ERG exon 7b skipping alters cell invasion in 
MG63 cell  
The modification of the transwell inserts using Geltrex, a basement membrane 
matrix, to mimic a cell basement medium allowed for the investigation of the 
effect of exon 7b skipping on cell invasion. The inserts were pre-coated with 
Geltrex to form an even thick layer for the cells to invade. The rest of the 
experimental set up and image acquisition was the same as for the transwell 
migration assay. Three biological repeats were assessed. Figure 4.8 shows that 
treatment with E7b5 SSO significantly reduced cell invasion (p<0.001) and the 
mean fold change was lower for E7b3 SSO (0.35; p<0.0001). 
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Figure 4.8 ERG exon 7b skipping causes reduction in MG63 cell invasion 
Following 24 hours of SSO treatment the transwell invasion assay was carried 
out to measure migration after a total of 48 hours of SSO treatment. Cells were 
counted on images taken of the bottom of the filters using a x20 objective on a 
light microscope. A. The arrows indicate cells in representative images of the 
filters. The darker spots and transparent circles visible are pores in the filters. 
Scale bar= 40 μm. B. Graphs represent the fold change in cell numbers when 
compared to the PBS control. (***p≤0.001). Error bars show 95% CI. C. ERG 
exon 7b skipping was confirmed using PCR. N=3. 
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4.7 ERG exon 7b skipping reduces tumour growth in an MG63 
xenograft mouse model 
To investigate the in vivo efficiency of ERG exon 7b targeting SSO a mouse 
xenograft model was established. Mice were injected intraperitoneally with 12.5 
mg/kg of control or E7b3 SSO which showed best efficacy in vitro, over a 63 
day period. Tumour volume, tumour weight and the body weight of the mice was 
also measured over the time course of treatment. Six mice were used per 
treatment group and the experiment was repeated three times.  
Although findings show a reduction of both tumour weight and volume, this was 
comparably similar between the control and E73b SSO and not statistically 
significant. The control SSO treated cells had an intermediate phenotype with a 
tumour volume smaller than the PBS tumours but greater than the E7b3 SSO 
treated tumours, suggesting that the chemistry of the SSOs may need to be 
revised to define if tumour growth inhibition observed is specific to exon 7b and 
not related to the toxicity of SSO chemistry. Body weight stayed fairly consistent 
between the treatment groups and over the time course of the experiment. It is 
important to stress that this data is preliminary but is proof of principle that 
indicates that the SSO may be effective in slowing down tumour growth in vivo. 
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Figure 4.9 Growth of MG63 xenograft mouse model tumours treated with 
ERG exon 7b SSO 
A. Tumour weights B. tumour volume and C. body weight of MG63 xenograft 
mouse model treated with 12.5mg/kg of control and E7b3 SSO for a 63 day 
period. An untreated PBS mouse cohort was also included. Mice were dosed at 
each time point seen on the graph. 
 Function of ERG exon 7b splice isoforms 
Samantha Jumbe- June 2019   149 
4.8 SSO-induced ERG exon 7b exon skipping alters TNSALP 
activity in MG63 cells in a time-dependent manner  
TNSALP expression can be used as a marker of cell differentiation in osteoblast 
and their derivative cells such as MG63 (Rutkovskiy, Stensløkken and Vaage, 
2016). Co-treatment with the active vitamin D metabolite calcitriol (1,25D) and 
FHBP, a lysophosphatidic acid analogue, promotes cell differentiation (Gidley 
et al., 2006). Therefore co-treatment with these reagents in the presence of 
SSO was carried out. Serum starved MG63 cells were treated with SSOs for 24 
hours, 48 and 72 hours. In each case after SSO treatment cells were treated 
with 1,25D and FHBP and given an additional dose of SSO before being 
incubated for a further 24 hours. TNSALP expression was assessed based on 
the well-established method of measuring p-NPP conversion to p-NP resulting 
in a yellow colour that can be quantified by measuring absorbance at 405nm. 
The p-NP levels reported were corrected for using the percentage difference in 
cell viability with cell in media alone being used as a baseline to compare other 
treatments. For all three time points five biological repeats were assessed. 
After a total 48 hours of SSO treatment the expected increase in p-NP 
production under co-stimulation of 1,25D and FHBP was observed and the 
addition of the control SSO did not lead to significant changes (Figure 4.10). In 
the presence of E7b3 SSO with the co-treatment this increase levels of p-NP 
was significantly lower when compared to the 1,25D and FHBP co-treatment 
(p=0.0110) and similarly control SSO with 1,25D and FHBP co-treatment 
(p=0.0013). The resazurin cell viability assay was confirmed changes observed 
with the TNSALP assay were not due to changes in cell number or health as 
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there were no significant changes in cell viability across the various treatments 
(Kruskal Wallis, p=0.0643). 
In contrast after 72 hours of SSO treatment although the co-treatment with 
1,25D and FHBP still increased TNSALP expression this was not observed at 
the same level in the presence of the SSOs including the control (Figure 4.11A). 
A significant reduction was observed for E7b3 SSO/co-treatment compared to 
1,25D and FHBP co-treatment alone (p=0.0074) but not control SSO/co-
treatment. Both E7b5 SSO/co-treatment (p=0.0406) and E7b3 SSO (p<0.0001) 
reduced TNSALP when compared to control SSO/co-treatment at 96 hours of 
SSO treatment (Figure 4.12 A) Even though the viability of E7b3 SSO treated 
cells was significantly reduced (Figure 4.11B and Figure 4.12B) all the p-NP 
concentrations reported were corrected for this effect.  
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Figure 4.10 TNSALP expression is attenuated after 48 hours of SSO induced 
ERG exon 7b skipping in MG63 cells 
A. TNSALP expression based on the concentration of p-NP in each sample was 
corrected for viability. MG63 cells were treated with SSOs for 24 hours prior to a 
second SSO dose as well as 1,25D and FHBP treatment for a further 24 hours. ERG 
SSO treatment were first compared to their respective equals in the presence of the 
control SSO. If significant change was observed an additional comparison was made 
to the non-SSO treated samples.  (* p≤ 0.05). B. Cell viability measured relative to 
total cell viability in media (100% viable) determined using the resazurin assay. 
Statistical significance was determined against the cells treated in media. (n.s. not 
statistically significant). Error bars show 95% CI. N=5. 
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Figure 4.11 TNSALP expression is attenuated after 72 hours of SSO 
induced ERG exon 7b skipping in MG63 cells 
A. TNSALP expression based on the concentration of p-NP in each sample 
corrected for viability. MG63 cells were treated with SSOs for 48h hours prior to a 
second SSO dose as well as 1,25D and FHBP treatment for a further 24 hours. ERG 
SSO treatment were first compared to their respective equals in the presence of the 
control SSO. If significant change was observed additional comparison was made to 
the non-SSO treated samples B. Cell viability against cells in media which was taken 
to be 100% viable and was determined using the resazurin assay. Statistical 
significance was determined against the cells treated in media. (*** p≤ 0.01, 
****p≤0.0001). Error bars show 95% CI. N=5. 
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Figure 4.12 TNSALP expression is attenuated after 96 hours of SSO induced 
ERG exon 7b skipping in MG63 cells 
A. TNSALP expression based on the concentration of p-NP in each sample 
corrected for viability. MG63 cells were treated with SSOs for 72 hours prior to a 
second SSO dose as well as 1,25D and FHBP treatment for a further 24 hours. ERG 
SSO treatment were first compared to their respective equals in the presence of the 
control SSO. If significant change was observed additional comparison was made to 
the non-SSO treated samples.  (* p≤ 0.05, ** p≤ 0.01, ****p≤0.0001). B. Cell viability 
relative to cells in media which was taken to be 100% viable and was determined 
using the resazurin assay. Statistical significance was determined against the cells 
treated in media. (n.s. not statistically significant). Error bars show 95% CI. N=5.  
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4.9 SSO-induced ERG exon 7b skipping alters the expression 
of TNSALP and other bone maturation genes in MG63 cells  
The expression of runt-related transcription factor 2 (RUNX2), osteopontin 
(OPN) and TNSALP are all genes are involved in the biogenesis of osteoblast 
cells (Rutkovskiy, Stensløkken and Vaage, 2016). The expression of these 
genes was assessed in cells treated for 48 hours with the ERG7b3 SSO 
treatment which was chosen as the focus for this experiment as this is the more 
efficient SSO. RNA was collected from cells that had been treated with media, 
co-treatment of 1,25D and FHBP, co-treatment with control SSO and co-
treatment with ERG7b3 SSO for 48 hours. In order to normalise the gene 
expression an exogenous spike made from the U13397 cDNA clone encoding 
the small RuBisCO subunit of Arabidopsis thaliana using in vitro transcription 
was added to each RNA sample prior to cDNA synthesis. The expression of the 
spike gene was also calculated and the mass of DNA obtained for each sample 
was normalised against this. Serial dilutions of known amounts of the U13397 
plasmid DNA were used to produce standard curves in order to facilitate 
quantitation. Overall mRNA expression is expressed as a percentage of the 
total RNA used to make the cDNA pool. 
Assessment of TNSALP expression showed significantly increased expression 
in the 1,25D and+ FHBP co-treated cells (p=0.0024) and in the presence of the 
control SSO (p=<0.0001) when compared to the media control (Figure 4.13A). 
The reduction of TNSALP mRNA levels in the presence of E7b3 SSO treatment 
was statistically significant when compared to control SSO levels (p=0.0498). 
These observations were in agreement with the TNSALP activity assay results.  
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Increased levels of OPN are observed in mature osteoblasts particularly during 
mineralisation as well as in proliferating cell in the pre-osteoblast stage. The 
highest levels of RUNX2 are expressed in pre-mature osteoblasts and levels 
drop off as cells become more mature (Rutkovskiy, Stensløkken and Vaage, 
2016, Figure 4.13D). Increased levels of OPN were observed following E7b3 
treatment when compared to both media control and combined 1,25D and 
FHBP treatment (p=<0.0001 and p=0.0005, respectively, Figure 4.13B). When 
compared to both the media control and 1,25D and FHBP co-treatment 
increased levels of RUNX2 expression were observed in the presence of E7b3 
SSO (p=0.027 and p=0.004, respectively, Figure 4.13C). 
To determine if the changes in TNSALP expression were a consequence of 
direct transcriptional control by ERG chromatin immunoprecipitation (ChIP) was 
carried out using MG63 cells. The ChIP analysis revealed an ERG binding site 
in the promoter of the TNSALP (-1114 to -85). Analysis of the TNSALP promoter 
using the Eukaryotic Promoter Database revealed the presence of a potential 
ERG binding site (AGAGGAAACG) within the region 1000bp upstream of the 
transcription start site one of them being within the region detected by the ChIP 
assay (Figure 4.14). 
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Figure 4.13 Expression of TNSALP, OPN and RUNX2 genes after 48h of 
1,25D and FHBP co-treatment in the presence of SSOs. 
Expression of A. TNSALP, B. OPN and C. RUNX2 is represented as a 
percentage of the total RNA used to make the cDNA library per sample. (* p≤ 
0.05) ** p≤ 0.01, ***p≤0.001, ****p≤0.0001). Error bars show 95% CI.  N=3. D. 
RUNX2 is important for osteoblast lineage commitment and maintains the 
expression of OPN. RUNX2 expression reduces in immature osteoblasts and 
TNSALP expression increases as osteoblast differentiate and mature. 
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Figure 4.14 ERG binds to the promoter of TNSALP 
A. Schematic of the TNSALP promoter showing the sequence of the predicted 
ERG binding site (-930 in red; note that the consensus is in the complementary 
sequence) and the primers designed to detect it. B. ChIP analysis using anti-
ERG detected TNSALP promoter DNA. An RNA Pol positive control was included 
to confirm the gene was be transcribed, non-specific IgG negative control was 
included to prove specific antibody binding and the input lane confirms the 
presence of the sequence in the original DNA sample prior to 
immunoprecipitation. The PCR product size is shown. 
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4.10 Summary of findings 
One of the hallmarks of cancer is uncontrolled cell proliferation. PRAD tumour 
samples showed more proliferative action compared to normal tissue controls. 
In addition ERG exon 7b skipping reduced cell growth and proliferation in MG63 
cells in a time-dependent manner. Two other cancer phenotypes migration and 
invasion decreased in the presence of SSOs. These observations correlate with 
previous studies where inclusion of ERG exon 7b was associated with 
increased proliferation, invasion and migration (J. Wang et al., 2008; Carver et 
al., 2009; Wu et al., 2013). Meanwhile the opposite was observed with 
apoptosis. Whereas ERG exon 7b inclusion is seen in cells with decreased 
apoptotic ability (J. Wang et al., 2008) SSO-induced skipping of exon 7b 
increased apoptosis in a time-dependent manner. Generally phenotype 
changes were more pronounced with an increased period of SSO treatment (i.e. 
48 to 72 hours). An explanation for this may be associated with more mRNA 
being translated into protein increasing protein activity and driving phenotype 
changes.  
Cell proliferation and migration are both known to be regulated by RAS/ERK 
signalling, a cell signalling pathway of critical importance in cancer. ETS factors 
and activator protein 1 (AP1) work together to regulate transcription of RAS 
responsive genes by binding specific enhancer sequences (Hollenhorst, 2012). 
In addition homo- and heterodimer formation of ETS factors (Carrère et al., 
1998) and post-translational modification of ETS factors (Hollenhorst, McIntosh 
and Graves, 2011) mean that the binding target combinations are extensive. 
Skipping exon 7b potentially alters ERK phosphorylation by removing the DEF 
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domain and a serine residue that is a potential phosphorylation target. 
Furthermore a modification of ERG’s AD will potentially alter its ability to 
dimerise or interact with other proteins.  
Additionally it may be that the altered cell phenotype may be due to changes in 
target gene transcription levels, or even in the profile of target genes. In the 
case of cell migration and invasion a potential gene that may be undergoing 
altered transcription is CXCR4 whose expression is regulated by ERG binding 
to its promoter. CXCR4, in association with C-X-C motif chemokine ligand 12 
(CXCL12), subsequently activates expression and secretion of matrix 
metalloproteinases which facilitate proteomic breakdown of the extracellular 
matrix contributing to cell migration and invasion in PCa cells (Chinni et al., 
2006; Singareddy et al., 2013).  
In terms of apoptosis, previous studies showed evidence that ERG and other 
ETS transcription factors are protective aiding cell survival (Birdsey et al., 2012; 
Tan et al., 2014). Inhibition of ERG in HUVEC cells increased apoptosis and 
this was shown to be mediated by VEGF/ VE-cadherin signalling suggesting 
ERG is required for cell survival. In angiogenesis the formation of new vessels 
requires a balance of pro- and anti-apoptotic factors. VE-cadherin associated 
with VEGF receptor 2 and other signalling pathway partners control levels of 
apoptotic proteins. VEGF receptor 2 activation by VEGF binding can activate 
Bcl proteins such as Bcl-2. Bcl-2 can activate caspases inducing apoptosis. VE-
cadherin interactions with β-catenin also increases apoptosis. ERG is able to 
disrupt both VEGF and VE-cadherin apoptotic pathways (Birdsey et al., 2008). 
Treatment-induced apoptosis was supressed in solid and haematopoietic 
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tumours with the EWS-ERG fusion, and knockdown of the fusion by RNAi 
resulted in cell death pointing to a protective role for aberrant ERG expression 
(Yi et al., 1997). Therefore the observations made in this study suggest that in 
addition to complete knockdown skipping of ERG exon 7b is sufficient to 
counteract the protective capacity of ERG expression in cancer cells.  
Within an in vivo MG63 xenograft model the ERG E7b3 SSO has been to have 
some efficacy reducing tumour volume and weight. Unfortunately the control 
SSO gave an intermediate effect. As the body weight of the mice was unaffected 
during the treatment it suggests that toxicity may not be the cause of this. 
Perhaps the moiety that facilitates transfection may be an issue, or perhaps 
there are off target effects of the control SSO. Further experimentation is 
needed but the data does suggest that the ERG exon 7b targeting SSO can be 
used in vivo. . 
A new role for ERG in bone osteogenesis and TNSALP expression has been 
revealed. The multi-step process involved in osteoblast maturation from 
mesenchymal stem cell is carefully controlled by several transcriptional 
regulators that initiate, maintain and terminate the process (Rutkovskiy, 
Stensløkken and Vaage, 2016). Thus there was an attempt made to understand 
if ERG contributes to this process specifically through the transcriptional 
regulation of the TNSALP gene and possibly other genes required for osteoblast 
differentiation.  
Addition of 1,25D and FHBP to the MG63 was used to establish a differentiation 
model in which increased TNSALP expression is observed. Expression of 
TNSALP was attenuated by ERG exon 7b skipping most especially when 
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induced by the 3´ splice site targeting SSO and this effect is time dependent. 
Two studies identified a reduction in alkaline phosphatase and mineralisation 
when the C-1-1 ERG variant, lacking exon 7, was expressed (Iwamoto et al., 
2000, 2001). This finding is consistent with my observations. As exon 7 also 
encodes for part of the AD it may be that ERG isoforms lacking exon 7b have a 
similar biological function in osteoblasts to C-1-1 in chondrocytes.  
When mRNA expression was investigated a reduction in TNSALP was also 
observed, and ERG was shown to bind to the promoter of TNSALP using ChIP 
analysis. Therefore changes in TNSALP levels may be due to altered 
transcriptional activity of ERG induced by SSO mediated exon 7b skipping. In 
addition increased expression of RUNX2 and OPN was observed in the 
presence of E7b3 SSO suggesting that ERG may be involved in regulation of 
the repression of these genes during osteoblast maturation. RUNX2 is a master 
regulator of osteoblast maturation and the activity of the factor depends on 
association with other protein factors that may acts as co-repressors or co-
activators (Komori, 2008). The expression of OPN is influenced by both RUNX2 
and ERG as the promoter has binding site for RUNX2, ERG and other ETS 
transcription factors. As a result an increase in RUNX2 expression does not 
necessarily correlate with the expression levels of the proteins target genes. 
RUNX2 increases OPN expression near 3 fold but in combination with 1,25D 
increase in OPN expression was increased 8 fold as 1,25D enhances VDR and 
RUNX2 recruitment to the OPN promoter (Shen and Christakos, 2005). In PCa 
cells ERG was shown to increase OPN expression and there was a significant 
positive correlation between TMPRSS2-ERG and OPN expression in prostate 
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patient tumours (Flajollet et al., 2011). Therefore although these genes were 
both found to be increased in agreement with an immature osteoblast 
phenotype effects by other ERG interactions may also be influencing their 
expression.  
In summary, ERG exon 7b skipping induces anti-oncogenic features in the 
MG63 cell line model suggesting that the exon does contribute to tumorigenicity 
of malignancies with aberrant ERG expression. This finding was supported by 
observations of reduce tumour growth in an MG63 xenograft model. 
Furthermore ERG may be an important regulator of osteoblast maturation, as 
the induction of TNSALP was compromised by the skipping of exon 7b. 
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5.1 Introduction 
The regulation of alternative splicing of ERG’s cassette exon 7b has not been 
investigated yet. Conservation analysis of the acceptor and donor site, branch 
point and polypyrimidine tract will potentially shed light on the functional 
importance of these key spliceosome assembly sites. Prediction of potential cis- 
and trans-elements will be coupled with in vitro validation of candidate splicing 
factors that may regulate ERG exon 7b splicing. Finally an RNA pull down of 
the exon 7b acceptor site will reveal splice factors that potentially regulate exon 
splicing at this site and, following siRNA knockdown of genes encoding the 
proteins detected in the pull down, the changes in PSI of exon 7b will be 
assessed. 
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5.2 Analysis of ERG exon 7b acceptor and donor splice sites  
The specification of the 5´ (donor) and 3´ (acceptor) splice site is greatly 
important for recognising an exon and regulating its splicing. The strength of 
splice sites is greatly influenced by the surrounding sequence where the splicing 
machinery binds leading to the splicing of the exon. Two important sites that 
also influence the splicing of an exon are the branch point and polypyrimidine 
tract. Therefore a comparative analysis of the ERG exon 7b splice sites, branch 
point and polypyrimidine tract was performed by using the DNA sequences of 
human, mouse, chicken, frog and sea urchin species to produce a Clustal 
Omega alignment (Figure 5.1A).  
Unsurprisingly the fairly degenerate splice site motifs were conserved across 
species as far back as sea urchin and more conservation was seen in exonic 
than in intronic sequences (Figure 5.1A). The conservation of two adenosine 
bases that may be potential branch points can be better seen in the sequence 
for the acceptor site and upstream intronic sequences. The polypyrimidine tract 
did appear to be particularly well conserved (Figure 5.1B). The sequence motif 
for the donor site graphically represents the good conservation of the 
consensus sequence based on the ERG donor site alignment (Figure 5.1C). 
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Figure 5.1 ERG exon 7b splice sites compared across metazoan species 
A. Clustal Omega alignment of the DNA sequence of ERG exon 7b and it flanking 
introns was carried out. Exon 7b is underlined in blue and the splice sites 
sequences are shown in blue boxes. The potential polypyrimidine tract is 
underlined in green and predicted branch points in the red box. Asterisks (*) are 
conserved bases. Ensembl and EnsemblMetazoa gene ID are as follows: Homo 
sapiens ENSG00000157554 (Human), Mus musculus ENSMUSG00000040732 
(Mouse), Gallus gallus ENSGALG00000016058 (chicken), Xenopus tropicalis 
ENSXETG00000023717 (frog) and Strongylocentrotus purpuratus SPU_018483 
(purple sea urchin). B. The sequence logo for the acceptor site, potential 
polypyrimidine tract (orange bracket) and branch point of ERG exon 7b produced 
from the sequences used in the alignment showing the probability of having a 
specific nucleotide (y-axis) at that position (x-axis). C. The sequence consensus 
for the donor site of ERG produced from the sequences used in the alignment 
showing the probability of having a specific nucleotide (y-axis) at that position (x-
axis). 
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5.3 Prediction of cis-acting splicing features that regulate exon 
7b splicing 
ESEs, short nucleotides sequences found with high frequency in alternatively 
spliced exons, are capable of regulating exon inclusion by facilitating the binding 
of splice factors, for example SR proteins. ESS sequences in contrast facilitate 
exon skipping. Regulatory sequences are also present in adjacent intronic 
sequences (ISEs and ISSs). The binding of SR proteins and other splice factors 
can cooperate with the core spliceosome machinery or override the effects of 
active ISSs or ESSs. To predict the effect that potential ESEs have on ERG 
exon 7b splicing two web server programs were sued to identify potential ESEs; 
RESCUE-ESE and ESEfinder (Cartegni et al., 2003; Fairbrother et al., 2004; 
Smith et al., 2006).   
RESCUE-ESE is an online server program that can find human hexamer ESEs 
that fulfil two main criteria; significant enrichment in exons compared to introns 
and the frequency is greater in exons with weaker splice sites. These criteria 
produced a list of 238 human ESEs but has been expanded to predict ESEs 
found in mouse, zebrafish and pufferfish species (Fairbrother et al., 2004). 
Therefore the sequences for human and mouse acceptor and donor sites were 
analysed initially but did not identify any ESE sequences. Next the sequence 
for exon 7b was analysed. Human and mouse ERG exon 7b share 98.6% 
identity with one nucleotide variation T to C shown in Figure 5.2. Of the potential 
ESE predicted, three in human and two in mouse were unique and the 
sequences were found near the nucleotide variation between the two species 
(Figure 5.2 A).  
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ESEfinder was then used to predict which SR proteins may bind to human ERG 
exon 7b and surrounding its splice sites based on weight matrices for the motifs 
of four human SR proteins; SRSF1, SRSF2, SRSF5 and SRSF6. These 
matrices are generated from the frequency of the motif in alignments with winner 
sequences of SELEX experiments (Cartegni et al., 2003). A threshold can be 
user-determined or server-determined and high scores are those that exceed it. 
Server-defined thresholds were used for this analysis.  
Across 15 motifs all four SR proteins were predicted to bind to the sequence 
and a cluster of eight SR motifs were found at the acceptor site compared to 
four at the donor site (Figure 5.2C). SRSF2 and SRSF6 were predicted to bind 
in humans at the nucleotide position that varies to mice (T>C). The highest 
scores for each of the individual SR proteins were determined at the splice sites. 
The motifs used in ESEfinder are longer than those for RESCUE-ESE but with 
that in mind overlap of ESE sequences was present in this region (Figure 5.2A 
and Figure 5.2C). 
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Figure 5.2 ESE prediction analysis for ERG exon 7b 
RESCUE-ESE was used to predict human (top of exon 7b sequence) and 
mouse (bottom of exon 7b sequence) ESEs that may be present in the A. 
human and B. mouse sequence of ERG exon 7b. Red asterisks (*) denote 
ESEs that are unique and the red box shows the position of variation in the 
nucleotide sequence (T>C). C. SRSF1, SRSF2, SRSF5 and SRSF6 are all 
predicted to bind to human ERG exon 7b and its flanking introns. The red hash 
tag (#) denote the highest score for each individual SR protein and the blue 
box demarcates exon 7b, intronic sequence is in lowercase.  
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5.4 Prediction of potential trans-acting splice factors that 
regulate exon 7b splicing 
In silico prediction of where splice factors and RNA binding proteins (RBPs) 
might bind can be informative of potential regulators for a specific splicing event. 
Using data from the RNAcompete assay RBPs that preferentially bind to ERG 
exon 7b and its flanking intron sequences was analysed. RNAcompete is an in 
vitro method utilising binding competitions for RBPs in the presence of a pool of 
RNAs in molar excess (Ray et al., 2009). Microarray and computational 
methods can then be used to assess the affinity selected recovered proteins to 
determine the sequence preference of a specific RBP (Ray et al., 2013).  
Data matching RNAcompete motifs to the sequence of ERG exon 7b and 200bp 
of its flanking intronic sequences (provided by Dr Eduardo Eyras) revealed 
many RBPs that potentially bind. Most RBPs predicted to bind with higher motif 
matching scores were found in the upstream intron sequence and hnRNPA1, 
hnRNPA2B1, matrin3 and splice factor 3b subunit 4 (SF3B4) had the highest 
scores in this region. Of those only matrin3 was predicted to bind within 50bp of 
the acceptor site. ELAV like RNA binding protein 1 (ELAVL1) and poly RC 
binding protein (PCBP) both had high scores and were predicted to bind exonic 
sequence. ELAVL1 was also highly predicted to bind the downstream intron and 
had the most number of motif matches in the entire sequence analysed (Figure 
5.3).  
Spearman’s correlations for SF and RBP that may potentially regulate exon 7b 
splicing were calculated by comparing normal and tumour samples from the 
PRAD TCGA cohort. For RBPs only those that are differentially expressed 
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between tumour and normal sample were used in this calculation whereas all 
SF were analysed regardless of differential expression.  
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Figure 5.3 RBPs predicted to bind to ERG exon 7b and its flanking introns 
Heat map showing motif matching scores (blue scale) of RBPs predicted to bind 
to ERG exon 7b and 200bp of flanking intronic sequence based on 
RNAcompete matrices. Each column represents 50bp bins except for the exon 
column which represents the entire 72bp of exon 7b. A total of 36 RBPs are 
presented.  
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Figure 5.4 Predicted SF and RBP regulators of ERG exon 7b alternative 
splicing 
The Spearman’s correlation A. SF proteins and B. RBPs that have high 
correlation with the PSI exon skipping values of ERG exon 7b. Only RBPs that 
are differentially expressed between prostate tumour and normal samples were 
used in this calculation whereas all SFs were analysed regardless of differential 
expression. The red indicates splice factors that generally upregulate exon 
inclusion and blue are those that downregulate exon inclusion. 
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5.5 The knockdown of several RBPs significantly changes 
ERG exon 7b splicing in MCF7 cells  
In collaboration with the University of Sherbrooke RNAomics Platform in 
Sherbrooke, Canada, alternative splicing using endpoint PCR coupled with 
microcapillary electrophoresis (ASPCR) was used to investigate how exon 7b 
inclusion might be regulated. A targeted RNAi screen of 56 RNA-binding 
proteins (RBPs) was coupled with high-throughput RT-PCR to identify RBPs 
that when knocked down would affect ERG alternative exon 7b inclusion. The 
RNAi screen used the human breast carcinoma cell line MCF7 and ERG exon 
7b inclusion was determined for each of the 56 RBPs, some of which are known 
splicing regulators.  
The results of this screen were represented in the heat map that expressed the 
change in PSI (PSI) in the knockdown MCF7 cells compared to a transfection 
control. It was established that ERG exon 7b splicing is affected by the 
knockdown of a number of RBPs and using a PSI >10% a total of 21 RBPs 
were identified which had the greatest impact on the PSI of ERG exon 7b were 
specifically identified (RBP names in red). Upon depletion of musashi RNA 
binding protein 2 (MSI2), RNA binding protein with serine rich domain 1 
(RNPS1), cyclin dependent kinase (CDK11), SFRS4, SNW domain containing 
1 (SNW1), transactivation response RNA-binding protein 1 (TARBP1), SFRS8, 
HNRNPL and steroid receptor RNA activator 1 (SR-A1) an increase in exon 7b 
inclusion was observed. In contrast, the knockdown of twelve RBPs (SF3A1, 
SF3A2, KHDRBS3, HEAB, PRPF8, RALY, RBM9, BRCA1, RNPC2, SF3B4, 
SFRS12 and U2AF1) resulted in decreased exon 7b inclusion (Figure 5.5A). 
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Figure 5.5 RNAi knockdown of RBPs change ERG exon 7b inclusion in MCF-7 
cells 
Alternative splicing using endpoint PCR coupled with microcapillary electrophoresis 
(ASPCR) revealed several RBPs that regulate ERG exon 7b alternative splicing. 
High-throughput PCR was performed to amplify +/-exon 7b isoforms in 56 MCF7 cell 
lines, each of which had a RBP knocked down. Expression of the isoforms is 
quantified by capillary electrophoresis of the PCR reactions. A. Heatmap showing 
splicing event. The top results with the most apparent changes in the ERG exon 7b 
exclusion and inclusion levels from the screen are represented in red. B. A 
schematic representation of the splicing event. C. Primers located in exon 7 and 
exon 8 were used to amplify the ERG -7b (100bp) and ERG+7b (172bp) isoforms. 
Changes in the peak height of the 172bp product represent increased (red) or 
decreased (blue) exon inclusion. 
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5.6 Several proteins interact with the 3´ splice site of ERG exon 
7b exon in vitro 
An RNA pull down assay was carried out to identify potential candidate trans-
acting factors that may regulate exon 7b splicing. A synthetic RNA oligo 
including the acceptor (3´) splice site of exon 7b and surrounding sequence (-
20 to 20) was designed and ordered. The RNA oligonucleotide was attached to 
magnetic streptavidin beads prior to incubation with nuclear extract from 
MOLT4 cells. Proteins that bound were eluted and in addition to the original 
nuclear lysate were separated on an SDS-PAGE gel. Gels were stained using 
coomassie blue to allow for visualisation of protein bands and were imaged. 
Further analysis of the protein bands from the RNA oligonucleotide bound 
sample as compared to a no RNA lysate only control was carried out using mass 
spectrometry (Proteomics Facility, University of Bristol).  
The oligo sequence was also analysed using SpliceAid2, which allows for cell 
line specific prediction of RBP that may bind to the query sequence. Figure 5.6A 
shows the results of this analysis based on the MOLT4 cell line as the lysate 
used for the pull down was from this cell line. The results of the mass 
spectrometry revealed numerous proteins were pulled down by the exon 7b 
splice site oligonucleotide. Figure 5.6B highlights the proteins that were 
particularly enriched in comparison to the no RNA control sample. Splicing 
factor proline and glutamine rich (SFPQ), SF3A2, hnRNPL, hnRNPD and 
SRSF5 were also identified in the ASPCR assay described in section 5.5. 
Peptide spectrum matches (PSM) ratios, a measure of the peptides that were 
more enriched in the exon 7b pull down sample compared to the no RNA 
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control, were calculated for all the proteins identified and Table 2 shows the 
values for the proteins highlighted in Figure 5.6 B.  
Interestingly U2AF65, a key component of the spliceosome that binds the 
pyrimidine tract near the acceptor site, was pulled down (Figure 5.6 B) and had 
a relatively high PSM ratio of 6.82. CELF1 and family with sequence similarity 
98 member B (FAM98B) had very high PSM ratios but were not predicted to 
bind to the RNA oligo by in silico analysis. Of the proteins predicted to 
specifically bind to the RNA oligo sequence by SpliceAid2 (Figure 5.6A) SRSF5, 
hnRNPF and PTBP1 were the three with the highest PSM ratios of 2.8, 4.14 
and 5.4 respectively (Table 2) and all three had corresponding bands on the 
RNA pull down gel although confirmation using western blot was not possible 
due to elution sample size limitations. 
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Figure 5.6 RNA pull down of ERG exon 7b acceptor site and surrounding 
sequence 
An RNA pull down of a synthetic RNA oligonucleotide of the acceptor splice site of 
ERG exon 7b was performed using nuclear protein lysate from MOLT4 cells. A. 
SpliceAid2 was used to predict which RBP may bind to the exon 7b acceptor splice 
site RNA oligo; exon 7b sequence is in uppercase and intron in lowercase. The length 
of each RBP box corresponds to the predicted motif. B. SDS-PAGE gel stained with 
Coomassie blue shows the results of the RNA pull down. A no RNA and lysate only 
control were run alongside the acceptor site oligo (ERG7b 3´ss). The molecular weight 
markers are shown on the left hand side. Proteins, identified in the mass spectrometry 
analysis, which have molecular weights that correspond with bands in the ERG7b 3´ss 
lane are shown. Proteins in green were also identified in the ASPCR assay in Figure 
5.5A. Red asterisks (*) represent the three proteins predicted to bind and had the 
highest PSM ratios. N=1  
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Protein identification PSM ratio 
hnRNPH1 1.80 
U2AF65 6.82 
CUGBP ELAV-like family member 1 
(CELF1) 
24.00 
SF3A2 3.00 
Matrin-3 6.03 
PTBP1 5.40 
hnRNPD 2.90 
SFPQ 1.48 
hnRNPL 7.00 
FAM98B 39.00 
SRSF5 2.80 
hnRNPF 4.14 
hnRNPH3 2.70 
hnRNPH2 1.88 
 
Table 2 RBPs from mass spectrometry of RNA pull down of exon 7b 
acceptor site 
The RBPs predicted to bind to the RNA oligonucleotide sequence, with a 
molecular weight that corresponds to the RNA pull down gel results and peptide 
spectrum matches (PSM) ratios greater than 1 are shown. The PSM ratio 
compares the PSM of the no RNA control and exon 7b RNA pull down sample. 
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5.7 Knockdown of PTBP1, SRSF5 and hnRNPF did not 
significantly alter ERG exon 7b splicing 
Results from the RNA pull down established a substantial list of potential RBPs 
that may regulate ERG exon 7b splicing. From this list three RBPs were 
knocked down to assess their potential in role in the regulation of exon 7b 
inclusion; SRSF5, PTBP1 and hnRNPF. The choice of RBPs was based on 
bioinformatic prediction, presence in the MCF7 ASPCR assay and mass 
spectrometry data from the RNA pull down assay.  
Firstly all three factors were predicted to bind to the synthetic RNA 
oligonucleotide used in the RNA pull down assay (Figure 5.6 B). SRSF5 was 
found in both the MCF7 ASPCR assay and RNA pull down assay (Figure 5.5A 
and Figure 5.6B). The correlation analysis in prostate tumours predicted 
hnRNPF and PTBP1 as a splice factors that down regulates exon 7b inclusion 
(Figure 5.4A). PTBP1 is known to bind to polypyrimidine tract and it RRM 
interacts with Matrin3 (Coelho et al., 2015). Matrin3 was pulled down (Figure 
5.6B), had a good PSM ratio (Table 2) and was predicted by the correlation 
analysis in prostate tumours (Figure 5.4A) and RNAcompete prediction (Figure 
5.3). However it was not predicted to bind to the ERG7b 3´ss RNA oligo and so 
PTBP1 was chosen to explore the possibility that it may be working with Matrin3 
to regulate ERG exon 7b alternative splicing. A list of RBPs from the RNA pull 
down that were found in significant abundance in the ERG sample compared to 
control, and a table comparing the prediction of RBPs in this study can be found 
in the appendix. 
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RNAi was used to knockdown SRSF5, hnRNPF and PTBP1. MG63 cells were 
transfected with control and RBP targeting siRNA for 48 hours. Changes in ERG 
exon 7b alternative splicing were assessed using standard PCR. Knockdown of 
all three RBPs did not cause significant changes in ERG exon 7b inclusion as 
confirmed by the PSI values which were similar between all controls and 
knockdowns (Figure 5.7A). Knockdown for SRSF5, hnRNPF and PTBP1 was 
confirmed at the mRNA level using qPCR (Figure 5.7B). 
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Figure 5.7 RNAi knockdown of SRSF5, hnRNPF and PTBP1 does not change 
ERG exon 7b alternative splicing  
RNAi was used to knockdown SRSF5, hnRNPF and PTBP1. Pools of siRNA 
targeting each RBP and a control siRNA pool was transfected into MG63 cells 
alongside a vehicle control and transfection control for 48 hours. A. Standard PCR 
of ERG exon 7b splicing following RNAi knockdown of PTBP1, SRSF5 and 
hnRNPF and the actin control. PSI values are shown under the corresponding lane. 
B. Knockdown of PTBP1, SRSF5 and hnRNPF using qPCR showing mRNA 
expression. Error bars show 95%CI. (*p≤0.05 and **p≤0.01). N=3 
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5.8 Summary of findings  
The SSOs designed to induce ERG exon 7b skipping in this study targeted 
the exon donor and acceptor sites. As successful skipping was achieved 
using both SSOs the conservation of the splice sites and their flanking 
sequences was examined as sequences that are conserved may play an 
important role in regulating the splicing of the exon. The human sequences 
were compared to other metazoan species for this analysis. The acceptor 
and donor splice site consensus sequences and branch point of ERG exon 
7b are well conserved across metazoan species. However the 
polypyrimidine tract is less conserved. The conservation of the acceptor and 
donor site is expected and has been reported before (Abril, Castelo and 
Guigó, 2005). The lack of conservation in the polypyrimidine tract suggests 
that proteins binding here may not be as important to regulation of the 
splicing of exon 7b. 
Analysis to identify SREs, SFs and RBPs revealed several cis- and trans-
acting elements were predicted to regulate ERG exon 7b splicing. Most 
predicted ESEs were conserved between human and mouse with ESEs 
unique to humans found near a single nucleotide variation between the two 
species (T>C) in the ERG exon 7b sequence. This is unsurprising as the 
change in sequence would create potential for organism specific splicing 
regulation. Several SR proteins were predicted to bind to the exon 7b 
sequence and most cluster around the splice sites where there is greater 
sequence conservation. Of particular interest was that all four SR proteins 
were predicted to bind to the 3´ splice site which when targeted with the 
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SSOs showed the most exon skipping. It may be that this splice site is more 
critical to determining the inclusion exon 7b.  
Prediction of splicing regulators is useful in providing potential targets for 
experimental validation as ERG exon 7b splicing regulators. RNACompete 
prediction provided several potential proteins, with those with the highest 
scores mainly binding in the intronic sequence both upstream and 
downstream of exon 7b. Matrin3, HNRNPA1, HNRNPA2B1, SF3B4 were 
predicted to bind in the upstream intron and ELAVL1, which was predicted 
to bind in the downstream intron, were among the highest scoring RBPs. 
Spearman’s correlations of SFs and RBPs that may regulate ERG exon 7b 
from the TCGA PRAD cohort also ascertained some potential regulators 
namely HNRNPL and CUGBP ELAV-like family member 2 (CELF2).  
Among splicing regulatory proteins (SFs and RBPs) able to modify ERG 
exon 7b inclusion the most significant changes seen in the ASPCR 
experiment in breast cancer cells (MCF7) were with knockdown of TARBP1 
and HNRNPL which increased ERG exon 7b inclusion. Knockdown of splice 
factor 3 subunit 1 (SF3A1) and breast cancer 1 (BRCA1) decreased exon 
7b inclusion. There is an added complication when considering the role of 
these splicing regulating proteins when one takes account of mutations that 
alter the splicing of the proteins themselves. Therefore there is a complex 
layering and interplay between mutations in trans- and cis-acting elements 
and how any changes in them may contribute to the pathogenesis related to 
any one splicing event that may be deemed significant. For instance that 
BRCA1 is an important regulatory factor in MCF7 cells in this study is not 
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unusual as overexpression and mutation in the protein is often seen in breast 
cancers (Vissac et al., 2002). However BRCA1 could be of less, equal or no 
importance in regulating ERG splicing in another cell line model, in vivo or 
human cancer patients.  
An RNA pull-down of ERG exon 7b acceptor site identified several splicing 
regulators. Choosing which proteins may regulate exon 7b splicing from the 
pool of potential regulators from the pull down and other predictive data lead 
to a choice of three initial candidates. The knockdown of PTBP1, HNRNPF 
and SRSF5 using siRNA did not significantly change exon 7b splicing 
suggesting they may not be relevant to ERG exon 7b splicing regulation. 
Further experimentation can be carried out from the data provided in this 
study. 
Although the details of the regulation of ERG exon 7b have not been 
determined definitively yet, several splice regulating proteins have been 
identified with some in vitro validated in an ASPCR assay of MCF7 cells. 
Further analysis could be carried out by knocking down other potential 
candidate splice factors identified in the RNA pull down. In addition the list 
of proteins that are predicted to bind and that also appear in the knockdown 
experiments could be used to inform decisions on future potential candidate 
regulators of exon 7b inclusion. 
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The aim of this study was to understand the function and regulation of inclusion 
of ERG exon 7b. The changes in the splicing of this exon were hypothesised to 
significantly alter the transcriptional function of ERG by changing the size and 
nature of the AD. The inclusion of exon 7b has been shown to increase in PCa 
(Hagen et al., 2014) and contribute to malignant cell behaviour (Wang et al., 
2008). Therefore further investigation of the expression of ERG exon 7b splice 
isoforms is of interest as it may help understand oncogenic processes. If this 
cassette exon significantly alters the function of ERG then the regulation of the 
cassette exon may go astray in cancer. As well as the ERG splice isoform itself, 
regulators of exon 7b splicing could themselves be targeted therapeutically.  
  
 188  Samantha Jumbe- June 2019 
6.1 Evolutionary conservation of ERG and its exon 7b  
As a starting point it was deemed important to understand and determine the 
evolutionary origins of exon 7b.The functional importance of ERG sequence 
was suggested by its conservation as far back as the metazoa with ERG being 
identified in what the authors of the study called an “unknown nematode” 
species (Degnan et al., 1993). Soon after this was reported a putative ERG 
gene was identified in the Nereis diversicolor species of worms (Lelibvre-
Chotteau et al., 1994). Previous conservation studies for ERG and other ETS 
factors had focused on the ETS and pointed domains. However a similar 
approach was adapted to investigate both ERG exon 7b and ERG conservation. 
This study has shown ERG exon 7b conservation in echinoderms including a 
sea urchin species. Previously the ETS domain was reported to be conserved 
in sea urchin species (Rizzo et al., 2006); in this study AD conservation was 
also demonstrated, including several serine residues that may be potential sites 
for post translational modification. ERG exon 7b encodes for part of the AD and 
within the AD itself are two serine residues one in exon 7 and the other in exon 
7b located downstream of the conserved DEF domain, an ERK docking site. 
Mutational changes in the AD have been shown to change transcriptional 
activity (Siddique et al., 1993). The DEF domain located in exon 7b is crucial to 
anchoring ERK and facilitates ERG phosphorylation at the aforementioned 
serine residues, most especially the serine in exon 7b (Huang et al., 2016), 
activating transcription of gene targets required for cellular processes such as 
migration (Kedage et al., 2017). Therefore the conservation of this exon may be 
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driven by the requirement of this phosphorylation site for appropriate signal 
transduction.  
Also the conservation of ERG has been shown to go even further back to the 
porifera phylum as ERG was identified in A. queenslandica sponge species. It 
is thought that sponges and metazoa diverged from an ancient common 
ancestor some hundred million years ago (Müller et al., 2001). The presence of 
ERG in a sponge points towards its possible presence and importance to the 
common ancestor for animals and the development of multicellular life. 
Therefore this study provides further evidence that ERG, including exon 7b, is 
among the most conserved metazoan proto-oncogenes, and this implies an 
essential role for the gene in development of a wide range of organisms across 
the taxa.  
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6.2 Role of ERG exon 7b in oncogenic processes 
Having established the conservation of ERG exon 7b, the extent of its inclusion 
was investigated in several cell lines both in vitro and in silico. Overall exon 7b 
inclusion was favoured in human cancer cell lines tested suggesting that the 
ERG transcriptional activity in these cells may be mainly attributed to exon 7b 
inclusion isoforms. RNA-seq data also showed a high level of ERG exon 
expression especially in the HUVEC cells. ERG is vital for regulating signalling 
pathways in endothelial cells (Birdsey et al., 2008; Yuan et al., 2009; Dryden et 
al., 2012), and so high expression of exon 7b in this context further points to it 
possible functional importance.  
SSOs were designed against the two splice sites to induce exon 7b skippingand 
caused exon 7b skipping in two cell lines, MOLT4 and MG63 showing that the 
SSOs are effective in various tissue types. Initially the in vitro cell experiments 
were going to be conducted in both VCaP prostate cancer and MOLT4 cell lines 
in this study and this is why prostate cancer data is included. However the SSO 
in vitro cell biology work was conducted by Dr Sean Porazinski and this in 
addition to the data from this study is published (Jumbe et al., 2019). 
Going forward the MG63 cell line was used as the experimental model as the 
dose used in MOLT4 cell lines was significantly higher than in MG63. Therefore 
the assumption was that lower doses would result in less off target effects. 
Moreover working with an adherent cell line presented practical advantages. 
Interestingly ERG expression and function in MG63 cells had not previously 
been reported; therefore better understanding of ERG in this context.  
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An additional amplicon could be detected in the ERG PCR using cDNA from 
MG63 cells that represented the exclusion of both exons 7 and 7b. Due to 
project time constraints this investigation only focused on exon 7b. Future 
studies looking at removal of the entire AD or specifically studying exon 7 
instead of exon 7b should be carried out using this cell line. Although exon 7 
exclusion has been reported it is less frequent and normally in minor isoforms 
which use less commonly used promoters (Zammarchi, Boutsalis and Cartegni, 
2013) perhaps explaining why exon 7 skipping was not detected in most other 
cell lines tested.  
The importance of the AD has been shown as mutation or elimination of the 
domain reduces ERG transcriptional activity (Siddique et al., 1993). 
Furthermore ERG protein activity is modulated by its phosphorylation status. 
The expression of the full length AD facilitates the phosphorylation of ERG by 
ERK via the DEF domain located in exon 7b in collaboration with the serine 
residue (S215) in the upstream exon 7 which in turn facilitates the 
phosphorylation of S96 (Selvaraj et al., 2015). If exon 7b is excluded S96 is not 
phosphorylated and therefore downstream targets and signal transduction 
pathways activated and repressed by ERG will vary when if exon 7b is not 
included. Kedage et al. (2017) demonstrated how phosphorylation of S96 
modulates the expression level of ERG target genes and enhances cell 
migration in RPWE cells.  In addition hypothetically the serine residue found in 
the protein sequence for exon 7b may be a site for further phosphorylation by 
other kinases.  
 192  Samantha Jumbe- June 2019 
A preference for exon 7b inclusion in several malignant cell lines and PRAD 
patients was observed and suggest that the full AD, with exon 7b amino-acids 
included, encodes an ERG isoform with a higher oncogenic potential. The data 
presented in this study demonstrates SSO induced ERG exon 7b skipping 
decreased cell migration, invasion and proliferation but increased apoptosis. 
This was in agreement with the hypothesis that ERG exon inclusion increases 
oncogenic potential, based on previous literature (Wang et al., 2008; Hagen et 
al., 2014). All of these observations lead me to hypothesise that full 
transcriptional activity may be favoured in a number of biological contexts 
including cancer. 
In particular Wang et al. (2008) found that TMPRSS2-ERG variants that 
included exon 7b increased proliferation and invasion and attributed this to 
potential protein folding and dimerization changes. As the splicing of exon 7b 
alters the polypeptide sequence it would be expected to result in a varied tertiary 
structure in the protein. It has been suggested that the proximity of the AD to 
both the pointed and ETS domain which are primarily involved in homo and 
hetero dimerization interactions may be required to facilitate the process 
(Carrère et al., 1998).  
Previous studies that investigated the role of ERG in proliferation (Thoms et al., 
2011), invasion (Singareddy et al., 2013), migration (Deplus et al., 2017) and 
apoptosis (Birdsey et al., 2008), and examined either native ERG, TMPRSS2-
ERG, other fusion variants (Irifune et al., 2005; Sotoca et al., 2015) or a 
combination. The present study did not assess whether or not MG63 cells 
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express any ERG fusion variants; however all ERG exon 7b containing isoforms 
would have been targeted by the SSOs.  
There is a potential that these isoforms may be potential biomarkers which may 
become a key part of cancer diagnosis, treatment and in determining prognosis. 
Currently ERG has been detected and monitored in PCa patients using urine-
based and immunological testing methods (Yao et al., 2014). The expression of 
TMPRSS2-ERG variants +7b is associated with a poorer outcome in most 
cases with a 58-80% chance of recurrence within 5 years (St. John et al., 2012). 
This suggest that clinical picture of a patient may be informed by the ERG or 
TMPRSS2-ERG status. However an interplay exists between native ERG 
variants and fusion variants that influences the tumorigenic potential of ERG 
(Mani et al., 2011), and so diagnostic tests should include the measurement of 
ERG alternative splicing too. 
Zammarchi et al. (2013) observed a specific expression profile of native ERG 
splice isoforms was identified in PCa cells compared to normal tissue and this 
led to the suggestion of a positive feedback loop with TMPRSS2-ERG variants 
that can circumvent androgen dependence. Of the three native ERG promoters, 
a switch occurs where promoter B replaces promoter C as the principle 
promoter in both from PCa samples and cell lines (Zammarchi, Boutsalis and 
Cartegni, 2013). Therefore the ERG splice isoforms expressed are changed. As 
promoter elements for the  MYC proto-oncogene, BHLH Transcription Factor 
(c-Myc), a downstream target gene of ERG elements are present on promoter 
B, it may be that ERG transcription can be maintained independent of the 
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androgen dependent TMPRSS2-ERG through a feed-forward loop between 
ERG and c-Myc (Zammarchi, Boutsalis and Cartegni, 2013).  
In addition the expression of ERG splice isoforms is complicated by the 
presence of the fusion with TMPRSS2 in prostate cancer. Changes in the 
androgen responsive element that mediates the androgen response of 
TMPRSS2 would also contribute to androgen driven ERG expression. Reduced 
binding to the androgen responsive element of TMPRSS2 was identified and 
shown to be caused by a single nucleotide polymorphism in the gene sequence 
(Clinckemalie et al., 2013). Therefore fusion genes with this mutation may not 
express ERG at comparative levels potentially reducing the clinical significance 
of the presence of the fusion. 
Similar analyses would need to be carried out in cancer cases involving FUS-
ERG and EWS-ERG fusion variants but what these studies highlight is the 
complication of understanding the clinical significance and contribution of native 
ERG and ERG fusion splice isoforms to cancer pathogenesis. Therefore 
although exon 7b inclusion generally seems to be an indicator of poor clinical 
outcome additional, detailed analysis of the expression profile of splice isoforms 
in different cancers needs to be carried out to validate the significance of exon 
7b as a clinical biomarker.  
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6.3 Therapeutic potential of SSOs 
To gain an indication of the in vivo efficacy and potential of the SSOs an MG63 
xenograft model was treated over a two month course period. Tumour volume 
and weight were both reduced by ERG E7b3 SSO over the time course. 
However the control SSO seemed to have undesirable effects as tumour weight 
and volume were both reduced with this treatment as well although not to the 
same extent as the ERG SSO. This may be a consequence of the toxicity of the 
chemistry of the vivo-morpholinos in this model, though mouse body weight was 
not affected over the treatment course between groups suggesting minimal 
toxicity at the systemic level. It may be that within the tumour milieu the potency 
of the SSO is altered by pharmacokinetic complications.  
Clinical trials in humans using SSOs are underway especially for neuromuscular 
diseases with the first ever treatment developed for spinal muscular atrophy the 
FDA approved ASO Spinranza® which has greatly increasing patient survival 
(Prakash, 2017). With regards to cancer ASO against eIF4E have been used in 
a clinical trial to treat advanced colorectal cancer. In patients treatment with the 
ASO alone and in combination with chemotherapy showed increased 
stabilisation of disease and survival but suggestions were made that efficacy 
was inhibited by stromal binding of the ASO (Duffy et al., 2016). Therefore the 
dose received by each mouse may be equal but the proportion of this that would 
be pharmaceutically active could vary.  
One of the benefits of vivo-morpholinos is that the same ASO can be used in 
cell culture and a variety of animal models as demonstrated by this 
investigation. Finally it must be acknowledged that this cohort was limited in size 
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and only a first pilot study and therefore further work is required to finesse the 
efficacy of SSOs in vivo. In light of all this encouragingly the SSOs have be 
proven to have potential for efficient inhibition of tumour growth in an in vivo 
context.  
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6.4 Role of exon 7b in osteoblast maturation 
TNSALP is used as a clinical marker in prostate cancer. Many prostate cancer 
patients with advanced disease develop metastases in their bones (Kamiya et 
al., 2012). The metastases are usually osteoblastic in nature, which is bone 
producing rather that osteoclastic which is bone destructive (Brown and Sim, 
2010). These lesions mimic de novo bone cancer and exhibit high levels of 
TNSALP which can be detected in the serum (Kamiya et al., 2012).  Individuals 
with high TNSALP levels have a poor progressive-free survival and overall 
survival rate (Li et al., 2018). This study investigated the relationship between 
TNSALP and ERG, two important prostate cancer biomarkers. 
The findings of this study have revealed an unexpected role for ERG in 
osteoblast maturation. The treatment of differentiating osteoblasts with SSOs 
attenuated the process which was measured in terms of TNSALP induction. 
TNSALP mRNA expression was downregulated and the expression of two 
important osteoblast genesis regulators, RUNX2 and OPN was upregulated. 
TNSALP is expressed at higher levels in more mature osteoblast cells. The 
reduction of activity and expression in the presence of SSO suggested that ERG 
may regulate its transcription.  
The initial characterisation of the TNSALP promoter revealed the presence of 
potential ERG binding sites in the TNSALP promoter and interaction of ERG on 
this promoter was confirmed using ChIP analysis. There are also potential 
binding sites for the ETS transcription factor SP1 (Terao et al., 1990). Inhibition 
of SP1 promoter binding by Mithramycin A in the presence of 1,25D/FHBP co-
treatment reduced the levels of TNSALP (Mansell et al., 2016) suggesting that 
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the SP1 promoter binding sites may have a biological function. Therefore there 
is potential to investigate if an ERG isoform-specific interaction with the 
TNSALP promoter is required to activate TNSALP transcription. Alternatively it 
is also possible that an interaction occurs between ERG isoforms and SP1, 
thereby activating TNSALP transcription. 
The observations may also suggest that ERG plays a role in bone mineralization 
regulation via interaction with 1,25D and LPA sensitive pathways. The 
expression of TNSALP is upregulated in the presence of 1,25D (Bonewald et 
al., 1992). Indeed TNSALP mRNA stability was shown to be increased by the 
addition of 1,25D to MG63 cells (Orimo and Shimada, 2006). However the exact 
mechanism of action remains unexplained. More recently the vitamin D receptor 
(VDR) was identified as a synergistic partner of the TMPRSS2-ERG gene fusion 
in PCa cell lines inducing the expression of CYP24A1, the enzyme responsible 
for the inactivation of 1,25D. The study carried out by Kim et al. (2014) 
expressed type VI ERG + exon 7b in LNCaP cells in a doxycycline-inducible 
dose-dependent manner and found that intracellular 1,25D levels were 
markedly lowered. In the case of this study it could be that ERG isoforms 
regulate TNSALP expression post-transcriptionally as well through interaction 
with the VDR induced by 1,25D. 
Wnt and Notch signalling pathways that regulate osteoblast differentiation are 
known to be targets of ETS transcription factors and more specifically ERG (Wu 
et al., 2013; Fish et al., 2017). Wnt signalling is a well-studied regulator of 
RUNX2. After stimulation at the cell surface via Wnt receptor a signal is 
transduced that leads to the translocation of beta-catenin to the nucleus where 
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it binds to TCF and LEF1 forming a complex (Wu et al., 2013). This complex is 
a transcriptional regulator and in osteoblasts activates the expression of RUNX2 
and other key osteogenic genes. ERG stabilizes beta-catenin through 
interaction with Frizzled-4, a Wnt receptor (Birdsey et al., 2015), and also 
interacts with LEF1 (Wu et al., 2013). Interestingly LPA has been shown to also 
upregulate beta-catenin dependent Wnt target gene expression via aggregation 
of beta 2 integrins in ovarian cancer cells (Burkhalter et al., 2015). Therefore 
increased levels of RUNX2 may be mediated by ERG isoform specific regulation 
as well as LPA mediated effects on Wnt signalling. 
Finally that the changes in osteoblast differentiation are triggered by the SSO-
induced skipping of ERG exon 7b provides an example of how the altered 
transcriptional activity of ERG significantly changes the biological function of the 
transcription factor. More work is required to specify which downstream targets 
and signalling pathways are being affected by this splicing event. However 
these data support the hypothesis that changes in the structure of the ERG AD 
caused by exon 7b skipping modulates cell functions as a result of changes in 
transcriptional transactivation. 
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6.5 Regulation of exon 7b inclusion 
Another aim of this project was to identify splicing regulators of ERG exon 7b. 
Aberrant regulation of alternative splicing is clearly associated with human 
disease including cancer. As ERG is an oncogenic transcription factor is not 
unreasonable to assume that changes in the alternative splicing of exon 7b may 
be driving increased inclusion that is observed in cancer cell lines and in 
patients. Using both in silico and in vitro methods a series of proteins were 
identified that potentially regulate exon 7b inclusion. However one of the main 
challenges to assess the biological relevance of these predictions was the in 
vitro validation of predicted regulators of alternative splicing.  
The ASPCR assay allowed for validation of some the predicted proteins that are 
present in the repertoire in vitro in MCF7 cells.  Several splice factors were also 
identified in the RNA pull down of the 3´ end of ERG exon 7b. However the 
splicing of a gene is not only species specific but may be tissue specific in some 
cases. Therefore although some SFs and RBPs were found in the RNA pull 
down, ASPCR and prediction results that different cell lines were used as the 
basis for these analyses may negate the relevance of some of these proteins 
as ERG exon 7b splicing regulators. This is because splice factors may regulate 
splicing in a tissue specific manner (Lee and Donald C Rio, 2015). 
SREs are relatively degenerate consensus sequences around 10 nucleotides 
in length and as such many splice factors may bind to them (Keren, Lev-Maor 
and Ast, 2010). These RBPs also possess a certain amount of redundancy 
depending on the structure of their RNA binding domain, which in turn is 
dependent on how the RBPs themselves are spliced (Hallegger, Llorian and 
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Smith, 2010). Further the activation of the spliceosome also relies on external 
ques such as the epigenetics, hormones and other small molecules (Luco et al., 
2011; Roy, Haupt and Griffiths, 2013).  
This may have been the reason as to why no changes were observed in exon 
7b splicing following siRNA knockdowns of PTBP1, HNRNPF and SRSF5. Of 
the three candidate proteins SRSF5 was detected in the pull down, ASPCR and 
in silico prediction whereas the other two were not detected in ASPCR assay. 
However the observations may have been affected by 1) experimental 
limitations (siRNA dose and treatment period) 2) mutations in these splice 
factors in the cell line derived nuclear extract preventing them from regulating 
exon 7b or 3) missing co-factors not present in the nuclear extract. Not only 
could the assay be repeated under different experimental parameters but 
different splice factors could also be targeted. Also to appropriately understand 
the splicing code for the splicing of ERG 7b would require further interrogation 
of possible combinations, possibly using a high throughput approach. 
As the most effective SSO targeted the 3´ splice site and this suggests that this 
splice site may be more influential in driving the splicing of the exon and this is 
why the RNA pull down focussed on this splice site. Analysis of ESEs also 
predicted that all four SRSF proteins analysed bind to this site at least once. 
However it would be wise to also conduct analysis of the 5´ splice site of exon 
7b, as well as intra-exonic sequences. Analysis actually predicted and highly 
scored many SFs and RBPs binding to the intronic sequence flanking exon 7b. 
Therefore although this study provides a good foundation for exon 7b inclusion 
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regulation analysis more work is required to fully understand how the event is 
regulated.  
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6.6 Main conclusions 
In conclusion, this study aimed to assess the contribution of ERG exon 7b to 
the oncogenic function of the transcription factor and elucidate the regulation of 
the alternative splicing of the exon. The conservation of ERG exon 7b in 
echinoderms points to its functional importance. Cancer cell lines and PRAD 
patients favour expression of ERG splice isoforms that include exon 7b. Cell 
biology analysis revealed SSO induced exon 7b skipping reduced in cancer 
hallmarks such as reduced proliferation, cell motility and cell survival. ERG exon 
7b specific changes in osteoblast differentiation partly mediated by ERG binding 
the TNSALP promoter is a clear example of exon 7b specific biological change. 
Therefore this study supports an oncogenic function for the full length AD of 
ERG which is more greatly expressed in cancer, and these results are in 
agreement with the observations and suggestions made in other studies (Wang 
et al., 2008; Hagen et al., 2014). In addition this study provides experimental 
tools in the form of the MG63 cell line as a new model in which to investigate 
ERG as well as validated SSOs that cause exon 7b skipping. 
The ERG targeting SSOs were able to reduce tumour growth in a mouse 
xenograft model. However size reduction was also observed with the control 
SSOs and therefore further in vivo work would require a new control SSO be 
designed. An alternative scrambled SSO was trialled but showed no reduced 
effect compared to the intron targeting SSO. Therefore further careful design of 
the SSO structure itself may be necessary going forward to ensure that 
chemistry toxicity is not masking sequence specific effects in vivo. 
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This study recognised a need to investigate the regulation of alternative splicing 
in ERG and other ETS transcription factors, particularly specific splicing event 
that may contribute to a disease phenotype. This study has begun to understand 
the splice regulators that may contribute to regulation of ERG exon 7b inclusion 
but more investigation must be performed to discern the specificities of the 
regulation of this splicing event. 
This study has highlighted the importance of the transactivation domain of ERG 
as a key site of regulation for the activity of the transcription factor. Truncating 
the domain produces a functional protein that has less oncogenic activity as 
supported by the data in this study. Therefore manipulation of the splicing of 
exon 7b is a feasible and potential therapeutic target to reduce disease burden 
in ERG related cancers.  
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6.7 Future Work 
6.7.1 Further study of the role of exon 7 in conjunction with exon 7b  
As both exon 7 and exon 7b encode for the AD study of the contribution of each 
individual exon and both exon to changing ERG function could be of interest. 
The approach for this could be two fold. SSOs could designed to cause exon 7 
skipping and skipping of both exons. Similarly gene editing methods such as 
clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR 
associate protein 9 (Cas9) could be used. CRISPR-Cas 9 uses specifically 
designed guide RNA to direct the Cas9 bacterial nuclease to the intended target 
site where the enzyme makes an incision in the genomic DNA. Formation of a 
double strand break leads to its repair via the non-homologous end joining 
(NHEJ) or homology-directed repair (HDR) pathway. It is at this point that users 
are able to apply their genomic manipulation to generate the desired 
modification (Gaj, Gersbach and Barbas, 2013; Ran et al., 2013; Munoz et al., 
2014).  
ERG variants lacking exon 7 and 7b separately and together could be generated 
in a cell line that does not normally express the mutation using CRISPR-Cas9. 
Upon successful generation the model cell line, cell biology assays as used in 
this study could assess the effect of that each genetic modification has in vitro. 
Further the exons could be removed in an ERG expressing cancer cell line to 
investigate if biological changes are cell line, cancer or tissue specific. These 
genome editing experiments would complement the SSO work for which cell 
biology analysis would also be carried out. The future use of the SSO would 
require the redesign of the SSO to reduce off target effects. Both standard and 
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scrambled controls were tested in the course of this study therefore alternatives 
would need to be used. An SSO with 5 or more base pairs mismatched to the 
target SSO could be an option. Similarly the chemistry of the vivo moiety on the 
morpholino could require be modification. Lastly these manipulations would 
allow for more powerful in vivo experiments in which the selected model cancer 
cells, now genetically modified, would be injected orthotopically into mouse 
either directly into the prostate or an alternative site. 
It would also be of interest to understand how the exclusion of exon 7 and 7b 
affect the RNA secondary structure of the ERG transcript and of the protein 
structure of ERG. It is known the RNA conformation can contribute to the 
regulation of splicing and the presence of structures such as hairpins and G4 
may drive splicing of these particular exons. Furthermore resolution of the 
protein structure could be informative of the binding interactions that occur 
within this domain. To study RNA structure chemical mapping and nuclear 
magnetic resonance could be used whereas X-ray crystallography could be 
used to study protein structure.  
To gain a better insight into transcriptional changes caused by alternative 
splicing qPCR of recognised ERG targets could be carried out alongside 
traditional transcriptional assays such as the renilla-luciferase assay. This 
would reveal promoters for which transcription is directly affected as well as 
target genes for which ERG alternative splicing may indirectly influence 
expression. In addition mutagenesis of phosphorylation sites in exon 7b (and 
perhaps exon 7) and the DEF domain prior to transcriptional investigation would 
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inform on the specific influence that these sites contribute to the changes seen 
in ERG function. 
  
 208  Samantha Jumbe- June 2019 
6.7.2 Further investigation of the regulation of ERG exon 7b regulation 
The data in this study with regards to ERG exon 7b regulation provides a robust 
resource from which to continue investigation. A number of approaches could 
be employed to gain further insight. Firstly mutagenesis of predicted ESEs could 
be carried out and the effect on exon 7b splicing discerned using PCR initially. 
ISE prediction could be carried out and these could also be investigated 
particularly in light of the RNACompete data that showed that a number of RBPs 
may be binding in the intronic sequence flanking exon 7b.  
Several ERG minigenes with mutations in the ESEs and ISEs would be 
designed and transfected into a cell line that does not normally express ERG. If 
the role of a specific splice factor were to be investigated alongside then an 
expression vector for the protein could be co-transfected.  
Certainly further refinement of the experimental conditions for the siRNA 
knockdowns of PTBP1, HNRNPF and SRSF5 could be carried out, and other 
proteins pulldown by at the acceptor site could be investigated as well. The RNA 
pull down experiment could be repeated based on results from the ESE and ISE 
mutagenesis screen to identify which proteins may be binding at these sites.  
The use of PCR to assess the extent of alternative splicing is simple, convenient 
and in this case allows for semi-quantitative determination of PSI. However a 
more sensitive method may reveal more subtle changes that may still be of 
relevance. An alternative method could be the use of carefully designed qRT-
PCR primers especially those that could detect the different splice variants with 
various combinations of exon 7b and exon 7. 
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6.7.3 The role of ERG in osteogenesis of osteoblasts  
SSO and genome editing approaches could be used to investigate the role of 
ERG in osteoblast maturation as well. Not only would alternative splicing of the 
AD be of interest but also knockdown and overexpression experiments could 
inform on the role of the complete profile of ERG splice variants. Coupled with 
the 1, 25D/FHBP co-treatment changes in TNSALP activity could be assessed 
when different exon 7b and 7 variants are expressed. Study of the role of ERG 
exon 7 and 7b in bone development would also be of interest as currently this 
is not really understood. 
Conditioned media could be collected from the various treatments and the 
presence of several osteogenic factors measured using biochemical assays. 
Drivers of osteogenesis that can be detected using radioimmunoassays and 
enzyme-linked immunoabsorbent assays include osteocalcin, osteoprotegrin, 
VEGF and transforming growth factor beta 1(TGF-β1). In addition to the MG63 
cell line model experiments could be carried out in primary osteoblasts.  
Gene expression studies could be carried out for more bone marker genes and 
this could be complemented with western blot analysis to assess changes at 
the protein level as well. Transcriptional assays could inform on which 
osteoblast genes may be directly regulated by ERG. Based on the findings of 
this study with regards to the TNSALP promoter it would be of interest to 
understand if ERG binds other promoters of key osteoblast genes.  
Finally knowing that ERG is an important Wnt signalling regulator investigation 
of the role of the transcription factor in this pathway should also be examined. 
Wnt signalling is a key regulator of bone homeostasis maintaining the balance 
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between formation and resorption of bone. PCR and western blot analysis of 
downstream Wnt signalling components could be performed initially then 
inhibition of any proteins that are seen to change could be carried out to see if 
changes can be detected. 
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Sequences of primers used in this study 
Primer Name Sequence (5´ to  3´) 
ERGex6F GAATATGGCCTTCCAGACGTCAAC  
ERGex8R CGGTCCAGGCTGATCTCCTG 
BactinF CCTGGCACCCAGCACAAT 
BactinR GCCGATCCACACGGAGTACT   
For ChIP 
ALPLF TCGCTGGAGGCATTCAAAC 
ALPLR CCCCTCTTTAACAGGCAGAC   
For qPCR 
qRUNX2 ex9 F CCAACCCACGAATGCACTATC 
qRUNX2 ex9 R TAGTGAGTGGTGGCGGACATAC 
qALP F CGTCGATTGCATCTCTGGGC 
qALP R GTCTCTTGCGCTTGGTCTCG 
qOPN F TGGCTAAACCCTGACCCATCT 
qOPN R TCATTGGTTTCTTCAGAGGACACA   
qHNRNPF F GGTTGAGAACAAAAACATGC 
qHNRNPF R ATGGTAATGAAATGTCCACG 
qSRSF5 F AGATTTCATGAGACAAGCTG 
qSRSF5 R CTCCCATTTATTTCCTTTCCAG 
qPTBP1F AGCGCGTGAAGATCCTGT TC 
qPTBP1R CAGGGGTGAGTTGCCGTAG 
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Sequencing results for PCR products in this this study  
> ERG top 
ATGATTACGAATCGATGGGAGGACTGTGCAAGATGACCAAGGACGACTTCCAGAGGCT
CACCCCCAGCTACAACGCCGACATCCTTCTCTCACATCTCCACTACCTCAGAGAGACT
CCTCTTCCACATTTGACTTCAGATGATGTTGATAAAGCCTTACAAAACTCTCCACGGT
TAATGCATGCTAGAAACACAGGGGGTGCAGCTTTTATTTTCCCAAATACTTCAGGATA
TCCTGAAGGTACGCAAAGAAACTTACTAGGCCAGATTTACCATATGAGCCCCCCTGGA
GATCTACCAGGACGGGTCGCGGCCACCGTTCCATAATACTATATATAACATATCTAAC
ATTTTGGACTAGAATTAAGTAGCTGATTTTCTTTTGCCACGTTTCCTGCCATAACTTC
ACCGAGTGTGGGTGTCGCATCTGAAGTCACAAACTAGTTTACATGTTACCAATATAGA
CTTTATATTCTCAATGTCTAGCCCAGTTCCTACCCTACTCTAACTGTTGCATTCTCTG
CAGGTTTCTCGAATGCAAGTGCGGGGAAAGTTACAAAACACGTCAGCAACCTCGGACC
AAAAATTCTGAGATCGGAGACATACTTGTACATGACACTCTTGCCATAACCTCTTTTC
TGGACTGTTGCAGAGGTGTAGTAGGAAGCAGACACTCTGTAGCCATCAAGATCTTCTT
ATGCAGCACCTGT 
 
> ERG middle  
ATGATACGAATCGATGGGAGGACTGTGCAAGATGACCAAGGACGACTTCCAGAGGCTC
ACCCCCAGCTACAACGCCGACATCCTTCTCTCACATCTCCACTACCTCAGAGAGACTC
CTCTTCCACATTTGACTTCAGATGATGTTGATAAAGCCTTACAAAACTCTCCACGGTT
AATGCATGCTAGAAACACAGATTTACCATATGAGCCCCCCAGGAGATCAGCCTGGACC
GGTCACGGCCACCCAGCCTCGTGTCCGCTCTGACCTAGTGCCTTCATTGATTCCCCCG
CTACCCCAAGCACATGAACCAGCACTACTTCTTACGCGGTCCCTGCCCGAAAGCAACA
TCAACGAGCATCTTCCTTCTTCTATGACGACGGCAACTACCAGACCAGCTCCGAAGTG
AAGTTCTAACTCCACACCGATCCGAACCGAATTGAGATGAATCGCATCCATCTCCGAG
AGGATCGTCACGTTCTGCGGCACATCCTGTAGTACCAGTACAACGTCCTCTCGTTCTA
TATCATAGGCGACAAGTAGAACATCGGCGTCTACGTGCAACATCCGCATCCGCCACAA
CGTCGAGGACGGG 
 
> ERG bottom  
ATTGCATTCCGACTCGATGGGAGGAACTGTGCAAGATGACCAAGGACGACTTCCAGAG
GCTCACCCCCAGCTACAACGCCGACATCCTTCTCTCACATCTCCACTACCTCAGAGAG
AATTTACCATATGAGCCCCCCAGGAGATCAGCCTGGACCGGTCACGGCCACCCCACGC
CCCAGTCGAAAGCTGCTCAACCATCTCCTTCCACAGTGCCCAAAACTGAAGACCAGCG
TCCTCAGTTAGATCCTTATCAGATTCTTGGACCAACAAGTAGCCGCCTTGCAAATCCA
G 
  
Exon 6 Exon 7 Exon 7b Exon 8 
Underlined bases are miscalled by sequencing reaction 
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Normalisation and quantification procedure for qPCR 
As stated in the qPCR method a spike was run for each sample to facilitate 
normalization. Linearized DNA for the same spike sequence was used to create 
a minimum five point 10-fold dilution standard curve included on each plate run. 
The following method describes how qPCR data was normalized and quantified.  
1. A standard curve was created of the mass of cDNA standard in nanogram 
(ng) (x-axis) and Ct (y-axis). The Ct values for each well was used to 
derive the mass of cDNA amplified in each sample.  
  
 
 
 
 
 
 
 
 
SPIKE SRSF5
Sample Ct
Amount of 
standard 
(ng)
Sample Ct
Amount of 
standard 
(ng)
untreated 16.62271 0.008966312 untreated 22.95869 0.00010412
untreated 16.53816 0.009515609 untreated 22.91039 0.00010772
untreated 16.62316 0.00896345 untreated 22.9103 0.00010772
transfection 16.22703 0.011842902 transfection 22.46821 0.00014701
transfection 16.25094 0.011645463 transfection 22.45071 0.00014883
transfection 16.39106 0.010552664 transfection 22.46825 0.000147
control sIRNA 17.10127 0.006404059 control sIRNA 22.13436 0.00018591
control sIRNA 17.07617 0.006518123 control sIRNA 22.11804 0.00018805
control sIRNA 17.08081 0.006496886 control sIRNA 21.95165 0.0002114
PTBP1 10 16.22092 0.011893907 PTBP1 10 22.4272 0.00015131
PTBP1 10 16.23546 0.011772929 PTBP1 10 22.37702 0.00015674
PTBP1 10 16.35033 0.010859274 PTBP1 10 22.45064 0.00014883
PTBP1 20 17.70487 0.004188979 PTBP1 20 23.10477 9.3955E-05
PTBP1 20 17.70528 0.004187788 PTBP1 20 22.95594 0.00010432
PTBP1 20 17.7716 0.003996943 PTBP1 20 23.18158 8.9015E-05
PTBP1 50 16.6717 0.008662668 PTBP1 50 22.6048 0.00013354
Amount of 
standard 
(ng)
Ct
1.86E-03 18.91226
1.86E-03 18.82157
1.86E-03 18.85822
1.86E-04 22.19721
1.86E-04 22.0679
1.86E-04 22.05155
1.86E-05 25.7451
1.86E-05 25.4576
1.86E-05 25.57102
1.86E-06 28.13166
1.86E-06 28.5323
1.86E-06 28.564
1.86E-07 31.42349
1.86E-07 31.94827
1.86E-07 32.89028
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2. As each sample was spiked with an equal mass of spike RNA the 
expression of the spike could be used to normalize expression across 
samples. A multiplication factor was derived for each sample using the 
equation below.  
𝑀𝑢𝑙𝑡𝑖𝑝𝑙𝑖𝑐𝑎𝑡𝑜𝑟 𝑓𝑎𝑐𝑡𝑜𝑟 =
largest mass of all spike cDNA samples
mass of spike cDNA in the sample 
 
3. To work out amount of gene expression. The mass of gene cDNA for each 
sample was normalized using the multiplication factor and converted to 
grams by multiplying the mass by 10-9. 
𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑐𝐷𝑁𝐴
= 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝐷𝑁𝐴 𝑖𝑛 𝑛𝑔 ×   𝑚𝑢𝑙𝑡𝑖𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 × 10−9  
4. The number of amplicons at the Ct value was calculated. Avogadro’s 
number = 6.02214 x 1023. 
number of amplicons at the Ct value =
(𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑐𝐷𝑁𝐴 𝑖𝑛 𝑔×𝑎𝑣𝑜𝑔𝑎𝑑𝑟𝑜′𝑠 𝑛𝑢𝑚𝑏𝑒𝑟) 
𝑎𝑚𝑝𝑙𝑖𝑐𝑜𝑛 𝑠𝑖𝑧𝑒
  
5. The molecular weight of the mRNA transcript was calculated. The largest 
transcript size for each gene was used for the calculation. The average 
molecular weight of an RNA nucleotide 320.5 and the addition of 159 
takes into account the molecular weight of a 5' triphosphate. 
molecular weight of the mRNA transcript
= (mRNA transcript × 320.5) + 159 
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6. The number of gene transcripts at Ct value was calculated. The 
normalized mass of the cDNA was divided by two to account for the single 
stranded nature of RNA vs cDNA. 
number of gene transcripts at Ct value
=
(𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑐𝐷𝑁𝐴 𝑖𝑛 𝑔 ÷ 2)
𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑚𝑅𝑁𝐴 𝑡𝑟𝑎𝑛𝑠𝑐𝑟𝑖𝑝𝑡
 × 𝐴𝑣𝑜𝑔𝑎𝑑𝑟𝑜′𝑠𝑛𝑢𝑚𝑏𝑒𝑟 
7. The total mass of gene transcript in the sample was calculated 
mass of gene transcript in the sample 
=
number of gene transcripts at Ct value
𝐴𝑣𝑜𝑔𝑎𝑑𝑟𝑜′𝑠𝑛𝑢𝑚𝑏𝑒𝑟
× 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑚𝑅𝑁𝐴 𝑡𝑟𝑎𝑛𝑠𝑐𝑟𝑖𝑝𝑡 
8. The expression of each gene is reported as a percentage of the total RNA 
used for the original cDNA synthesis reaction.  
% 𝑡𝑜𝑡𝑎𝑙 𝑅𝑁𝐴 𝑖𝑛𝑝𝑢𝑡 (𝑓𝑜𝑟 𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡)
=
mass of gene transcript in the sample 
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑅𝑁𝐴 𝑢𝑠𝑒𝑑 𝑓𝑜𝑟 𝑐𝐷𝑁𝐴 𝑠𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑠 
× 100 
 
An example is shown of the next page to illustrate the method. This is how the 
expression of SRSF5 could be calculated in an untreated sample. Note that the 
experimetns were carried out in with three technical repeats. What is shown 
below is one of the three technical repeats. The method below starts at step 3 
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Step 3 
A B C D 
Sample Amount of DNA 
(ng) 
Multiplication 
factor 
Normalised 
amount of DNA 
(g) 
 
untreated 0.00010412 
 
1.4 
 
=B3*C3*(10^-9) 
 
Step 4 and 5 
E F J K 
Amplicon 
size 
Amplicon number at Ct Transcript  
size 
MW of SRSF5 
transcript 
141 =((D3*(6.02214*10^23))/(E3)) 2815 =(J3*320.5)+159 
 
Step 6, 7 and 8 
L M N 
Transcript number at Ct Mass of transcript (g) Percentage of total RNA 
=(((D3)/2)/K3)*(6.02214* 
10^23) 
=((L3)/(6.02214*10^23))* 
K3 
=(M3/(200*10^-9))*100 
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PSI and ΔPSI values for high throughput RNAi experiment 
Gene PSI  Gene ΔPSI 
Lipo MCF7 tr100 0.567  A1-6 -1.0 
DEK MCF7 tr100 0.548  BRCA1 -19.7 
HMGA1 MCF7 tr100 0.645  CCNH 2.5 
PRPF8 MCF7 tr100 0.449  CDC5L 7.5 
Lipo MCF7 tr102 0.524  CDK11 17.6 
CCNH MCF7 tr102 0.549  CLK1 5.3 
CRK7 MCF7 tr102 0.464  CRK7 -6.0 
SFRS16 MCF7 tr102 0.612  CTNNB1 2.1 
Lipo MCF7 tr104 0.599  DDX39 0.6 
KHDRBS1 MCF7 tr104 0.569  DDX6 7.6 
Lipo MCF7 tr105 0.639  DEK -1.9 
CDC5L MCF7 tr105 0.714  FMR1 -3.9 
KHDRBS3 MCF7 tr105 0.392  FUS -7.2 
MBNL1 MCF7 tr105 0.648  FXR1 -9.2 
Lipo MCF7 tr108 0.656  HEAB -17.1 
ZNF638 MCF7 tr108 0.631  HMGA1 7.8 
Lipo MCF7 tr110 0.563  HNRPD 3.3 
CDK11 MCF7 tr110 0.739  HNRPL 20.8 
CTNNB1 MCF7 tr110 0.584  KHDRBS1 -3.0 
Lipo MCF7 tr111 0.532  KHDRBS3 -24.7 
DDX6 MCF7 tr111 0.608  KHSRP -4.0 
THOC1 MCF7 tr111 0.570  MBNL1 0.9 
Lipo MCF7 tr115 0.589  MSI2 15.7 
FUS MCF7 tr115 0.517  NPM1 -4.7 
FXR1 MCF7 tr115 0.498  PRPF4B -8.0 
PRPF4B MCF7 tr115 0.509  PRPF8 -11.8 
SAFB MCF7 tr115 0.614  RALY -11.8 
SF3B4 MCF7 tr115 0.428  RBM3 -8.6 
Lipo MCF7 tr123 0.389  RBM9 -16.8 
SFRS4 MCF7 tr123 0.536  RNPC2 -28.1 
SR-A1 MCF7 tr123 0.652  RNPS1 16.7 
Lipo MCF7 tr125 0.525  RPL22 3.8 
BRCA1 MCF7 tr125 0.329  RPN1 -3.0 
Lipo MCF7 tr127 0.517  SAFB 2.5 
HEAB MCF7 tr127 0.347  SF3A1 -35.3 
MSI2 MCF7 tr127 0.675  SF3A2 -28.2 
Lipo MCF7 tr129 0.657  SF3A3 -5.3 
NPM1 MCF7 tr129 0.610  SF3B4 -16.1 
RPL22 MCF7 tr129 0.695  SFPQ -2.0 
RPN1 MCF7 tr129 0.627  SFRS10 -5.1 
Lipo MCF7 tr44 0.497  SFRS12 -17.3 
TIAL1 MCF7 tr44 0.410  SFRS16 8.8 
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Lipo MCF7 tr68 0.488  SFRS3 -3.4 
SFRS3 MCF7 tr68 0.454  SFRS4 14.7 
SFRS5 MCF7 tr68 0.586  SFRS5 9.8 
Lipo MCF7 tr75 0.515  SFRS8 14.6 
SNRP70 MCF7 tr75 0.506  SNRP70 -0.9 
U2AF1 MCF7 tr75 0.352  SNW1 12.3 
Lipo MCF7 tr78 0.600  SR-A1 26.4 
RBM9 MCF7 tr78 0.432  SRPK1 -2.7 
Lipo MCF7 tr82 0.569  SYNCRIP -7.1 
CLK1 MCF7 tr82 0.622  TARBP1 32.6 
RNPS1 MCF7 tr82 0.736  THOC1 3.8 
Lipo MCF7 tr83 0.509  U2AF1 -16.2 
SF3A3 MCF7 tr83 0.456  ZNF638 -2.4 
Lipo MCF7 tr84 0.535  TIAL1 -8.6 
A1-6 MCF7 tr84 0.525  
Lipo MCF7 tr86 0.579  
DDX39 MCF7 tr86 0.585  
KHSRP MCF7 tr86 0.539  
Lipo MCF7 tr88 0.609  
RBM3 MCF7 tr88 0.523  
RNPC2 MCF7 tr88 0.328  
SFRS12 MCF7 tr88 0.436  
Lipo MCF7 tr89 0.439  
FMR1 MCF7 tr89 0.400  
SFRS8 MCF7 tr89 0.586  
TARBP1 MCF7 tr89 0.765  
Lipo MCF7 tr95 0.582  
RALY MCF7 tr95 0.465  
SFPQ MCF7 tr95 0.563  
SNW1 MCF7 tr95 0.705  
SRPK1 MCF7 tr95 0.556  
Lipo MCF7 tr96 0.443  
HNRPD MCF7 tr96 0.476  
Lipo MCF7 tr97 0.577  
SF3A1 MCF7 tr97 0.225  
SF3A2 MCF7 tr97 0.296  
Lipo MCF7 tr99 0.560  
HNRPL MCF7 tr99 0.769  
SFRS10 MCF7 tr99 0.509  
SYNCRIP MCF7 tr99 0.490  
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Proteins identified in mass spectrometry of RNA pull down 
Description 
Sc
or
e 
A
2 
Co
ver
age 
A2 
# 
Pep
tide
s 
A2 
# 
PS
M 
A2 
Sc
or
e 
B2 
Co
ver
age 
B2 
# 
Pep
tide
s 
B2 
# 
PS
M 
B2 
M
W 
[k
Da
] 
#P
SM 
rat
io 
Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 - 
[NUCL_HUMAN] 
12
8.
86  
32.
68 
25 43 56
3.
91  
54.
37 
40 20
4 
76
.6 4.
74 
Heterogeneous nuclear ribonucleoprotein M 
OS=Homo sapiens GN=HNRNPM PE=1 SV=3 - 
[HNRPM_HUMAN] 
19
9.
96  
45.
34 
30 77 56
2.
35  
71.
37 
52 21
8 
77
.5 2.
83 
Heterogeneous nuclear ribonucleoprotein K, isoform 
CRA_d OS=Homo sapiens GN=HNRPK PE=4 SV=1 - 
[A0A024R228_HUMAN] 
13
4.
90  
51.
84 
21 55 55
1.
41  
64.
79 
30 20
2 
51
.2 3.
67 
Polypyrimidine tract-binding protein 1 OS=Homo 
sapiens GN=PTBP1 PE=1 SV=1 - 
[A0A0U1RRM4_HUMAN] 
91
.1
1  
37.
41 
14 30 53
1.
30  
58.
67 
26 16
2 
62
.4 5.
40 
Matrin-3 OS=Homo sapiens GN=MATR3 PE=1 SV=1 
- [A8MXP9_HUMAN] 
88
.8
3  
29.
50 
21 34 47
2.
74  
69.
39 
60 20
5 
99
.9 6.
03 
Poly(rC)-binding protein 1 OS=Homo sapiens 
GN=PCBP1 PE=1 SV=2 - [PCBP1_HUMAN] 
87
.9
7  
56.
74 
13 32 31
8.
32  
71.
91 
16 94 37
.5 2.
94 
Heterogeneous nuclear ribonucleoprotein H 
OS=Homo sapiens GN=HNRNPH1 PE=1 SV=4 - 
[HNRH1_HUMAN] 
13
5.
05  
42.
09 
14 56 28
4.
61  
50.
78 
16 10
1 
49
.2 1.
80 
Heterogeneous nuclear ribonucleoprotein F 
OS=Homo sapiens GN=HNRNPF PE=1 SV=3 - 
[HNRPF_HUMAN] 
60
.3
5  
26.
02 
6 22 26
9.
34  
51.
08 
15 91 45
.6 4.
14 
Heterogeneous nuclear ribonucleoprotein M 
(Fragment) OS=Homo sapiens GN=HNRNPM PE=1 
SV=1 - [M0QZM1_HUMAN] 
10
3.
41  
47.
26 
14 41 26
8.
50  
67.
10 
21 10
3 
40
.0 2.
51 
Heterogeneous nuclear ribonucleoprotein A1 
OS=Homo sapiens GN=HNRNPA1 PE=1 SV=2 - 
[F8W6I7_HUMAN] 
11
1.
09  
63.
84 
19 42 25
2.
94  
64.
82 
21 10
2 
33
.1 2.
43 
Heterogeneous nuclear ribonucleoprotein D (AU-rich 
element RNA binding protein 1, 37kDa), isoform 
CRA_e OS=Homo sapiens GN=HNRPD PE=4 SV=1 - 
[A0A024RDF4_HUMAN] 
65
.9
8  
43.
46 
16 31 24
0.
74  
52.
29 
21 90 32
.8 
2.
90 
Splicing factor U2AF 65 kDa subunit OS=Homo 
sapiens GN=U2AF2 PE=1 SV=4 - [U2AF2_HUMAN] 
35
.1
4  
25.
47 
7 11 22
0.
50  
46.
53 
15 75 53
.5 6.
82 
HNRNPL protein (Fragment) OS=Homo sapiens 
GN=HNRNPL PE=2 SV=2 - [Q6NTA2_HUMAN] 
31
.5
6  
20.
80 
7 9 18
1.
43  
51.
05 
19 63 61
.9 7.
00 
Poly(U)-binding-splicing factor PUF60 (Fragment) 
OS=Homo sapiens GN=PUF60 PE=1 SV=1 - 
[A0A0J9YVP6_HUMAN] 
34
.9
4  
24.
72 
8 13 17
2.
49  
50.
94 
21 56 57
.4 4.
31 
Heterogeneous nuclear ribonucleoproteins A2/B1 
OS=Homo sapiens GN=HNRNPA2B1 PE=1 SV=2 - 
[ROA2_HUMAN] 
10
6.
27  
55.
81 
18 40 15
9.
43  
57.
51 
21 61 37
.4 1.
53 
Splicing factor 1, isoform CRA_a OS=Homo sapiens 
GN=SF1 PE=4 SV=1 - [A0A024R566_HUMAN] 
32
.6
1  
21.
19 
8 11 15
8.
04  
35.
73 
15 62 61
.8 5.
64 
Heterogeneous nuclear ribonucleoprotein H3 
OS=Homo sapiens GN=HNRNPH3 PE=1 SV=2 - 
[HNRH3_HUMAN] 
42
.6
5  
33.
24 
8 20 15
2.
54  
53.
76 
12 54 36
.9 2.
70 
Heterogeneous nuclear ribonucleoprotein H2 
OS=Homo sapiens GN=HNRNPH2 PE=1 SV=1 - 
[HNRH2_HUMAN] 
66
.2
2  
28.
51 
10 33 13
7.
68  
40.
53 
14 62 49
.2 1.
88 
Protein FAM98B OS=Homo sapiens GN=FAM98B 
PE=1 SV=1 - [FA98B_HUMAN] 
1.
91  
3.9
4 
1 1 12
4.
91  
46.
06 
11 39 37
.2 
39
.0
0 
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Heterogeneous nuclear ribonucleoprotein D-like 
OS=Homo sapiens GN=HNRNPDL PE=1 SV=1 - 
[A0A087WUK2_HUMAN] 
34
.7
8  
26.
45 
8 14 10
8.
25  
31.
96 
14 40 40
.0 2.
86 
Mitochondrial antiviral-signaling protein OS=Homo 
sapiens GN=MAVS PE=1 SV=2 - [MAVS_HUMAN] 
        10
7.
07  
35.
37 
10 32 56
.5 
32
.0
0 
G-rich sequence factor 1 OS=Homo sapiens 
GN=GRSF1 PE=1 SV=3 - [GRSF1_HUMAN] 
2.
82  
4.3
8 
2 2 10
0.
37  
45.
21 
16 35 53
.1 
17
.5
0 
Heterogeneous nuclear ribonucleoprotein A0 
OS=Homo sapiens GN=HNRNPA0 PE=1 SV=1 - 
[ROA0_HUMAN] 
36
.3
0  
25.
25 
7 12 99
.1
9  
42.
95 
11 34 30
.8 2.
83 
Splicing factor, proline- and glutamine-rich 
OS=Homo sapiens GN=SFPQ PE=1 SV=2 - 
[SFPQ_HUMAN] 
56
.2
7  
29.
99 
17 25 93
.7
1  
28.
43 
17 37 76
.1 1.
48 
Heterogeneous nuclear ribonucleoprotein A/B 
OS=Homo sapiens GN=HNRNPAB PE=1 SV=1 - 
[D6R9P3_HUMAN] 
42
.6
5  
34.
64 
10 16 85
.5
5  
36.
43 
11 35 30
.3 2.
19 
Serine/arginine-rich splicing factor 1 OS=Homo 
sapiens GN=SRSF1 PE=1 SV=2 - [SRSF1_HUMAN] 
23
.9
2  
31.
85 
8 14 85
.4
0  
47.
18 
13 37 27
.7 2.
64 
Splicing factor U2AF 35 kDa subunit-like protein 
OS=Homo sapiens GN=U2AF1L5 PE=3 SV=1 - 
[U2AF5_HUMAN] 
10
.0
3  
16.
25 
3 4 84
.2
1  
47.
08 
8 31 27
.9 7.
75 
RNA-binding protein 10 OS=Homo sapiens 
GN=RBM10 PE=1 SV=3 - [RBM10_HUMAN] 
1.
86  
1.2
9 
1 1 73
.9
9  
19.
25 
16 31 10
3.
5 
31
.0
0 
Ribonucleoprotein PTB-binding 1 OS=Homo sapiens 
GN=RAVER1 PE=1 SV=1 - [A0A087WZ13_HUMAN] 
4.
38  
5.6
8 
2 3 73
.6
2  
32.
61 
15 30 77
.8 
10
.0
0 
RNA-binding protein 12 OS=Homo sapiens 
GN=RBM12 PE=1 SV=1 - [RBM12_HUMAN] 
        70
.7
3  
19.
85 
17 35 97
.3 
35
.0
0 
Cap-specific mRNA (nucleoside-2'-O-)-
methyltransferase 1 OS=Homo sapiens GN=CMTR1 
PE=1 SV=1 - [CMTR1_HUMAN] 
        67
.5
4  
18.
92 
15 28 95
.3 
28
.0
0 
Pre-mRNA-splicing factor RBM22 OS=Homo sapiens 
GN=RBM22 PE=1 SV=1 - [RBM22_HUMAN] 
1.
92  
2.6
2 
1 1 64
.2
5  
28.
57 
11 28 46
.9 
28
.0
0 
CUG triplet repeat, RNA binding protein 1, isoform 
CRA_c OS=Homo sapiens GN=CELF1 PE=1 SV=1 - 
[G5EA30_HUMAN] 
        63
.6
3  
23.
54 
13 24 55
.1 
24
.0
0 
Polypyrimidine tract-binding protein 3 OS=Homo 
sapiens GN=PTBP3 PE=1 SV=2 - [PTBP3_HUMAN] 
1.
72  
1.0
9 
1 1 59
.9
9  
23.
91 
12 28 59
.7 
28
.0
0 
Serine/arginine-rich splicing factor 3 OS=Homo 
sapiens GN=SRSF3 PE=1 SV=1 - [SRSF3_HUMAN] 
25
.9
1  
31.
10 
5 11 50
.6
7  
39.
63 
7 21 19
.3 1.
91 
Serine/arginine-rich splicing factor 5 OS=Homo 
sapiens GN=SRSF5 PE=1 SV=1 - [SRSF5_HUMAN] 
9.
01  
8.4
6 
2 5 38
.2
3  
25.
00 
6 14 31
.2 2.
80 
Serine/arginine-rich splicing factor 9 OS=Homo 
sapiens GN=SRSF9 PE=1 SV=1 - [SRSF9_HUMAN] 
        26
.6
4  
40.
27 
11 16 25
.5 
16
.0
0 
Polypyrimidine tract-binding protein 2 OS=Homo 
sapiens GN=PTBP2 PE=1 SV=1 - [PTBP2_HUMAN] 
        26
.5
0  
14.
31 
7 14 57
.5 
14
.0
0 
RNA-binding protein 42 OS=Homo sapiens 
GN=RBM42 PE=1 SV=1 - [K7EQ03_HUMAN] 
        18
.7
1  
16.
43 
6 7 44
.6 7.
00 
Probable RNA-binding protein 19 OS=Homo sapiens 
GN=RBM19 PE=1 SV=3 - [RBM19_HUMAN] 
        16
.0
3  
6.4
6 
5 6 10
7.
3 
6.
00 
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RNA-binding protein 5 OS=Homo sapiens GN=RBM5 
PE=1 SV=2 - [RBM5_HUMAN] 
        10
.2
3  
6.0
1 
4 4 92
.1 4.
00 
Splicing factor 3A subunit 2 OS=Homo sapiens 
GN=SF3A2 PE=1 SV=2 - [SF3A2_HUMAN] 
        8.
08  
3.8
8 
1 3 49
.2 
3.
00 
Cold-inducible RNA-binding protein OS=Homo 
sapiens GN=CIRBP PE=1 SV=1 - [CIRBP_HUMAN] 
        5.
78  
12.
79 
2 2 18
.6 
2.
00 
RNA-binding protein 38 OS=Homo sapiens 
GN=RBM38 PE=1 SV=1 - [F6VZ39_HUMAN] 
        4.
58  
21.
14 
2 3 13
.6 
3.
00 
RNA-binding protein fox-1 homolog 2 (Fragment) 
OS=Homo sapiens GN=RBFOX2 PE=1 SV=1 - 
[A0A0G2JSB3_HUMAN] 
        4.
57  
16.
67 
3 3 20
.2 3.
00 
Nucleoporin 153kDa, isoform CRA_a OS=Homo 
sapiens GN=NUP153 PE=4 SV=1 - 
[A0A024QZW7_HUMAN] 
        3.
42  
1.0
2 
1 1 15
3.
9 
1.
00 
RNA-binding protein MEX3B OS=Homo sapiens 
GN=MEX3B PE=1 SV=1 - [MEX3B_HUMAN] 
        2.
54  
5.1
0 
2 4 58
.8 
4.
00 
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Summary of splicing regulatory proteins identified in this study 
Protein 
Mass 
Spectro
metry 
MCF 
assay 
RNA 
Compete 
Motif 
SF 
correlatio
n 
RBP 
correlatio
n 
Splice 
Aid2 
A1-6  Y     
BRCA1  Y     
CCNH  Y     
CDC5L  Y     
CDK11  Y     
CELF1 Y  Y   Y 
CELF2   Y Y Y Y 
CELF4   Y Y   
CELF5   Y Y Y  
CIRBP Y      
CLK1  Y     
CMTR1 Y      
CPEB2   Y    
CPEB4   Y    
CRK7  Y     
CTNNB1  Y     
DDX39  Y     
DEK  Y     
ELAVL1   Y Y   
ENOX1   Y Y   
FAM98B Y      
FMR1  Y Y    
FUS  Y  Y  Y 
FXR1  Y Y Y   
GRSF1 Y      
HEAB  Y     
HMGA1  Y     
HNRNPA0 Y      
HNRNPA1 Y  Y   Y 
HNRNPA2B1 Y  Y Y   
HNRNPAB Y      
HNRNPD Y Y     
HNRNPDL Y      
HNRNPF Y     Y 
HNRNPH1 Y     Y 
HNRNPH2 Y     Y 
HNRNPH3 Y     Y 
HNRNPK Y     Y 
HNRNPL Y Y Y Y   
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HNRNPM Y      
KHDRBS1  Y    Y 
KHDRBS3  Y  Y  Y 
KHSRP  Y  Y  Y 
MATRIN3 Y  Y Y   
MAVS Y      
MBNL1  Y   Y Y 
MEX3B Y      
MSI2  Y     
NPM1  Y     
NUP153 Y      
PABP   Y    
PCBP1 Y  Y    
PCBP2   Y    
PCBP3   Y  Y  
PRPF4B  Y     
PRPF8  Y     
PTBP1 Y  Y   Y 
PTBP2 Y   Y Y  
PTBP3 Y      
PUF60 Y      
RALY  Y  Y Y  
RAVER Y      
RBFOX2 Y      
RBM10 Y      
RBM12 Y      
RBM19 Y      
RBM22 Y      
RBM24   Y    
RBM28   Y Y   
RBM3  Y Y    
RBM38 Y   Y Y  
RBM42 Y  Y    
RBM5 Y  Y Y   
RBM6   Y    
RBM9  Y  Y Y  
RBMS1   Y    
RBP1   Y    
RNPC2  Y     
RNPS1  Y     
RPL22  Y     
RPN1  Y     
SAFB  Y     
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SF1 Y   Y   
SF3A1  Y  Y   
SF3A2 Y Y     
SF3A3  Y     
SF3B4  Y Y    
SFPQ Y Y  Y   
SNRP70  Y  Y   
SNW1  Y     
SR-A1  Y     
SRPK1  Y     
SRSF1 Y   Y   
SRSF10  Y Y    
SRSF12  Y     
SRSF16  Y     
SRSF3 Y Y    Y 
SRSF4  Y     
SRSF5 Y Y    Y 
SRSF8       
SRSF9 Y  Y   Y 
SXL   Y    
SYNCRIP  Y  Y   
TARBP1  Y    Y 
THOC1  Y     
TIAL1  Y  Y  Y 
U2AF1  Y     
U2AF1L5 Y      
U2AF2 Y  Y    
YBX   Y   Y 
ZNF638  Y     
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